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ABSTRACT 
XIN MING: Role of Basolateral Efflux Transporters in Intestinal Absorption 
of Drugs and Prodrugs 
(Under the direction of Dhiren R. Thakker, Ph.D.) 
Polarized expression and cooperation of drug transporters in epithelial cells are 
critical in governing systemic exposure and thereafter drug actions. However, mechanisms 
for the basolateral efflux of hydrophilic compounds from intestine remain elusive. Studies 
described in this dissertation provide novel insights about the role of basolateral transporters 
in intestinal drug absorption: they are critical for the transcellular transport of hydrophilic 
drugs when apical transporters mediate uptake efficiently, or when prodrugs are metabolized 
into hydrophilic drugs intracellularly after diffusion through the apical membrane. 
Investigation of the absorptive transport of fexofenadine in Caco-2 cells provided 
evidence for a vectorial transport system in its intestinal absorption, consisting of organic 
anion transporting polypeptide 2B1 for apical uptake and multidrug-resistance associated 
protein 3 (MRP3) for basolateral egress. The MRP inhibitor decreased the absorptive 
transport of fexofenadine moderately; further, this decrease was more pronounced when P-
glycoprotein was also inhibited. It appears that apical efflux by P-glycoprotein may be the 
rate-limiting step in intestinal absorption of fexofenadine; however, MRP3-mediated 
basolateral efflux may control its absorption where P-glycoprotein expression/effect is low. 
Adefovir dipivoxil, an ester prodrug of adefovir with improved bioavailability, 
diffuses across cell membranes readily and is rapidly hydrolyzed to adefovir intracellularly. 
 iv 
In MRP4-knockdown Caco-2 cells, basolateral availability of adefovir upon dosing the apical 
compartment with [3H]adefovir dipivoxil was reduced at the level comparable to the 
chemical inhibition of MRPs in wild-type cells. Results showed that MRP4 is localized in the 
basolateral membrane of Caco-2 cells and mediates the basolateral efflux of adefovir 
generated intracellularly.  
The diamidine drug, furamidine, was identified as a substrate for organic cation 
transporter 1 (OCT1), an intestinal basolateral transporter. It mediates efflux of furamidine at 
much lower rate than its uptake. A diamidoxime prodrug of furamidine diffuses into OCT1 
transfected MDCKII cells, and is metabolized intracellularly to furamidine, which egresses 
across the basolateral membrane by OCT1-mediated transport. However, its significance is 
still questionable under physiological conditions due to the inefficient efflux and the low 
expression in vivo.  
Overall, this work has provided new insights about carrier-mediated basolateral efflux 
mechanisms and defined when and how these basolateral transporters affect intestinal drug 
absorption.
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CHAPTER 1 
 
 
  
INTRODUCTION
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A. INTRODUCTION 
Oral administration is the primary drug delivery route and accounts for over 70% of 
all medications. In order to achieve pharmacological actions, oral drugs must dissolve in the 
stomach and then cross intestinal epithelium to arrive in the bloodstream. The villi of the 
intestinal epithelium and the presence of microvilli in each epithelial cell vastly increase the 
surface area for maximal absorption (Figure 1.1). The epithelial cell monolayer in the 
intestine constitutes a selective barrier to nutrients and xenobiotics (Figure 1.1). The 
intercellular spaces located between the enterocytes are around 10 Å in size and occupy less 
than 0.1% of the total surface area of the intestinal epithelium (Fordtran et al., 1968; Schultz 
et al., 1974). These spaces are further sealed by the presence of tight junctions, which 
effectively limit intestinal absorption through the paracellular spaces. Tight junctions also 
restrict the movements of lipids and proteins along the exoplasmic leaflet of the plasma 
membrane and separate the apical and basolateral membranes in the polarized enterocytes. 
Tight junctions and two membranes are the permeation barrier for intestinal drug absorption. 
In addition, abundant soluble and membrane bound enzymes, such as esterases and 
cytochrome P450 enzymes, are expressed inside the enterocytes to metabolize the drugs 
before they arrive in the blood circulation and these enzymes are the enzymatic barrier for 
drug absorption. 
Bioavailable drugs overcome the barrier in the intestine in different ways (Figure 
1.2). Lipophilic compounds traverse the intestinal epithelium via transcellular passive 
diffusion and are generally well-absorbed; in contrast, small hydrophilic compounds, which 
pass through the narrow paracellular pores, are generally poorly absorbed. However, 
nutrients and some hydrophilic drugs utilize carrier mediated transport systems and achieve 
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higher bioavailability than that expected from their physicochemical properties. Recently, 
drug vectorial transport systems have been established in elimination of drugs in the liver and 
kidney, in which uptake transporters in the basolateral membrane and efflux transporters in 
the apical membrane share similar substrate specificity, and the synergy of these transporters 
in polarized epithelial cells facilitates the unidirectional transport of a compound into the bile 
or urine (Ito et al., 2005). Accordingly, vectorial transport systems for intestinal drug 
absorption involve uptake transporters in the apical membrane and efflux transporters in the 
basolateral membrane of the intestine (Figure 1.2). Depending on their relative efficiency and 
capacity, apical uptake transporters or basolateral efflux transporters may control the 
transepithelial movement when the corresponding transport step becomes rate-limiting 
(Cheeseman, 1992). Knocking out the basolateral transporter organic solute transporter αβ 
(Ostαβ) in mice almost abolished transileal transport of taurocholate (Rao et al., 2008), 
which indicted that basolateral transporters are likely to be as important as apical transporters 
in efficient transcellular transport of hydrophilic compounds in the intestine. 
Conceivably, intestinal basolateral transporters may also mediate efflux of 
hydrophilic compounds generated in the enterocytes, being either the active drugs from their 
prodrugs or the metabolites of the parent drugs (Figure 1.2). Due to the high lipophilicity of 
the parent compounds, they cross the apical membrane by passive diffusion and apical uptake 
transporters may not contribute to this process. However, they may be metabolized into more 
hydrophilic and/or charged metabolites by highly expressed esterases and CYP450 enzymes 
in the intestine, when the efflux transporters in the apical or basolateral membrane are needed 
to pump them out of the cells. The roles of the efflux transporters, in the canalicular (apical) 
and sinusoidal (basolateral) membranes, in elimination of the metabolites formed in the 
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hepatocytes has been well established (Zamek-Gliszczynski et al., 2006). However, the roles 
of the same transporters, such as MRP2 and MRP3, in the intestine have been unclear. In 
addition to mediating efflux of substrates out of the enterocytes, intestinal basolateral 
transporters in the solute carrier superfamily (SLC) may also play a role in intestinal 
secretion of xenobiotics via uptake of substrates from the blood circulation into the 
enterocytes (Arimori and Nakano, 1998). Mouse organic cation transporter 1 (mOct1) is 
functionally expressed in the intestinal basolateral membrane and facilitates the secretion of 
its substrates from the circulating blood into the intestinal lumen by mediating the basolateral 
uptake process (Jonker et al., 2001; Wang et al., 2002). 
In this review, current advances of the research on intestinal basolateral transporters 
are summarized and the relevant apical transporters are also included in order to better 
describe the functions of the basolateral transporters. The following overview highlights 
members of both the SLC and ATP-binding cassette (ABC) superfamily of drug transporters 
with respect to intestinal expression, localization, substrate specificity, and contribution to 
intestinal drug absorption. 
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B. AMINO ACID TRANSPORTERS 
A large number of amino acid transporters exist in both the apical and basolateral 
membranes of the intestinal epithelium and primarily mediate absorption of amino acids 
obtained from the diet (Figure 1.3, Table 1.1). Amino acid transporters represent the biggest 
transporter class and span eight of the total 46 SLC families. Many of these transporters have 
narrow substrate specificities transporting amino acids with molecular weight below 100, 
and, thus, are not significantly involved in absorption of drugs with typical molecular weight 
over 150. Only the transporters for large and neutral amino acids have been reported to 
contribute to the absorption of amino acid-like drugs, such as L-dopa and gabapentin, and 
will be discussed here. 
B.1. Apical Transporters 
Multiple transporters in the intestinal apical membrane are involved in uptake of large 
neutral amino acids, including ATB0,+ (SLC6A14), B0AT1 (SLC6A19), and b0,+AT 
(SLC7A8). ATB0,+ is a Na+ and Cl- dependent amino acid transporter for hydrophobic neutral 
and cationic amino acids including amino acid-like drugs (Sloan and Mager, 1999). 
Valacyclovir, the valine prodrug of acyclovir, is substrate for ATB0,+, suggesting that this 
transporter can be applied for improved oral absorption of amino acid prodrugs (Hatanaka et 
al., 2004; Umapathy et al., 2004). The regional expression of ATB0,+ in the colon may be 
beneficial for colonic drug delivery. b0,+AT forms a heterodimer with its heavy subunit 
binding partner rBAT and translocates cationic and neutral amino acids as well as L-cysteine 
in an exchange fashion (Chillaron et al., 1996). Recently, it was reported that uptake of 
dipeptides via oligopeptide transporter 1 (PepT1) enhanced the uptake of gabapentin via 
trans-stimulation of b0,+AT exchange in rat intestine, indicating that apical uptake of 
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gabapentin is mediated by b0,+AT (Nguyen et al., 2007). However, whether gabapentin is a 
substrate for this transporter needs to be confirmed. B0AT1 is localized in the apical 
membrane of the intestine and renal proximal tubule and transports neutral amino acids in a 
Na+ dependent manner (Broer et al., 2004). Mutations in this transporter gene cause Hartnup 
disorder (Broer et al., 2004; Kleta et al., 2004; Seow et al., 2004). However, it has not been 
established whether it is involved in intestinal absorption of amino acid-like drugs. 
B.2. Basolateral Transporters 
B.2.a LAT1 (SLC7A5) and LAT2 (SLC7A8) 
LAT1 and LAT2 are hetero(di)meric amino acid transporters composed of a catalytic 
subunit (LAT1 or LAT2, light chain) associated covalently with a glycoprotein 4F2hc/CD98 
(heavy chain), transporting large branched and aromatic neutral amino acids (Verrey, 2003). 
LAT1 and LAT2 are obligatory amino acid exchangers with 1:1 stoichiometry and do not 
mediate net uptake of large and neutral amino acids (Meier et al., 2002). The net directional 
transport of amino acids depends on the parallel expression of a unidirectional transporter 
with overlapping selectivity, which recycles amino acids and drives the exchange function of 
LAT1 and LAT2 (Meier et al., 2002; Bauch et al., 2003). Both LAT1 and LAT2 transport L-
dopa (Verrey et al., 2004), but only LAT1 transports gabapentin (Cundy et al., 2004). LAT1 
is mainly expressed in growing cells. The presence of LAT1 in both luminal and abluminal 
membranes of microvessel endothelial cells in brain (Duelli et al., 2000) suggested that 
LAT1 plays an important role in large and neutral amino acids transfer across the blood-brain 
barrier, making LAT1 a good target to deliver amino acid-like drugs, such as L-dopa and 
gabapentin, to the brain (Pardridge, 2007). In rat intestine, LAT1 protein is most abundant in 
the colon but low in the small intestine, in contrast to the relatively homogeneous presence of 
7 
LAT2 throughout the digestive tract (Fraga et al., 2005). LAT2 is highly expressed in the 
basolateral membrane in mouse small intestine (Dave et al., 2004), indicating that it is mainly 
involved in the basolateral efflux step in transepithelial transport of amino acids. Both 
transporters are present in intestinal cell lines Caco-2 and IEC-6 cells at mRNA and protein 
levels (Fraga et al., 2005) and function as exchangers of neutral amino acids (Fraga et al., 
2002). 
B.2.b LAT3 (SLC43A1) and LAT4 (SLC43A2) 
LAT3 and LAT4 belong to a new gene family of SLC43; they transport large and 
neutral amino acids in Na+-, Cl-- and pH-independent fashion (Babu et al., 2003; Bodoy et 
al., 2005). Northern blot analysis showed that LAT3 mRNA was expressed at high level in 
pancreas, liver and skeletal muscle (Babu et al., 2003). A recent study using GeneChip arrays 
showed that LAT3 mRNA is also highly expressed in human duodenum (Kim et al., 2007). 
Subcellular localization of LAT3 in polarized cells has not been attempted. LAT4 mRNA is 
restricted to the epithelial cells of the distal tubule and the collecting duct in the kidney. 
However, it is mainly present in the cells of the crypt in the intestine (Bodoy et al., 2005). 
This transporter is expressed in the basolateral membrane of PCT kidney cells (Bodoy et al., 
2005). LAT3 and LAT4 mediate net uptake of large and neutral amino acids (Babu et al., 
2003; Bodoy et al., 2005), and may play a more important role than LAT1 and LAT2 in 
intestinal absorption of amino acids and amino acid-like drugs. However, substrate activity of 
amino acid-like drugs, such as L-dopa and gabapentin, towards these two novel transporters 
has not been studied. 
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B.2.c y+LAT1 (SLC7A7) and y+LAT2 (SLC7A6) 
y+LAT1 and y+LAT2 were first identified on the basis of homology to LAT1 and 
were shown to function as obligatory amino acid exchangers of neutral and cationic amino 
acids. Transport of neutral amino acids by these two transporters is coupled to Na+ (Torrents 
et al., 1998; Pfeiffer et al., 1999). y+LAT1 was localized in the basolateral membrane in 
kidney proximal tubule (Bauch et al., 2003) and small intestine (Dave et al., 2004). In 
contrast to y+LAT1, y+LAT2 is widely expressed in non-epithelial and epithelial tissues 
(Verrey et al., 2004). The role of these transporters in intestinal drug absorption is not clear at 
present. 
B.2.d TAT1 (SLC16A10) 
T-type amino-acid transporter-1 (TAT1, SLC16A10) is highly expressed in the 
basolateral membrane of rat and mouse intestinal cells (Kim et al., 2001; Ramadan et al., 
2006). TAT1 does not transport monocarboxylates, such as lactate and pyruvate, although 
most of members in the SLC16 family are monocarboxylate cotransporters (Kim et al., 
2001). TAT1 mediates both uptake and efflux of aromatic amino acids, including L-dopa, in 
a Na+- and pH-independent facilitative manner (Kim et al., 2001; Ramadan et al., 2006). 
TAT1 is able to mediate a net efflux of aromatic amino acids into the blood (Ramadan et al., 
2006). Sequentially, these aromatic amino acids may drive obligatory exchange of other 
neutral amino acids into the blood via other basolateral transporters such as y+LAT1 and 
LAT2 (Ramadan et al., 2006). 
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C. PEPTIDE TRANSPORTERS 
C.1. Apical Peptide Transporters 
Apical peptide transporters, mainly in the SLC15 family, are secondary active 
transporters that utilize the proton-motive force for uphill transport of short chain peptides 
and peptidomimetics into a variety of cells (Liang et al., 1995). Oligopeptide transporter 1 
(PepT1, SLC15A1), the first identified peptide transporter (Fei et al., 1994), is mainly 
expressed in intestine with the highest expression in duodenum (Herrera-Ruiz et al., 2001). 
PepT1 expression has also been detected in Caco-2 cells, the most widely used in vitro model 
of intestinal epithelium (Brandsch et al., 1994). PepT1 transports a large variety of di- and 
tripeptides in a stereoselective manner (Terada and Inui, 2004), and also interacts with many 
peptide-like drugs, including β-lactam antibiotics cephalexin (Tamai et al., 1997), the ACE 
inhibitor enalapril (Zhu et al., 2000; Shu et al., 2001), and the anti-viral prodrug valacyclovir 
(Balimane et al., 1998; Ganapathy et al., 1998; Sugawara et al., 2000). The finding that 
intestinal PepT1 transports L-valine prodrugs such as valacyclovir provided a major advance 
toward the development of novel intestinal delivery systems via uptake transporters (Brodin 
et al., 2002). However, a recent study found that no correlation was observed between 
absorption of valacyclovir and PepT1 expression in human duodenum (Landowski et al., 
2003). Interestingly, this study showed a significant positive correlation between valacyclovir 
absorption and the expression levels of human peptide transporter 1 (HPT1, also called 
Cadherin 17), which is also able to transport valacyclovir (Landowski et al., 2003). These 
results strongly supported the major contribution of HPT1 in intestinal absorption of peptides 
and peptide-like drugs, which was supported by a recent study showing that HPT1 mRNA 
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level is the highest among 36 drug transporters in human jejunum (Hilgendorf et al., 2007). 
The knowledge about the apical transporters is summarized in Figure 1.3 and Table 1.1. 
C.2. Basolateral Peptide Transporter 
The basolateral peptide transporter, mediating the efflux of small peptides and 
peptide-like drugs from enterocytes to the blood, has not been cloned, although its functional 
activity was observed in the basolateral membrane in Caco-2 cells many years ago (Saito and 
Inui, 1993; Matsumoto et al., 1994). The proposed peptide transport model consists of active 
uptake by PepT1 and/or HPT1 driven by proton gradient followed by a downhill egress by 
the basolateral transporter to the mesenteric circulation (Terada and Inui, 2004). Functional 
activity of the basolateral peptide transporter has been studied in Caco-2 monolayers and the 
basolateral peptide transporter demonstrated the properties distinguished from the apical 
PepT1. Firstly, the basolateral uptake into Caco-2 cells led to the intracellular concentration 
of the substrates equal to the extracellular concentration and was shown to be less sensitive to 
the pH, suggesting that the basolateral peptide transporter in Caco-2 cells is a proton-
independent facilitative transporter (Terada et al., 1999; Irie et al., 2001). This transporter can 
transport di- and tripeptides, peptide-like drugs and non-peptide PepT1 substrates (Terada et 
al., 2000). Consistent with the bi-directional property of facilitative transporters, the 
basolateral peptide transporter mediates both uptake and efflux of its substrates (Irie et al., 
2004). The substrates showed much lower affinity for the basolateral peptide transporter at 
the intracellular side (Km = 30 mM) compared to PepT1 (Km = 1.6 mM) (Terada et al., 2000; 
Irie et al., 2004). This property may be adaptive to the higher intracellular concentration in 
the intestinal lumen, achieved by active uptake by PepT1. Low affinity of the basolateral 
peptide transporter prevents saturation of this carrier in order to retain its activity. This 
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kinetic property of peptide transporters is similar to that of the glucose transport system in 
the intestine, which consists of a secondary active transporter in the apical membrane, Na+-
glucose cotransporter (SGLT1, Km = 0.8 mM), and low affinity basolateral facilitate glucose 
transporter (GLUT2, Km = 15-20 mM) (Hediger and Rhoads, 1994). 
A candidate protein of the basolateral peptide transporter was identified in rat 
jejunum by photoaffinity labeling (Shepherd et al., 2002). A single protein with the 
molecular weight of 112 kDa and pI of 6.5 was isolated and identified as a novel protein 
based on dissimilarity to PepT1 in protein sequence (Shepherd et al., 2002). However, no 
further studies on molecular cloning and kinetic characterization of this novel protein have 
been reported since this initial study. Therefore, the basolateral efflux transporter is still the 
major missing link in vectorial transport of small peptides and peptide-based drugs in the 
intestine. 
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D. NUCLEOSIDE TRANSPORTERS 
D.1. Concentrative Nucleoside Transporters 
Concentrative nucleoside transporters (CNTs, SLC28 family) mediate active, Na+-
dependent uptake of naturally occurring nucleosides and nucleoside-based drugs, such as 
zidovudine and 2’-2’-Didioxyinosine (Balimane and Sinko, 1999; Gray et al., 2004). The 
three subtypes differ in their substrate specificities: CNT1 transports pyrimidine-nucleoside, 
CNT2 prefers purine-nucleoside, and CNT3 transports both nucleosides (Gray et al., 2004). 
CNTs determine response to a variety of anticancer and antiviral nucleoside analogs, as they 
mediate the entry of these drugs into target cells (Cass et al., 1999). All three CNTs’ mRNAs 
have been detected in the intestine (Wang et al., 1997; Ngo et al., 2001; Ritzel et al., 2001) 
but CNT2 showed the highest expression (Meier et al., 2007).  CNT1 or CNT2 mRNAs were 
not found in Caco-2 cells suggesting that this model may not be appropriate to study 
nucleoside absorption (Ward and Tse, 1999). A recent study confirmed the expression of 
CNT1 and CNT2 mRNAs in the enterocytes in human duodenum using an in situ 
hybridization technique and localized their proteins predominantly in the apical membrane 
using immunohistochemical staining (Govindarajan et al., 2007). The broad substrate 
specificity of CNTs and intestinal expression suggest that these transporters play critical roles 
in intestinal nucleoside salvage and the absorption of nucleoside-based drugs. 
D.2. Equilibrative Nucleoside Transporters 
Equilibrative nucleoside transporters (ENTs, SLC29 family) transport naturally 
occurring nucleosides and nucleoside-based drugs in a Na+-independent, bi-directional 
fashion. ENT1, ENT2 and ENT3 possess similar broad substrate specificities for purine and 
pyrimidine nucleosides, the latter two possessing additional activity to transport nucleobases 
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(Baldwin et al., 2004). ENT1 and ENT2 transport many anti-viral and anti-cancer drugs 
containing nucleoside moieties (Balimane and Sinko, 1999; Cass et al., 1999; Baldwin et al., 
2004).  All subtypes are widely distributed in mammalian tissues including human intestine, 
but at lower levels than CNT2 (Meier et al., 2007). In polarized cells, ENT1 is expressed in 
the basolateral membrane (Lai et al., 2002). However, a recent study showed that ENT1 and 
ENT2 mRNAs are present in the crypt cells, but not the absorptive enterocytes in the tip of 
villi in human duodenum (Govindarajan et al., 2007). Although their proteins are localized in 
the lateral membrane in the crypt cells, they are not co-localized with CNT1 and CNT2 in the 
same cells (Govindarajan et al., 2007), indicating they may not play a role in intestinal 
absorption of nucleoside-based drugs. 
ENT4 was originally identified by genome database analysis and assigned to the 
SLC29 family based on the gene sequence homology (Acimovic and Coe, 2002). More 
recent studies showed that this transporter transports organic cations, such as TEA, MPP+ 
and metformin, in a Na+-independent and membrane potential-sensitive manner (Engel and 
Wang, 2005; Zhou et al., 2007). Thereafter, it was given a new name, plasma membrane 
monoamine transporter (PMAT), recognizing its function as a polyspecific organic cation 
transporter.  PMAT protein is expressed in human small intestine and localized into the 
apical membrane of the enterocytes (Zhou et al., 2007), indicating that it may mediate apical 
uptake of cationic drugs such as metformin in the intestine. 
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E. BILE ACID TRANSPORTERS 
E.1. Apical Sodium-Dependent Bile Salt Transporter (ASBT, SLC10A2)  
It has been clearly established that bile acids are taken up at the ileal brush border 
membrane through a carrier-mediated, Na+-dependent process in the intestine (Gallagher et 
al., 1976) and Caco-2 cells (Hidalgo and Borchardt, 1990). The molecular mechanism of ileal 
transport of bile acids was further clarified after molecular cloning of apical sodium-
dependent bile salt transporter (ASBT, SLC10A2) from mouse (Saeki et al., 1999), rat 
(Shneider et al., 1995), and human (Wong et al., 1995) ileum. Transport of endogenous bile 
salts, including taurocholate, cholate, glycodeoxycholate, glycochenodeoxycholate, and 
glycoursodeoxy-cholate, by ASBT is electrogenic and Na+-dependent (Weinman et al., 
1998). ASBT plays an essential role in the (re-)absorption of bile acids that are secreted from 
the liver into bile and subsequently passed into the intestine, which has been proved by the 
studies showing that deficiency of the ASBT gene was associated with intestinal bile acid 
mal-absorption in humans (Oelkers et al., 1997), and targeted deletion of the ASBT gene 
eliminates enterohepatic cycling of bile acids in mice (Dawson et al., 2003). 
ASBT has been utilized as a prodrug target to improve oral bioavailability 
(Balakrishnan and Polli, 2006). One bile acid conjugate of acyclovir achieved 16-fold greater 
acyclovir accumulation within hASBT transfected cells and a 2-fold increase in the 
bioavailability of acyclovir (Tolle-Sander et al., 2004).  Further efforts have been expended 
in finding bile acid analogs with better substrate activity for hASBT (Balakrishnan et al., 
2006a; Balakrishnan et al., 2006b). However, these efforts have resulted in limited success. 
 
 
15 
E.2. Organic Solute Transporter αβ (OSTαβ)  
Similar to other intestinal transport systems, the identification of the basolateral efflux 
transporter of bile acids lagged behind the discovery of the apical transporter. The 
heteromeric transporter Ostαβ, was identified first in the liver of marine vertebrates using the 
expression cloning approach (Wang et al., 2001), and then in humans and mice (Seward et 
al., 2003). In contrast to other organic anion transporters identified to date, transport activity 
of this transporter requires the coexpression of two distinct gene products: a 340-amino acid 
protein with a predicted seven-transmembrane domain (OSTα) and a putative 128-amino 
acid ancillary polypeptide with a single-transmembrane domain (OSTβ) (Wang et al., 2001; 
Seward et al., 2003). This transporter was first regarded as a steroid transporter capable of 
transporting endogenous and xenogenous steroid compounds, including estrone 3-sulfate, 
digoxin, taurocholate and prostaglandin E2 (Wang et al., 2001; Seward et al., 2003; Ballatori, 
2005). A role for Ostαβ in intestinal basolateral egress of bile acids was suggested after it 
was found that Ostαβ mRNAs are highly expressed in ileum and the protein is largely 
restricted to the basolateral membrane of ileal enterocytes (Ballatori et al., 2005; Dawson et 
al., 2005). In addition, expression levels of Ostαβ mRNAs are positively regulated via the 
bile acid-activated nuclear receptor farnesoid X receptor (FXR) (Boyer et al., 2006; Landrier 
et al., 2006; Lee et al., 2006). In a recent study, transileal transport of taurocholate was 
reduced by >80% in Ostα knockout mice compared to wild-type mice; the residual 
taurocholate transport was further reduced to background levels in gut sacs prepared from 
Ostα and Mrp3 double knockout mice (Rao et al., 2008). This result finally established the 
predominant role of Ostαβ in intestinal basolateral efflux of bile acids with MRP3 playing a 
minor role, which represents one of the most important advances in the area of intestinal 
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basolateral transporters in the past 5 years and proves that basolateral transporters are as 
important as apical transporters in efficient transcellular transport. Transport mediated by 
OSTαβ is facilitated diffusion (Ballatori et al., 2005); thus, OSTαβ may also play a role as 
the basolateral uptake transporter in intestinal secretion of steroid compounds such as 
digoxin. 
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F. ORGANIC CATION TRANSPORTERS 
F.1. OCT1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3) 
Organic cation transporters (OCTs) in the SLC22A family, which are mainly 
expressed in the elimination organs such as the kidney (basolateral membrane of tubular 
cells) and liver (sinusoidal membrane of hepatocytes), have been most extensively studied in 
regards to hepatic and renal transport of relatively small organic cations (Koepsell et al., 
2007). There are three distinct OCT transporters, namely OCT1, OCT2, and OCT3, which 
mainly mediate the entry of organic cations into cells (Koepsell et al., 2007). In humans, 
hOCT1 is the predominant OCT transporter expressed in the liver while hOCT2 is expressed 
predominantly in the kidney (Koepsell et al., 2007). The majority of OCT substrates are 
monovalent, and comparatively small, cations, the so called type I organic cations (Meijer et 
al., 1999; Wright, 2005) as exemplified by the prototypical substrates TEA and the 
neurotoxin, MPP+ (Koepsell et al., 2007). In addition, OCTs interact with many drugs, 
including the H2 antagonist ranitidine (Bourdet et al., 2005), the antidiabetic drug metformin 
(Wang et al., 2002) and the anticancer drug oxaliplatin (Yokoo et al., 2007). Transport via 
OCTs is facilitative and driven by the negative membrane potential inside the cell. Uptake of 
positively charged molecules is thermodynamically favorable, which can produce over 10-
fold higher intracellular concentrations compared with the dose concentration (Koepsell et 
al., 2007). 
In contrast to the established role of OCTs in hepatic and renal disposition of organic 
cations, the roles of these transporters in intestinal absorption and secretion of cationic 
compounds have yet to be firmly established, although evidence for their expression in the 
intestinal tissues of humans and preclinical species have been reported (Grundemann et al., 
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1994; Kekuda et al., 1998). Recently, quantification of mRNAs for OCTs by real-time RT-
PCR showed that OCT1 and OCT3 are expressed in human intestine but at lower levels than 
in the elimination organs liver and kidney, and the expression of OCT2 was very low or 
undetectable (Terada et al., 2005; Hilgendorf et al., 2007). Immunostaining of OCT1 in 
human small intestine showed lateral localization (Muller et al., 2005). In Oct1-null mice, 
accumulation of TEA (Jonker et al., 2001) and metformin (Wang et al., 2002) was lower than 
wild type after intravenous administration, indicating that Oct1 is expressed in the basolateral 
membrane of mouse intestine and facilitates the elimination of its substrates from the 
circulating blood into the intestinal lumen. OCT1 is also capable of mediating efflux of 
cations, such as TEA and MPP+, out of cells (Zhang et al., 1999; Keller et al., 2005). 
However, whether OCT1 plays a role in absorptive transport of cationic drugs by mediating 
basolateral egress has not been clear. Conceivably, efflux of cations by OCT1 may not be as 
efficient as the uptake process, because OCT1-mediated transport is driven by the membrane 
potential of positive outside and negative inside, which favors, thermodynamically, the 
uptake of positively charged molecules but resists the efflux process (Koepsell et al., 2007). 
Surprisingly, immunostaining of OCT1 (Ng, 2003) and OCT3 (Muller et al., 2005) has 
shown that both transporters are localized in the apical membrane of Caco-2 cells, which is 
consistent with the carrier mediated mechanism of uptake of ranitidine and metformin, OCT1 
substrates, across the apical membrane of Caco-2 cells (Bourdet and Thakker, 2006; Proctor 
et al., 2008b). These observations from an in vitro transport model need to be validated in 
transport studies using in vivo models such as in situ intestinal perfusion. 
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F.2. OCTN1 (SLC22A4) and OCTN2 (SLC22A5) 
 Novel organic cation transporter 1 (OCTN1) and 2 (OCTN2) are expressed in human 
intestine (Terada et al., 2005; Hilgendorf et al., 2007; Meier et al., 2007). Indeed, they can be 
considered as zwitterion transporters because they transport zwitterions such as ergothioneine 
(OCTN1) and L-carnitine (OCTN2) much more efficiently than the prototypical OCT 
substrate TEA (Grundemann et al., 2005). OCTN1 is expressed in kidney, skeletal muscle, 
placenta, prostate, and heart with strong expression in erythrocytes and monocytes 
(Grundemann et al., 2005), which may be relevant to the protective role of ergothioneine, an 
intracellular antioxidant. Decreased proliferation and erythroid differentiation was observed 
in K562 cells depressed of OCTN1 gene expression by siRNA knockdown, indicating this 
transporter may play a protective role in humans (Nakamura et al., 2007). OCTN1 also 
mediates renal excretion of an amino acid-type drug gabapentin, which is also a zwitterion, 
and genetic mutations of this transporter decreased renal clearance of gabapentin in humans 
(Urban et al., 2007). The subcellular localization of OCTN1 in the intestine has not been 
shown; therefore, the definite function in intestinal transport is unknown. 
OCTN2 (SLC22A5) is a high-affinity, sodium-dependent transporter that plays a key 
role in the cellular uptake of L-carnitine (Koepsell et al., 2007). An important physiological 
role for L-carnitine involves transporting long-chain fatty acids across the inner 
mitochondrial membrane for oxidation. OCTN2 mRNA have been detected in kidney, heart, 
skeletal muscle, intestine and placenta by Northern blotting (Tamai et al., 1998). In the Octn2 
deficient mice, reduced oral bioavailability of L-carnitine was observed compared with wild-
type mice, suggesting the possible involvement of Octn2 in the intestinal absorption of L-
carnitine (Yokogawa et al., 1999). OCTN2 transports L-carnitine in a Na+-dependent fashion 
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and small organic cations such as TEA in a Na+-independent fashion (Wagner et al., 2000; 
Ohashi et al., 2001). OCTN2 also transports many drugs including β-lactam antibiotics 
cephaloridine (Ganapathy et al., 2000) and calcium channel blocker verapamil (Grube et al., 
2006). In the Caco-2 model, hOCTN2 has been localized to the apical membrane using 
immunohistochemical technique, suggesting a potential role in mediating absorption of L-
carnitine and cationic drug substrates (Elimrani et al., 2003). Despite the demonstrated 
expression and localization of OCTN2 in the intestine, their role in mediating drug 
absorption has not been fully established. 
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G. Organic Anion Transporting Polypeptides (OATP/SLCO Superfamily) 
Organic anion transporting polypeptides (OATPs, SLCO superfamily) mediate 
bidirectional, Na+-independent, pH-dependent transport of anions (Hagenbuch and Meier, 
2004). Known substrates cover a wide range of chemical structure, including bile salts, 
steroid hormones and conjugates, thyroid hormones, and various drugs such as atorvastatin, 
fexofenadine, bencylpenicillin and enalapril, which are generally anionic amphipathic 
molecules with a molecular mass greater than 450 Daltons (Hagenbuch and Meier, 2004). 
Despite widespread study of OATPs expression and function in liver and other tissues, their 
role in the intestine remains unclear and controversial. Although multiple OATP isoforms 
have been suggested to be expressed in the intestine, only three of them have shown 
functional activity, however, none of them are localized in the basolateral membrane of the 
intestine. 
G.1. Oatp1a5 (Slco1a5) 
The first identified OATP isoform in the intestine is Oatp1a5 (Slco1a5, previously 
rOatp3), which was cloned from rat small intestine and localized to the apical membrane 
(Walters et al., 2000). It was suggested that Oatp1a5 plays a role as an influx transporter in 
the intestinal absorption of fexofenadine in rats (Kikuchi et al., 2006). However, the human 
homolog of this transporter has not been cloned (Hagenbuch and Meier, 2004), therefore, 
extrapolation of the results involving Oatp1a5 from rats to humans is questionable. 
G.2. OATP1A2 (SLCO1A2) 
OATP1A2 (SLCO1A2, previously OATP-A) is the first discovered human OATP 
transporter, which was originally cloned from a human liver cDNA library, but showed its 
strongest expression in human brain (Kullak-Ublick et al., 1995). Beside transporting 
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endogenous substances such as bile acids and steroid conjugates, OATP1A2 also transports 
some important pharmaceutical drugs such as the antihistamine fexofenadine (Cvetkovic et 
al., 1999), the HIV protease inhibitor saquinavir (Su et al., 2004), the anticancer agent 
methotrexate (Badagnani et al., 2006) and the antibacterial agent levofloxacin (Maeda et al., 
2007). The oral bioavailability of metabolically stable fexofenadine in humans was 
significantly reduced when administered in the presence of fruit juices (Dresser et al., 2002; 
Dresser et al., 2005). In vitro results have demonstrated that grapefruit, orange, and apple 
juices inhibit fexofenadine transport by OATP1A2 suggesting that the observed decrease in 
oral bioavailability may result from inhibition of OATP1A2-mediated absorption (Dresser et 
al., 2002). More recently, it has been shown that OATP1A2 is expressed in the apical domain 
of intestinal enterocytes (Glaeser et al., 2007). However, the studies from other groups did 
not find the presence of OATP1A2 mRNA in human intestines, casting doubt upon the role 
OATP1A2 in intestinal drug absorption (Tamai et al., 2000; Hilgendorf et al., 2007; Meier et 
al., 2007). In addition, the Michaels-Menten constant (Km) of fexofenadine uptake by 
OATP1A2 is 6.4 µM (Cvetkovic et al., 1999). Following oral administration of a 
fexofenadine tablet, a concentration of greater than 1 mM in the intestinal lumen is achieved, 
indicating that OATP1A2 could be saturated completely and fail to play an important role 
even assuming its presence in human intestine. 
G.3. OATP2B1 (SLCO2B1) 
Initial investigation of human OATP isoform expression in the intestine has revealed 
the presence of mRNAs for OATP2B1 (previously OATP-B), OATP3A1 (previously OATP-
D), and OATP4A1 (previously OATP-E) (Tamai et al., 2000). However, recent studies using 
real-time PCR showed that the expression of OATP2B1 is much higher than the other two 
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subtypes (Sai et al., 2006; Hilgendorf et al., 2007). OATP2B1 protein is localized at the 
brush-border (apical) surface of both human small intestine (Kobayashi et al., 2003) and 
Caco-2 cells (Sai et al., 2006). In contrast, it is localized to the basolateral membrane in the 
liver, showing an organ-specific membrane localization pattern. Functional studies 
demonstrated that OATP2B1 transports bile acids and endogenous sulfate conjugates such as 
estrone-3-sulfate (Nozawa et al., 2004), and the greater activity at lower pH broadens its 
specificity to include some clinically used drugs such as the HMG-CoA reductase inhibitor 
pravastatin, the antihistamine fexofenadine and the antidiabetic glibenclamide (Kobayashi et 
al., 2003). These studies clearly suggest a potential role for OATP2B1 in the intestinal 
absorption of anionic or zwitterionic drugs such as pravastatin and fexofenadine. Citrus 
juices and constituents are also able to inhibit OATP2B1 activity, identifying OATP2B1 as a 
potential site for diet-drug interactions (Satoh et al., 2005). The physiological and 
pharmacological roles of OATP2B1 in intestinal absorption may also vary between 
individuals as a single nucleotide polymorphism of this transporter in humans leads to over 
50% reduction of its activity (Nozawa et al., 2002). 
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H. Multiple-Resistance Associated Proteins (MRPs) 
One of the largest sub-families of the ATP-binding cassette (ABC) transporters 
affecting drug disposition is the ABCC family (multidrug resistance-associated protein, 
MRP). MRPs can transport a large range of organic anions, including anionic drugs and 
drugs conjugated to glutathione (GSH), sulfate, or glucuronate, in contrast to P-gp 
transporting lipophilic cationic compounds (Reid et al., 2003b). MRPs 1-5 are expressed in 
the intestine with differential expression profiles in human intestinal segments (Zimmermann 
et al., 2005), however, only MRP2, MRP3 and MRP4 showed evidence of protein expression 
and functional activities in the intestine and are discussed here. 
H.1. MRP2 (ABCC2) 
MRP2 (ABCC2) is localized exclusively to the apical membrane of polarized cells, 
such as hepatocytes, renal proximal tubule epithelia and intestinal epithelia (Buchler et al., 
1996). This localization supports the function of MRP2 in the terminal excretion and 
detoxification of endogenous and xenobiotic organic anions, particularly the substances 
conjugated with glutathione, glucuronate, or sulfate (Zamek-Gliszczynski et al., 2006). 
Compared to the extensively studied and established role of MRP2 in detoxification of drugs 
in the liver, its role in the intestine has been less well studied. MRP2 is highly expressed in 
human jejunum (Hilgendorf et al., 2007). Studies utilizing wild-type and Mrp2 deficient rats 
have clearly demonstrated a significantly reduced intestinal excretion of MRP2 substrate 
DNP-SG in the deficient rat after intravenous administration of the unconjugated parent 
(Gotoh et al., 2000). However, MRP2 may be less important than P-gp in limiting the 
absorption of drugs, because an 8.5-fold increase in oral bioavailability of paclitaxel in 
Mdr1a-/b- mice was observed compared to the wild-type mice, whereas change was not 
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detected in Mrp2-/- mice, although Mrp2 plays an important role in biliary excretion of  
paclitaxel (Lagas et al., 2006). 
H.2. MRP3 (ABCC3) 
MRP3 transports organic compounds conjugated to glutathione, sulfate, or 
glucuronate, also bile salts and unconjugated drugs such as methotrexate (Borst et al., 2007). 
Studies in knockout mice have shown that Mrp3 contributes to the transport of morphine-3-
glucuronide (Zelcer et al., 2005) and fexofenadine (Matsushima et al., 2008a; Tian et al., 
2008a) from the liver into blood. MRP3 mRNA is highly expressed in human jejunum with a 
similar level as P-gp (Hilgendorf et al., 2007), and increases to even higher levels in ileum 
and colon (Zimmermann et al., 2005). Mrp3 protein is localized in the basolateral membrane 
in rat small intestine and colon (Rost et al., 2002). Mrp3 plays a minor role (<20%) in the 
basolateral efflux of bile acids (Zelcer et al., 2006; Rao et al., 2008). Studies in rat intestinal 
basolateral membrane vesicles (BLMV) demonstrated uptake of MRP3 substrates estradiol-
17-β-glucoronide and taurocholate is ATP-dependent and correlated with the expression 
levels of Mrp3 in the BLMV prepared from rat jejunum, ileum, and colon (Shoji et al., 2004), 
which showed the functional activity of Mrp3 in the basolateral membrane of rat intestine. 
Clearly, further studies will be necessary for a more complete understanding of the 
physiological and pharmacological roles of MRP3 in intestinal absorption. 
H.3. MRP4 (ABCC4) 
MRP4, the fourth member of the ABCC family, was initially identified as a homolog 
of MRP1 (ABCC1) by screening databases of human expressed sequence tags (Kool et al., 
1997). MRP4 was the first identified MRP isoform without a third (N-terminal) membrane 
spanning domain (Kool et al., 1997). The “short” members of the family, MRP4, MRP5, 
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MRP8 and MRP9, are distinguished by their ability to confer resistance to nucleoside based 
agents and to transport cyclic nucleotides (Kruh et al., 2007). The substrate specificity of 
MRP4 is particularly broad and it transports cAMP, cGMP, p-aminohippurate, urate, 
dehydroepiandrosterone sulfate, methotrexate, and estradiol-17β-D-glucuronide as well as 
adefovir (Schuetz et al., 1999; van Aubel et al., 2002; Zelcer et al., 2003; van Aubel et al., 
2005). MRP4 is the only transporter in ABCC family that shows tissue specific localization: 
it assumes basolateral localization in most organs such as liver (Rius et al., 2003), whereas in 
kidney proximal tubules it is located at the apical surfaces (van Aubel et al., 2002). A recent 
study clearly showed the protein expression of Mrp4 in mouse intestine (Belinsky et al., 
2007). Mrp4-/- mice were significantly more sensitive to adefovir and histopathological 
analysis indicated that small intestine and colon suffered increased toxicity in the knockout 
mice as compared to wild-type mice (Belinsky et al., 2007). These results supported the 
notion that MRP4 reduces the accumulation of adefovir entering into the enterocytes from 
the blood side, and protects the enterocytes from adefovir cytotoxicity. The results also 
provide circumstantial evidence that MRP4 is present in the basolateral membrane of the 
enterocytes. However, Mrp4 was localized primarily to the basal cytoplasmic region, but not 
distinctly localized to the basolateral membrane of enterocytes in rats (Johnson et al., 2006). 
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I. CONCLUSION 
Understanding the roles of transport proteins in the basolateral membrane of the 
intestine represents a major missing link in transporter mediated drug absorption. The 
majority of drug transporters in the intestine have been identified in the apical membrane 
with very few identified in the basolateral membrane. In addition, the functional roles of 
some known basolateral transporters in intestinal absorption are still not clear. For example, 
MRP3 is highly expressed in the basolateral membrane of the intestine and capable of 
transporting bile acids, however, its role in bile acids absorption was proved to be neglectable 
by the studies using Mrp3 knockout mice (Zelcer et al., 2006; Rao et al., 2008). Without 
significant progress in understanding the roles and functions of intestinal basolateral 
transporters, a complete understanding of vectorial transport in drug absorption will remain 
lacking. 
Compared to the slow progress in the research on the mechanisms of basolateral 
efflux in drug absorption, several vectorial transport systems for nutrient absorption have 
been established and lessons can be learned from the basolateral efflux mechanisms in 
nutrient absorption. The first example of a vectorial transport system was identified in 
intestinal absorption of D-glucose (Hediger and Rhoads, 1994), which was described as a 
classic model of transcellular transport (Lodish et al., 2000). In this model, Na+-K+ pump in 
the basolateral membrane transports Na+ out of the cells to generate an inward Na+ gradient, 
which is utilized by the apical sodium/glucose cotransporters 1 (SGLT1) for uphill transport 
of glucose into the enterocytes. Facilitative glucose transporter (GLUT2), which possesses 
similar substrate specificity to SGLT1 but is expressed in the basolateral membrane, 
mediates the egress of glucose into the blood circulation. The features of this model include:  
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1. Apical uptake transporters are secondary active transporters that mediate uphill 
transport into cells by utilizing ion gradients; 
2. Basolateral efflux transports are facilitative transporters that mediate downhill 
transport of substrates, and their affinity is lower than apical transporters in order not to be 
saturated by the high intracellular concentration. 
This model of vectorial transport can be applied to the absorption systems for other 
nutrients. For example, the neutral amino acids transport system consists of ATB0,+ (Na+ and 
Cl- dependent) plus B0AT1 (Na+ dependent) in the apical membrane and TAT1 (facilitative) 
plus LAT2 (exchanger) in the basolateral membrane; small peptide transport system is the 
apical PepT1 and/or HPT1 (H+ dependent) coupled to the basolateral peptide transporter 
(facilitative); bile acids transport system includes the apical ASBT (Na+ dependent) and the 
basolateral OSTαβ (facilitative). Identification of OSTαβ as the major basolateral efflux 
transporter of bile acids represents one of the most important steps forward in this area in the 
past 5 years. Knocking out Ostα in mice almost abolished transileal transport of taurocholate 
(Rao et al., 2008), which indicted that basolateral transporters are as important as apical 
transporters in efficient transcellular transport. Many nutrient transporters also transport 
drugs containing the chemical moiety that can be recognized by the transporters. Therefore, it 
is desired to continue studying these vectorial transport systems of nutrients and explore their 
pharmacological functions in drug absorption. According to this vectorial model, OATP2B1, 
which can utilize H+ gradient in small intestine, may represent another vectorial transport 
system for drugs when coupled with the basolateral transporters with similar substrate 
selectivity such as MRPs since they have similar substrate specificity in transporting anionic 
and zwitterionic compounds. Apical and basolateral OCTs also have similar substrate 
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specificity; however, efflux by OCTs is thermodynamically unfavorable and thus inefficient, 
which may not play a role in intestinal absorption of cationic compounds under physiological 
conditions. 
The vectorial transport system in the intestine is fundamentally different from those in 
the liver and the kidney, which consist of a facilitative transporter, for the basolateral uptake 
of drugs into the hepatocytes or renal tubular cells, and a primary active transporter in ABC 
superfamily for the apical efflux of drugs into the bile or urine. For example, hepatic 
excretion of pravastatin involves the basolateral uptake via OATP1B1 and the apical efflux 
by MRP2 (Matsushima et al., 2005), whereas renal excretion of adefovir involves the 
basolateral uptake via organic anion transporter 1 (OAT1) (Cihlar et al., 1999) followed by 
efflux into the urine via the apical MRP4 (Imaoka et al., 2007). Clearly, intestinal drug 
transport lags behind the current understanding of hepatic and renal drug transport. The 
strategies that are successful in studying the hepatic and renal vectorial systems should be 
applied to identify those systems for drug absorption in the intestine. Those technological 
advances include transcellular transport studies in double transfected cells with uptake and 
efflux transporters in two membranes (Ito et al., 2005) and organ perfusion techniques in 
transporter knockout mice (Tian et al., 2008a). Renal tubular cell lines LLC-PK1 and 
MDCKII cells are routinely used to construct double transfected transporter systems. 
Differences in localization of the transporters in the enterocytes and renal cells should be 
noticed. For example, OATP2B1 is an apical transporter in the intestine (Kobayashi et al., 
2003). However, it is expressed in the basolateral membrane upon transfection into MDCKII 
cells (Kopplow et al., 2005), therefore, it will not form a vectorial transport system with a 
basolateral transporter to study intestinal drug transport involving OATP2B1. Transport of 
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bile acids using everted gut sac of Ostα-/- and Ostα-/-Mrp3-/- mice (Rao et al., 2008) 
represents a breakthrough in this area because it was the first study of the in vivo functions of 
intestinal basolateral transporters. This technique will be applied to study other intestinal 
basolateral transporters in the near future.  
To fully establish the function of intestinal basolateral transporters, information from 
clinical studies is needed. Recently, understanding the impacts of genetic variations in drug 
transporters on drug disposition is beginning to emerge. Clearly, a loss or reduction of 
transporter activities due to genetic variation in intestinal basolateral transporters could 
potentially limit intestinal absorption of their substrates. Therefore, clinical studies on the 
effect of genetic variation in intestinal basolateral transporters on drug absorption will be an 
important area of future research. The oral bioavailability is determined by both the fraction 
absorbed in the intestine and the presystemic elimination, mainly in the liver and the 
intestine. Because many transporters are expressed in both intestine and liver, clarification of 
mechanisms of altered drug bioavailability in the intestine or liver will be difficult. A human 
in vivo jejunal perfusion technique enables direct determination of the effective jejunal 
permeability of drugs (Tannergren et al., 2003b) and will help understand mechanisms about 
intestinal transporters from clinical data in the future. 
In conclusion, the research on intestinal basolateral transporters will lead to a more 
complete understanding of carrier-mediated intestinal drug absorption and help design and 
develop successful oral drugs and delivery systems. Further, understanding of species 
differences in intestinal transporter expression and function may lead to choosing the right 
animal models to predict absorption in humans. Strategies to utilize intestinal vectorial 
transport systems may aid in improving absorption of poorly absorbed drugs. Knowledge of 
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drug-drug interactions via transporters and their genetic variations may reduce the potential 
of therapeutic failure and toxicity when co-administration of oral drugs is needed. 
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J. RATIONALE AND OVERVIEW OF PROPOSED RESEARCH 
Polarized expression and functional synergy of drug transporters in the apical and 
basolateral membranes of epithelial cells are critical in determining the net transcellular 
transport and, ultimately, in governing drug disposition in the body. Compared to the 
abundant information about apical transporters in the intestine, understanding of the roles of 
intestinal basolateral transporters has remained missing in carrier mediated drug absorption. 
Indeed, very few transporters are identified in the basolateral membrane and function of 
known basolateral transporters in intestinal drug absorption is often unclear. However, 
several vectorial transport systems in the absorption of nutrients, such as glucose and bile 
acids, have been elucidated, clearly showing that the basolateral transporters are as important 
as the apical transporters in an efficient transcellular transport of the substrates in the 
intestine. The overall objective of this project is to understand the roles of the basolateral 
transporters in intestinal absorption of drugs and prodrugs. The central hypothesis of this 
project is that basolateral transporters can determine the transcellular transport rate when 
(i) apical transporters mediate uptake efficiently, or (ii) prodrugs diffuse through the apical 
membrane and are metabolized efficiently within the enterocytes into hydrophilic drugs. 
Transport of fexofenadine and adefovir dipivoxil was investigated in Caco-2 cell monolayers 
to test the two aspects of this hypothesis. 
Fexofenadine, a zwitterionic anti-allergy medicine, represents a large class of drugs 
that contain both acidic and basic groups and possess molecular weight over 300 (Table 1.3). 
The charged nature of fexofenadine at the pH values encountered in the gastrointestinal 
lumen makes it hard to permeate the cell membranes of enterocytes. In addition, 
fexofenadine is an excellent substrate for P-glycoprotein (P-gp) (Cvetkovic et al., 1999), 
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which would make its intestinal absorption even less effective. However, fexofenadine 
achieves greater bioavailability than that expected from its physicochemical properties and 
efflux by P-gp. Therefore, vectorial transport systems, including apical uptake and 
basolateral efflux transporters, have been suggested to explain this dichotomy. Literature 
knowledge of intestinal transporters for fexofenadine is limited to the apical transporters. 
OATP1A2 was reported to mediate apical uptake of fexofenadine in the intestine (Cvetkovic 
et al., 1999), however, whether this transporter is expressed in the intestine is still 
controversial.  
Adefovir is a nucleoside drug for treatment of hepatitis B (Table 1.3). Mrp4 knockout 
mice showed severe toxicity in the intestine compared to wild-type mice, which indicated 
that Mrp4 prevents entry of adefovir into enterocytes from the mesenteric circulation, and 
thus protects the intestine. The prodrug of adefovir, adefovir dipivoxil (Table 1.3), is 
completely metabolized into active adefovir in the enterocytes during absorptive transport. 
Therefore, MRP4 may be a good candidate as a basolateral transporter that mediates egress 
of adefovir formed from its prodrug during oral absorption. 
Besides the main body of the studies, this dissertation project will continue the 
research in the Thakker laboratory on the role of OCT transporters in drug absorption by 
testing whether OCT1 can mediate the basolateral efflux of cations in the intestine. 
Theoretically, efflux by OCT1 is thermodynamically unfavorable. However, OCT1 is the 
only cation selective transporter expressed in the basolateral membrane of the intestine, 
therefore to evaluate the efflux function of OCT1 is of interest. Disposition of diamidine 
compounds like pentamidine (Table 1.3) in the body suggests that the diamidine drug, 
furamidine (Table 1.3) may be a substrate for OCT1. Furamidine diamidoxime (Table 1.3) is 
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metabolized to active furamidine in the enterocytes, and OCT1 might mediate the egress of 
the active drug from enterocytes to the blood circulation.  
The major goals of this research plan are: 
Specific Aim 1: To elucidate vectorial transport of fexofenadine. 
1a) Determine substrate activity toward apical transporters in singly transfected cells. 
1b) Evaluate the role of MRP3 and OSTαβ in the basolateral egress of fexofenadine 
in Caco-2 cells. 
Specific Aim 2: Evaluate the role of MRP4 in intestinal transport of adefovir 
dipivoxil. 
2a) Determine cellular localization of MRP4 in Caco-2 cells. 
2b) Evaluate the role of MRP4 by knocking it down in Caco-2 cells using MRP4-
specific siRNA. 
Specific Aim 3: Evaluate the efflux function of hOCT1 in the basolateral membrane. 
3a) Determine uptake and efflux of furamidine by hOCT1 in hOCT1 transfected cells. 
3b) Evaluate the role of hOCT1 in transport of furamidine diamidoxime in hOCT1 
transfected MDCKII cells. 
Several in vitro cell models including transfected cell models and Caco-2 cells that 
retain intestinal transport mechanisms are utilized to identify apical uptake transporters and 
basolateral efflux transporters and determine their relative roles in intestinal drug absorption. 
This project will generate new knowledge about: 1. novel substrate activity of test 
compounds towards intestinal transporters; 2. expression and localization of candidate 
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transporters in Caco-2 cells; 3. the roles and importance of the basolateral transporters in 
intestinal absorption of drugs and prodrugs; 4. the factors influencing the importance of the 
intestinal basolateral transporters in drug absorption. This information will provide a 
theoretical foundation in understanding drug-drug and food-drug interactions, predicting 
individual variability in drug absorption, designing drugs that will be effective when 
administered orally, and developing strategies to optimize oral absorption.  
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Table 1.1. Major Human Intestinal Nutrient Transporters 
Protein 
Name 
Gene 
Symbol 
Localizationa Transport typeb 
/Coupling ions 
Substrates 
ATB0,+ SLC6A14 AP C/Na+, Cl- Neutral and cationic amino acids 
B0AT1 SLC36A1 AP C/Na+ Neutral amino acids 
b0,+AT SLC7A9 AP E Cationic amino acids, large 
neutral amino acids 
LAT1 SLC7A5 BL E Large neutral amino acids 
LAT2 SLC7A8 BL E Large neutral amino acids 
LAT3 SLC43A1 Unknown F Large neutral amino acids 
LAT4 SLC43A2 BL F Large neutral amino acids 
y+LAT1 SLC7A7 BL E Cationic and neutral amino acids 
y+LAT2 SLC7A6 BL E Cationic and neutral amino acids 
TAT1 SLC16A10 BL F Aromatic amino acids 
PepT1 SLC15A1 AP C/H+ Di- and tripeptides 
HPT1 CDH17 AP C/H+ Di- and tripeptides 
CNT1 SLC28A1 AP C/Na+ Pyrimidine nucleosides, 
adenosine 
CNT2 SLC28A2 AP C/Na+ Purine nucleosides, uridine 
CNT3 SLC28A3 AP C/Na+ Broadly selective for 
pyrimidines and purines 
ENT1 SLC29A1 BL F Purine and pyrimidine 
nucleosides  
ENT2 SLC29A2 BL F Purine and pyrimidine 
nucleosides and nucleobases 
ENT4 SLC29A4 AP F Adenosine, organic cations 
ASBT SLC10A2 AP C/Na+ Bile acids 
OSTαβ  BL F Bile acids, steroids 
a AP: apical; BL: basolateral. 
b C: cotransporters; E: exchangers; F; facilitative transporters.
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Table 1.2 Major Human Intestinal Transporters for Xenobiotics 
Protein 
Name 
Gene 
Symbol 
Localizationa Transport typeb 
/Coupling ions 
Substrates 
OCT1 SLC22A1 BL F Organic cations 
OCT3 SLC22A3 AP F Organic cations 
OCTN1 SLC22A4 Unknown F or E/H+ 
 
Ergothioneine, organic cations 
OCTN2 SLC22A5 AP C/Na+ ( L-
carnitine) or F 
(organic cations) 
L-carnitine; organic cations 
OATP2B1 SLCO2B1 AP F Bulky organic anions 
OATP1A2 SLCO1A2 AP F Bulky organic anions 
MDR1/P-gp ABCB1 AP ABC Broad substrate selectivity, 
preferring cationic compounds 
BCRP ABCG2 AP ABC Broad substrate selectivity 
MRP2 ABCC2 AP ABC Organic anions, conjugates 
MRP3 ABCC3 BL ABC Organic anions, conjugates and 
bile salts 
MRP4 ABCC4 BL ABC Organic anions, conjugates, 
bile salts and nucleotides 
a AP: apical; BL: basolateral. 
b C: cotransporters; E: exchangers; F; facilitative transporters; ABC: ABC transporters. 
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Table 1.3. Structures and Physicochemical Properties of Test Compounds 
Name Structure Log P pKa(s) Molecular Weight 
Fexofenadine 
 
4.8 4.3, 9.5 501.66 
Adefovir 
 
-2.1 2.0, 6.8 273.19 
Adefovir 
dipivoxil 
 
2.4  501.47 
Pentamidine 
 
1.7 11.6 340.42 
Furamidine 
 
2.7 10.4, 
11.8 
304.35 
Furamidine 
diamidoxime 
 
3.1 4.4, 5.2 336.34 
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CHAPTER 2 
 
 
 
VECTORIAL TRANSPORT OF FEXOFENADINE ACROSS CACO-2 CELLS: 
INVOLVEMENT OF APICAL UPTAKE AND BASOLATERAL EFFLUX 
TRANSPORTERS 
 
 
 
 
 
 
 
 
 
  
 
 
This chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics and is presented in the style of that journal.
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A. ABSTRACT 
Fexofenadine (Allegra®) is a non-sedative antihistamine that exhibits good oral 
bioavailability despite its zwitterionic chemical structure and efflux by P-gp. Evidence exists 
that multiple uptake and efflux transporters play a role in hepatic disposition of fexofenadine. 
However, the roles of specific transporters and their inter-relationship in intestinal absorption 
of this drug are not yet clear. The purpose of this study was to elucidate vectorial absorptive 
transport of fexofenadine across Caco-2 cells involving specific apical uptake and basolateral 
efflux transporters. Studies with cellular models (e.g. MDCKII and CHO cells) expressing 
single transporters showed that OATP2B1 stimulated uptake of fexofenadine at pH 6.0. 
Apical uptake of [3H]fexofenadine into Caco-2 cells was decreased by 45% with 200 µM 
estrone 3-sulfate (E1S), an OATP inhibitor, at pH 6.0, but not at pH 7.4, indicating that 
OATP2B1 mediates apical uptake of fexofenadine into these cells. Examination of 
fexofenadine efflux from pre-loaded Caco-2 cells in the presence and absence of the MRP 
inhibitor MK-571 and the P-gp inhibitor GW918 showed that P-gp and MRP both play a role 
in the apical efflux, whereas MRP plays a role in the basolateral efflux. These results also 
showed that while OSTαβ is functionally active in the basolateral membrane of Caco-2 cells, 
it does not play a role in the transport of fexofenadine as evidenced digoxin and E1S, 
substrates for OSTαβ, not having any effect on its transport. MK-571 decreased the 
absorptive transport of fexofenadine by 17%. However, the decrease in absorptive transport 
by MK-571 was 42% when P-gp was inhibited by GW918. The results showed apical entry 
of fexofenadine into Caco-2 cells is predominantly attenuated by P-gp, with a small 
contribution by MRP2; whereas basolateral efflux is predominantly mediated by MRP3.  It 
appears that apical efflux by P-gp may be the rate-limiting step in the absorptive transport of 
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fexofenadine across intestinal epithelium; however, basolateral efflux by MRP3 may control 
absorption rate of fexofenadine where P-gp expression/effect is low. 
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B. Introduction 
Fexofenadine, a zwitterionic anti-allergy medicine, has been used as a probe to 
investigate carrier mediated transport processes due to its low passive permeability and 
relatively low extent of metabolism (Molimard et al., 2004). Fexofenadine is charged at 
physiological pH because it is a zwitterion with two pKa’s of 4.25 and 9.53 (Yasui-Furukori 
et al., 2005). Fexofenadine is an excellent substrate for P-glycoprotein (P-gp) and its limited 
brain penetration has been suggested to arise from P-gp mediated efflux and low intrinsic 
membrane permeability (Cvetkovic et al., 1999; Chen et al., 2003; Polli et al., 2003; Petri et 
al., 2004). Despite its zwitterionic chemical structure and efflux by P-gp, fexofenadine has 
33% bioavailability in humans (Dresser et al., 2005). Both hepatic and renal excretion 
contribute to elimination of fexofenadine in the body (Tahara et al., 2006) because it is a 
substrate for renal organic anion transporter 3 (OAT3) (Tahara et al., 2006) and hepatic 
organic anion transporting polypeptides 1B3 (OATP1B3) and 1B1 (OATP1B1) (Shimizu et 
al., 2005; Matsushima et al., 2008b). Hepatic disposition of fexofenadine has been studied 
extensively and multiple transporters have been found to be involved. After uptake by 
OATP1B3 and OATP1B1 into hepatocytes, fexofenadine is excreted into the bile by multiple 
efflux transporters in the canalicular membrane including multidrug resistance-associated 
protein 2 (Mrp2) (Tian et al., 2008b) and bile salt export pump (BSEP) (Matsushima et al., 
2008a). Surprisingly, P-gp does not seem to contribute to the biliary excretion of 
fexofenadine, at least in mice, although it plays a major role in the efflux of fexofenadine in 
the intestine and blood-brain barrier (Tahara et al., 2005b). In addition, efflux by Mrp3 in the 
sinusoidal membrane attenuates hepatic excretion of fexofenadine (Matsushima et al., 2008a; 
Tian et al., 2008a).  
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Fexofenadine was initially used as an in vivo P-gp probe (Cvetkovic et al., 1999; 
Yasui-Furukori et al., 2005; Shimizu et al., 2006). Interestingly, using a human in vivo 
jejunal perfusion technique, concurrent administration of verapamil or ketoconazole, P-gp 
inhibitors, failed to increase the effective jejunal permeability of fexofenadine (Tannergren et 
al., 2003a; Tannergren et al., 2003b). This observation may be explained when one considers 
that verapamil and ketoconazole not only inhibit P-gp, but also other transporters that 
facilitate absorptive transport of fexofenadine in the intestine, for example, OATPs. This 
notion was supported by a clinical study, which  showed that fruit juices decreased oral 
absorption of fexofenadine by inhibiting the uptake transporter in apical membrane of 
enterocytes (Dresser et al., 2002). Fruit juices inhibit multiple OATP isoforms including 
OATP1A2 (SLCO1A2, formerly OATP-A) (Dresser et al., 2002) and OATP2B1 (SLCO2B1, 
formerly OATP-B) (Satoh et al., 2005). Fexofenadine is a substrate for OATP1A2 
(Cvetkovic et al., 1999); however, conflicting results have been reported in the literature 
about the substrate activity of fexofenadine towards OATP2B1 (Nozawa et al., 2004; 
Shimizu et al., 2005). OATP1A2 gene does not appear to be expressed in human jejunum 
(Tamai et al., 2000; Hilgendorf et al., 2007; Meier et al., 2007), the major absorption site of 
fexofenadine (Petri et al., 2006), whereas OATP2B1 is highly expressed in this region 
(Hilgendorf et al., 2007; Meier et al., 2007) and has been localized in the apical membrane of 
human small intestine (Kobayashi et al., 2003). In addition, human organic cation transporter 
3 (hOCT3, SLC22A3) (Muller et al., 2005) and human organic cation/carnitine transporter 
(hOCTN2, SLC22A5) (Elimrani et al., 2003) are also present in the apical membrane of 
enterocytes. They transport cations and zwitterions with 1-methyl-4-phenylpyridinium 
(MPP+) and L-carnitine as their protypical substrates, respectively (Koepsell et al., 2007). It 
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is conceivable that these transporters, particularly hOCTN2, may play a role in the absorptive 
transport of fexofenadine because of its zwitterionic functionality. 
Intestinal absorptive transport involves entry into the enterocytes across the apical 
membrane from gastrointestinal lumen followed by intracellular translocation and exit from 
the cells across the basolateral membrane. Depending on their relative efficiency and 
capacity, an uptake transporter in the apical membrane or an efflux transporter in the 
basolateral membrane can become rate-limiting for transepithelial movement (Cheeseman, 
1992). However, it is still unclear whether basolateral transporters play an important role in 
intestinal transport of fexofenadine, and if so, which one. Limited information is available 
about transporters that are expressed in the basolateral membrane in intestine. Among the 
known basolateral transporters in the intestine, two classes of transporters may contribute to 
basolateral efflux of fexofenadine: heteromeric organic solute transporter αβ (OSTαβ) and 
multidrug resistance-associated protein 3 (MRP3). 
Ostαβ is highly expressed in ileum as evidenced by the presence of mRNA levels in 
this tissue; the expression appears to be largely restricted to the lateral and basal membranes 
of ileal enterocytes (Ballatori et al., 2005; Dawson et al., 2005). It was recently established 
that Ostαβ plays the predominant role in egress of bile acids through the ileal basolateral 
membrane - transileal transport of taurocholate was reduced by >80% in Ostα knockout mice 
compared to wild-type mice (Rao et al., 2008). Transport activity of Ostαβ requires the 
coexpression of two distinct gene products, a predicted seven-transmembrane domain protein 
(OSTα) and a putative single-transmembrane domain ancillary polypeptide (OSTβ) (Wang et 
al., 2001; Seward et al., 2003). Transport mediated by OSTαβ is facilitated diffusion, 
indicating this transporter plays dual roles of basolateral efflux in intestinal absorption and 
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basolateral uptake in intestinal secretion (Ballatori et al., 2005). Besides bile acids, Ostαβ is 
capable of transporting other endogenous and xenogenous steroid compounds including E1S, 
digoxin, and prostaglandin E2 (Wang et al., 2001; Seward et al., 2003; Ballatori, 2005). 
Interestingly, these compounds are also substrates for OATPs.  
Multidrug resistance-associated proteins (MRPs) belong to the subfamily C of the 
ABC gene superfamily (ABCC). The members of MRPs predominantly transport anionic 
substances, which contrasts with P-gp transporting lipophilic cationic compounds (Reid et 
al., 2003b). MRPs 1-5 are expressed with differential expression profiles in human intestinal 
segments; MRP3 is the most abundantly expressed isoform in the human intestine, followed 
by MRP2 (Zimmermann et al., 2005). In Caco-2 cells, MRP2 is the most highly expressed 
MRP isoform, followed by MRP3 and MRP4 (Prime-Chapman et al., 2004). MRP2 was 
localized to apical membranes in rat small intestine (Mottino et al., 2000). Basolateral 
localization was assumed for other MRPs (Deeley et al., 2006); however, only Mrp3 showed 
clear basolateral localization in rat small intestine and colon (Rost et al., 2002). MRP4 shows 
tissue-specific localization, which is expressed in apical membrane of kidney tubules (van 
Aubel et al., 2002) and in basolateral membrane of hepatocytes (Rius et al., 2003). However, 
its localization in enterocytes is unclear. 
In this study, vectorial transport of fexofenadine involving specific apical uptake and 
basolateral efflux transporters was studied in Caco-2 cells. The results showed that 
OATP2B1 mediates apical uptake of fexofenadine and that P-gp, and to a lesser extent 
MRP2, attenuates the uptake across this membrane. The results also show that MRP3 
mediates its efflux across the basolateral membrane, and may play a critical role in the 
intestinal absorption of fexofenadine under certain circumstances. 
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C. MATERIALS AND METHODS 
Materials 
MDCKII, CHO and Caco-2 cells were obtained from the American Tissue Culture 
Collection (Manassas, VA). Dulbecco's Modified Eagle Medium (DMEM), F-12 Nutrient 
Mixture and Eagle's minimum essential medium (EMEM) with Earle's salts and L-glutamate, 
nonessential amino acids (NEAA, 100x), N-hydroxyethylpiperazine-N'-2-ethanesulfonate 
(HEPES, 1M) and penicillin-streptomycin-amphotericin B solution (100x) were obtained 
from Gibco Laboratories (Grand Island, NY). Fetal bovine serum (FBS) and trypsin-EDTA 
solution (1x) were obtained from Sigma Chemical Co. (St. Louis, MO). Hank's balanced salt 
solution (HBSS) was obtained from Mediatech, Inc. (Herndon, VA). Geneticin and 
hygromycin B were obtained from Invitrogen Co. (Carlsbad, CA). [3H]E1S (77 Ci/mmol), 
[3H]L-carnitine and [3H]MPP+ (85 Ci/mmol) were obtained from American Radiolabeled 
Chemicals (St. Louis, MO). [3H]fexofenadine (53 Ci/mmol) was obtained as a gift from 
GlaxoSmithKline (Research Triangle Park, NC) and originally custom synthesized by 
Amersham Life Sciences (Piscataway, NJ). GW918 was obtained as a gift from 
GlaxoSmithKline (Research Triangle Park, NC). Other chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO). 
OCTN2 and OATP2B1 cDNAs in pcDNA3.1/hygro vector were provided by 
Professor Heyo K. Kroemer (Ernst Moritz Arndt University, Germany) and Professor 
Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany), respectively. 
hOCT3 cDNA in pSPORT1 vector was provided by Dr. Vadivel Ganapathy (Medical 
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College of Georgia, Augusta, GA) and was subcloned into pcDNA3.1 vector (Invitrogen, 
Carlsbad, CA). 
Cell Culture and Transfection 
MDCKII cells were transfected with pcDNA3.1 empty vector or the vectors 
containing the full-length hOCTN2 and OATP2B1 cDNAs using the Nucleofector System 
(Amaxa, Gaithersburg, MD) according to the manufacturer's protocol. Transfectants were 
selected with 0.2 mg/ml hygromycin B for 10 days. A clone with the highest uptake activity 
with respect to the probe substrate, [3H]L-carnitine and [3H]E1S for hOCTN2 and 
OATP2B1, respectively, was chosen as a stably transfected cell line for further studies. The 
stably transfected MDCKII cells were cultured in DMEM with 10% FBS, 10% NEAA, 100 
unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B plus 0.2 mg/ml 
hygromycin B. CHO cells, stably transfected with hOCT3, and the mock cells were 
constructed with a similar method. The transfectants were selected with 0.5 mg/ml geneticin, 
and further screened for the highest uptake activity of model substrate, [3H]MPP+.  The 
stably transfected CHO cells were cultured in F-12 Nutrient Mixture with 10% FBS, 100 
unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B plus 0.5 mg/ml 
geneticin. Caco-2 cells were cultured in EMEM, supplemented with 10% FBS, 1% NEAA, 
100 unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. Caco-2 cells 
were seeded at a density of 60,000 cells/cm2 on TranswellTM filters. Medium was changed 
the day after seeding, and every other day thereafter. The cells were cultured for 21-25 days 
before use. All cell lines were grown at 37°C in a humidified atmosphere with 5% CO2. 
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RT-PCR 
Total RNA was isolated from Caco-2 cells using TRIzol® reagent (Invitrogen, 
Carlsbad, CA). First-strand cDNA synthesis was performed with 1 µg total RNA and random 
hexamer primers. Normalized first-strand cDNA from human ileum was a part of the Human 
Digestive System MTCTM panel (BD Clontech, Palo Alto, CA). Gene-specific primers were 
designed based on the published gene sequences (Seward et al., 2003). Multiplex 
amplification reactions (target gene and β-actin) were performed on a Robocycler 96 PCR 
system (Stratagene, La Jolla, CA) for 25 cycles. Reactions contained 5 ng of cDNA from 
tissue mRNA or 150 ng of cDNA from Caco-2 total RNA. The PCR products were analyzed 
by electrophoresis in agarose gel containing ethidium bromide. 
Uptake Studies 
Stably transfected MDCKII or CHO cells were grown in monolayers in 24-well 
plates. Medium was changed every other day. The cells were used 5-7 days post-seeding. 
Cells were pre-incubated for 30 minutes at 37ºC in transport buffer (HBSS with 25 mM D-
glucose and 10 mM HEPES pH 7.4). Experiments were initiated by replacement of the 
transport buffer with 400 µl ml of dose solution. Uptake was determined within the linear 
uptake region after which the dose solution was aspirated and cells were washed three times 
with 4ºC transport buffer. Cells were dissolved in 500 µl 0.1 N NaOH/0.1% SDS for 4 hours 
with shaking. Radioactivity was determined by scintillation counting. Protein content was 
determined by the BCA protein assay (Pierce, Rockford, IL) with bovine serum albumin as a 
standard. 
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Uptake studies were also conducted in Caco-2 cells grown on TranswellTM filters. 
Cell monolayers were pre-incubated for 30 min at 37ºC in transport buffer. Experiments were 
initiated by replacement of the apical transport buffer with 400 µl of transport buffer 
containing test compounds in the absence or presence of inhibitors. Uptake was determined 
within the linear uptake region, after which the monolayers were washed three times and 
dissolved in 500 µl 0.1 N NaOH/0.1% SDS for 4 hours with shaking. Radioactivity was 
determined with the same method as the uptake study in the transfected cells. 
Efflux Studies 
Caco-2 cell monolayers were incubated for 1 hour with 100 µM fexofenadine in both 
apical and basolateral sides in the absence or presence of inhibitors. After washing both sides 
3 times with cold transport buffer, efflux was determined over 2 minutes in the absence or 
presence of inhibitors. Then monolayers were dissolved in 300 µl 1% Triton X-100 for 4 
hours with shaking and the solution was extracted with 1 ml ethyl acetate. The organic phase 
was evaporated to dryness under nitrogen gas, and the residue was reconstituted with 200 µl 
25% methanol. The effluxed and cellular samples were analyzed by LC-MS/MS with 
cetirizine as an internal standard. The effluxed and cellular amounts together added up to the 
total loaded amount in the cells, and efflux clearance was calculated based efflux rates and 
cellular concentration after loading. 
Transport Studies 
Caco-2 cell monolayers were incubated for 30 min with the transport buffer with or 
without inhibitors. Transport studies were initiated by replacing donor chambers with 10 µM 
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fexofenadine in the absence or presence of inhibitors. Receptor chambers were sampled at 
selected times and analytes were quantified by LC-MS/MS. 
LC-MS/MS Analysis of Fexofenadine 
LC-MS/MS was performed using API-4000 triple-quadropole mass spectrometer 
(Applied Biosystems, Foster City, CA). Mobile phases of 0.1% formic acid in water and 
0.1% formic acid in methanol were used with a 5-95% methanol linear gradient. The column 
used was a Phenomenex Synergy Polar RP, 30 x 2 mm (Phenomenex, Torrance, CA). A flow 
rate of 0.8 ml/min and injection volume of 15 µl were utilized. Samples were ionized using 
APCI and ions were monitored at the following transitions: 503/466 for fexofenadine and 
389/201 for the internal standard, cetirizine.  
Immunofluorescent Staining 
 Caco-2 cells were grown on 6.5-mm diameter TranswellTM inserts for the purpose of 
immunostaining. Inserts were washed three times in phosphate-buffered saline (PBS); similar 
washes were included between each of the following stages. Cells were fixed in 1% 
paraformaldehyde for 15 min and then permeabilized with 0.1% Triton X-100 for 10 min. 
Nonspecific binding sites were blocked by incubation for 30 min with 5% normal sheep 
serum. Inserts were incubated in primary antibody M3II-9 (Covance, Berkeley, CA) (diluted 
to 5 µg/ml with PBS) for 60 min. Primary antibody was detected by incubation with Alexa 
Flour 488 goat anti-mouse antibody for 60 min. Inserts were washed and mounted in 
Permount* Mounting Medium (Fisher Scientific, Pittsburgh, PA). Staining was viewed using 
a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss Inc., Thornwood, NY). 
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Data Analysis 
Data are expressed as mean ± S.D. from three measurements unless otherwise noted. 
Statistical significance was evaluated using unpaired t tests or ANOVA followed by 
Dunnet’s test for multiple comparisons as appropriate. The data were analyzed with 
SigmaStat 2.0 (Systat Software, Inc., San Jose, CA). Uptake clearance (CLup) was determined 
using Equation (1): 
o
up C
dt
dX
CL =      (1) 
where dX/dt is the flux determined from the amount taken up (X) over time (t) during the 
experiment, and Co is the initial concentration in the donor side. Kinetic constants (Jmax, Km 
and Kd) were obtained by fitting a model incorporating saturable and nonsaturable 
components to the uptake data at 37ºC. The following model was utilized: 
                                                 CK
CK
CJJ d
m
**max ++=     (2) 
where Jmax is the maximal uptake rate, Km is the kinetic constant for saturable uptake, Kd is 
the kinetic constant for nonsaturable uptake, and C is the fexofenadine concentration. 
Apparent permeability (Papp) was determined using Equation (3): 
o
app CA
dt
dQ
P ⋅=      (3) 
where dQ/dt is the flux determined from the amount transported (Q) over time (t) during the 
experiment, A is the surface area of the porous membrane, and Co is the initial concentration 
in the donor side. Efflux clearance (CLeff) was calculated using Equation (4): 
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o
eff C
dt
dX
CL =      (4) 
where dX/dt is the amount effluxed (X) over time (t) determined in the linear region of efflux 
and Co is the initial concentration of fexofenadine loaded in the cells. Initial intracellular 
concentrations were calculated using the amount loaded at t = 0 and Caco-2 cellular volume 
of 3.66 µl/mg protein (Bourdet and Thakker, 2006). 
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D. RESULTS 
Uptake of Fexofenadine into MDCKII Cells that are Stably Transfected with 
OATP2B1, hOCT3, and hOCTN2 
As shown in Figure 2.1A, uptake of 10 nM [3H]E1S at pH 6.0 into the OATP2B1-
expressing MDCKII was 8.7-fold (p < 0.001) greater than that in the mock cells and was 
abolished by 200 µM unlabeled E1S. Uptake of [3H]fexofenadine at pH 6.0 into MDCKII-
OATP2B1 cells was 2.3-fold (p < 0.01) greater than that into the mock cells, and was also 
abolished by 200 µM unlabeled E1S (Figure 2.1B). Uptake of [3H]MPP+ (model substrate for 
hOCT3) and [3H]L-carnitine (model substrate for hOCTN2) into CHO-hOCT3 or MDCK-
hOCTN2 cells was 7.7-fold or 89-fold greater, respectively, than those into the mock cells, 
and was abolished by high concentrations of the unlabeled model substrates (Figures 2.2A 
and 2.3A). However, uptake of [3H]fexofenadine into CHO-hOCT3 and MDCK-hOCTN2 
cells was equivalent to the control and was not affected by the unlabeled model substrates 
(Figures 2.2B and 2.3B). 
pH-dependent Apical Uptake of Fexofenadine into Caco-2 Monolayers 
As shown in Figure 2.4A, uptake of 10 nM [3H]E1S at pH 6.0 was 1.7-fold (p < 0.05) 
greater than that at pH 7.4 into the apical membrane of Caco-2 cells and was reduced by 200 
µM unlabeled E1S (p < 0.01). As shown in Figure 2.4B, uptake of 100 nM [3H]fexofenadine 
at pH 6.0 was 1.9-fold (p < 0.01) greater than that at pH 7.4 into the apical membrane of 
Caco-2 cells, and unlabeled E1S (200 µM) reduced the uptake at pH 6.0 by 40% (p < 0.05), 
but not at pH 7.4. 
72 
Basolateral Uptake of Fexofenadine into Caco-2 Monolayers 
As shown in Figure 2.5, RT-PCR of RNA isolated from Caco-2 cells and human 
ileum gave the bands at 526 and 254 base pairs for OSTα and OSTβ, respectively, and 
demonstrated the presence of mRNAs of these two subunits in Caco-2 cells. Basolateral 
uptake of [3H]E1S into Caco-2 cells showed a combination of saturable and passive diffusion 
mechanism (Km = 589 µM, Vmax = 36 pmol/mg/min, and Kd = 0.012 µl/mg/min) (Figure 
2.6A). The Km value was comparable with that in oocytes expressing hOSTαβ (320 µM) 
(Seward et al., 2003). Digoxin (500 µM), another hOSTαβ substrate/inhibitor (Seward et al., 
2003), inhibited basolateral uptake of [3H]E1S (10 nM) by 45% (p < 0.01), whereas 500 µM 
fexofenadine did not reduce it in Caco-2 cells (Figure 2.6B). In addition, both E1S and 
digoxin at 500 µM did not reduce the basolateral uptake of 100 nM [3H]fexofenadine in 
Caco-2 cells, neither did 500 µM unlabeled fexofenadine (Figure 2.6C). 
Apical and Basolateral Efflux of Fexofenadine in Caco-2 Monolayers 
The cellular localization of MRP3 in Caco-2 was examined by confocal laser 
scanning microscopy. As shown in Figure 2.7, MRP3 was localized in the basolateral 
membrane of Caco-2 cells, as expected based on its localization in rat intestine (Rost et al., 
2002). As shown in Figure 2.8A, GW918 (1 µM) and MK-571 (25 µM) stimulated the 
accumulation of fexofenadine into Caco-2 cells by 4-fold (p < 0.01) and 2-fold (p < 0.05), 
respectively, when cells were exposed from both sides. After preloading, fexofenadine was 
preferentially transported out of the cells across the apical membrane (2-fold, p < 0.01), 
whereas efflux to the basolateral side was preferred by 1.5-fold (p < 0.01) when P-gp was 
inhibited (Figures 2.7B and 2.7C). MK-571 inhibited the efflux of cellular fexofenadine 
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across the apical and basolateral membranes by 41% (p < 0.05) and 57% (p < 0.05), 
respectively (Figures 2.8B and 2.8C).  GW918 nearly completely inhibited apical efflux (p < 
0.01) and also inhibited basolateral efflux of fexofenadine (p < 0.05) (Figure 2.8B). 
Absorptive and Secretory Transport of Fexofenadine across Caco-2 Monolayers 
As shown in Figure 2.9A, MK-571 (25 µM) decreased absorptive transport by 17% 
whereas GW918 (1 µM) increased the transport by 2.3-fold (p < 0.01). When P-gp was 
inhibited with GW918, further treatment with MK-571 decreased the transport rate by 42% 
(p < 0.01).  MK-571 alone increased secretory transport of fexofenadine by 32% (p < 0.05) 
(Figure 2.9B). 
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E. DISCUSSION 
Fexofenadine is a zwitterionic compound that must depend on one or more intestinal 
transporter(s) for oral absorption.  The observation that fruit juices decreased oral absorption 
of fexofenadine in humans, possibly by inhibiting intestinal uptake transporter, supported the 
notion that transporters contribute to intestinal absorption of fexofenadine (Dresser et al., 
2002). However, the identity of the specific uptake transporter involved in the intestinal 
absorption of fexofenadine remains unclear. OATP1A2 was first suggested to mediate the 
apical uptake of fexofenadine into enterocytes (Dresser et al., 2002; Glaeser et al., 2007). 
However, the studies from several other groups did not show the presence of OATP1A2 
mRNA in human intestine (Tamai et al., 2000; Hilgendorf et al., 2007; Meier et al., 2007) or 
Caco-2 cells (Hilgendorf et al., 2007), casting doubt on the role of OATP1A2 in the intestinal 
absorption of fexofenadine.  OATP2B1 is highly expressed in human jejunum (Hilgendorf et 
al., 2007; Meier et al., 2007) and Caco-2 cells (Hilgendorf et al., 2007), and has been 
localized in the apical membrane of human small intestine (Kobayashi et al., 2003). The 
results of this study showed that among the apical intestinal transporters tested, OATP2B1, 
but not OCT3 or OCTN2, stimulated uptake of [3H]fexofenadine into transfected cells. In 
addition, apical uptake of [3H]fexofenadine in Caco-2 cells was decreased by 45% with 200 
µM E1S at pH 6.0, but not at pH 7.4, which is consistent with a greater activity of OATP2B1 
at lower pH (Nozawa et al., 2004; Shimizu et al., 2005). This result supported the proposition 
that OATP2B1 mediates apical uptake of fexofenadine into Caco-2 cells at acidic pH because 
OATP2B1 is the only OATP isoform showing pH dependent activity. OATP2B1-mediated 
uptake of fexofenadine may be the major transport mechanism in vivo because of the acidic 
microclimate in small intestine (Daniel et al., 1985). These results also explain why 
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OATP2B1 would not play a significant role in hepatic uptake of fexofenadine because of the 
minimal activity of this transporter in fexofenadine uptake at neutral pH of the blood. 
This study also showed that basolateral efflux of fexofenadine is mediated by a MK-
571-sensitive transporter,3 but not OSTαβ in Caco-2 cells. OSTαβ is a bidirectional 
facilitative transporter mediating both uptake and efflux processes. In this report, we first 
showed the presence of OSTαβ mRNAs (Figure 2.5) and the functional activity of E1S 
transport in the basolateral side of Caco-2 cells (Figure 2.6A). However, fexofenadine did not 
inhibit the basolateral uptake of E1S in Caco-2 cells, although the OSTαβ substrate, digoxin, 
inhibited E1S uptake by this transporter (Figure 2.6B). In additioin, OSTαβ 
substrates/inhibitors did not decrease uptake of [3H]fexofenadine across the basolateral 
membrane of Caco-2 cells (Figure 2.6C). Furthermore, the basolateral uptake of 
fexofenadine, up to 500 µM, did not show a saturable mechanism (Figure 2.6C). Therefore, 
we concluded that the basolateral transport of fexofenadine does not involve OSTαβ. 
However involvement of other facilitative transporters cannot be ruled out. 
In contrast, the MRP inhibitor, MK-571, reduced the basolateral efflux of 
fexofenadine from pre-loaded Caco-2 cells, suggesting that the basolateral MRPs mediate 
transport of fexofenadine out of Caco-2 cells. The leukotriene LTD4 receptor antagonist 
MK-571 specifically modulates MRP associated multidrug resistance, but not the drug 
resistance of P-gp (Gekeler et al., 1995). MK-571 is an effective inhibitor of MRP2 (Chen et 
al., 1999), MRP3 (Zeng et al., 2001) and MRP4 (Reid et al., 2003a), and showed the highest 
potency (IC50 ≈ 5 µM), inhibiting MRP3-mediated methotrexate transport among 17 
inhibitors tested in that study (Zeng et al., 2001). MK-571 also inhibits hepatic transporter 
OATP1B3 (Letschert et al., 2005). However, this transporter is not expressed in human 
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intestine and Caco-2 cells (Hilgendorf et al., 2007). Furthermore, MK-571 at 25 µM did not 
inhibit apical and basolateral uptake of fexofenadine into Caco-2 cells. Also, at this 
concentration MK-571 did not inhibit uptake of [3H]E1S in OATP2B1 transfected MDCKII 
cells; only at the highest concentration tested (500 µM), it inhibited [3H]E1S uptake by 30%. 
These results indicated that the modulation of fexofenadine transport by MK-571 in Caco-2 
cells is not due to inhibition of OATPs. While this article was in preparation, Matsushima et 
al. reported that fexofenadine was a substrate for MRP3, but not for MRP4 (Matsushima et 
al., 2008a), and that Mrp3 played an important role in sinusoidal efflux of this drug in mice 
(Matsushima et al., 2008a; Tian et al., 2008a). Immunofluorescence studies using laser 
scanning confocal microscopy showed that MRP3 was localized to the basolateral membrane 
of Caco-2 cells. Combination of the results from the literature and this study led to the 
conclusion that basolateral MRP3 in Caco-2 cells mediates the efflux of fexofenadine out of 
the cells. The results also showed that MK-571 reduced the apical efflux of fexofenadine 
from preloaded Caco-2 cells. MRP2 was localized to the apical membrane of enterocytes 
(Mottino et al., 2000), indicating that MRP2 may be another transporter mediating apical 
efflux of fexofenadine besides P-gp. A recent study on hepatic disposition of fexofenadine 
supported this observation, showing that Mrp2 is primarily responsible for the biliary 
excretion of fexofenadine in mice (Tian et al., 2008b). 
Inhibition of MRPs reduced the absorptive transport moderately, whereas inhibition 
of P-gp increased the transport over 2-fold. The results showed that when P-gp is present, 
modulation of MRPs does not affect the overall transport rate dramatically, indicating that 
apical entry, predominantly influenced by P-gp-mediated efflux is rate-limiting in absorptive 
transport of fexofenadine in Caco-2 cells. However, when P-gp is inhibited, MRP inhibition 
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can decrease the overall rate by over 40%, clearly providing evidence for the role of an MRP 
transporter, presumably MRP3, in the basolateral efflux and vectorial absorptive transport of 
fexofenadine in Caco-2 cell monolayers. The role of MRP3 in mediating basolateral efflux 
was likely underestimated because apical MRP2 is also inhibited with MK-571, and this 
inhibition leads to an increase in the absorptive transport rate, counteracting the effect of 
inhibition of basolateral MRP3. Further work is needed to design effective siRNA sequence 
to suppress MRP2 or MRP3 specifically in Caco-2 cells in order to fully elucidate the roles 
of apical MRP2 and basolateral MRP3 in the intestinal absorption of fexofenadine. It is 
conceivable that basolateral efflux by MRP3 may control absorption rate of fexofenadine in 
human small intestine when P-gp is not fully effective in attenuating the cellular entry of this 
drug across the apical cell membrane. 
Studies described in this report provide a novel insight about the roles of basolateral 
transporters in intestinal drug absorption. In order for a drug with poor membrane 
permeability to cross the intestinal epithelia efficiently, the basolateral transporter is required 
for egress of the drug into the blood side after apical transporters mediate uptake into 
enterocytes. This notion has been established in a study of bile acid absorption, showing that 
knocking out the basolateral transporter Ostαβ in mice almost abolished transileal transport 
of taurocholate (Rao et al., 2008). Altered drug absorption of fexofenadine due to modulation 
of MRP3 activity may have important clinical implications. Concomitant administration of 
the P-gp inhibitor verapamil (1 mM in the jejunal perfusate) failed to increase the effective 
jejunal permeability of fexofenadine (Tannergren et al., 2003b). Verapamil at 1 mM inhibits 
MRP3 activity by 70% (Zeng et al., 2001). Therefore, reduction of MRP3 mediated 
basolateral efflux by verapamil simultaneously may partially explain the failure of 
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modulation of fexofenadine permeability by this P-gp inhibitor. On the other hand, in the 
patients with diminished P-gp activity due to genetic variations or coadministration with a P-
gp inhibitor, inhibition of intestinal MRP3 may reduce fexofenadine bioavailability 
dramatically. Furthmore, hepatic MRP3 attenuates hepatic elimination of fexofenadine 
(Matsushima et al., 2008b; Tian et al., 2008a) and, thus, increases the systemic exposure of 
this drug, which is synergistic with the function of intestinal MRP3 defined in this study. 
Therefore, the synergistic action of MRP3 in the intestine and liver will produce more 
dramatic effects on pharmacokinetics of fexofenadine, and, thereafter, the magnitude and 
duration of fexofenadine actions. Pharmacokinetic studies of fexofenadine in Mrp3 knockout 
mice, and further studies in humans are required to define the in vivo function of MRP3 in 
oral absorption of drugs. Collectively, the vectorial transport system consisting of apical 
OATP2B1 and basolateral MRP3 (and/or other basolateral MRPs) may be an important 
pathway to deliver hydrophilic anionic and zwitterionic drugs such as pravastatin and 
fexofenadine into human bodies. 
79 
F. ACKNOWLEDGEMENTS 
We gratefully acknowledge Professor Heyo K. Kroemer (Ernst Moritz Arndt 
University, Germany) for providing the plasmid of pcDNA3.1/hygro/hOCTN2, Professor 
Dietrich Keppler (German Cancer Research Center, Germany) for providing the plasmid of 
pcDNA3.1/hygro /OATP2B1 and Dr. Vadivel Ganapathy (Medical College of Georgia, 
USA) for providing the plasmid of pSPORT1/hOCT3. Xin Ming was supported by Eli Lilly 
Pre-Doctoral Fellowship. 
 80 
 
Figure 2.1. Uptake clearance of [3H]E1S (A) and [3H]fexofenadine (B) in MDCKII cells 
stably transfected with OATP2B1. MDCKII cells stably transfected with empty plasmid 
(Mock) or OATP2B1 cDNA (OATP2B1) were incubated with 10 nM  [3H]E1S (A) or 100 
nM [3H]fexofenadine (B) in the absence (solid bar) or presence (blank bar) of 200 µM 
unlabelled E1S for 3 minutes and uptake clearance of test compounds in these cells was 
determined. Data represent mean ± S.D. of a representative experiment in triplicate. *** p < 
0.001, ** p < 0.01 and * p < 0.05 compared with uptake in mock cells. 
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Figure 2.2. Uptake clearance of [3H]MPP+ (A) and [3H]fexofenadine (B) in CHO cells stably 
transfected with hOCT3. CHO cells stably transfected with empty plasmid (Mock) or hOCT3 
cDNA (hOCT3) were incubated with 1  µM  [3H]MPP+ (A) or 100 nM [3H]fexofenadine (B) 
in the absence (solid bar) or presence (blank bar) of 500 µM unlabelled MPP+ for 3 minutes 
and uptake clearance of test compounds in these cells was determined. Data represent mean ± 
S.D. of a representative experiment in triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 
compared with uptake in mock cells. 
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Figure 2.3. Uptake clearance of [3H]L-carnitine (A) and [3H]fexofenadine (B) in MDCKII 
cells stably transfected with hOCTN2. MDCKII cells stably transfected with empty plasmid 
(Mock) or hOCTN2 cDNA (hOCTN2) were incubated with 10 nM  [3H]L-carnitine (A) or 
100 nM [3H]fexofenadine (B) in the absence (solid bar) or presence (blank bar) of 500 µM 
unlabelled L-carnitine for 3 minutes and uptake clearance of test compounds in these cells 
was determined. Data represent mean ± S.D. of a representative experiment in triplicate. *** 
p < 0.001, ** p < 0.01 and * p < 0.05 compared with uptake in mock cells. 
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Figure 2.4. pH-specific apical uptake clearance of [3H]E1S (A) and [3H]fexofenadine (B) in 
Caco-2 cells. Caco-2 cells were incubated at pH 6.0 and pH 7.4 from the apical side with 10 
nM  [3H]E1S (A) or 100 nM [3H]fexofenadine (B) in the absence (solid bar) or presence 
(blank bar) of 200 µM unlabelled E1S for 3 minutes and uptake clearance of test compounds 
in these cells was determined. Data represent mean ± S.D. of a representative experiment in 
triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with control. 
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Figure 2.5. Detection of hOSTαβ mRNA in Caco-2 cells by RT-PCR. Lane 1, 100 bp DNA 
ladder; Lane 2, hOSTα in Caco-2 cells; Lane 3, hOSTα in human ileum; Lane 4, hOSTα in 
water; Lane 5, hOSTβ in Caco-2 cells; Lane 6, hOSTβ in human ileum; Lane 7, hOSTβ in 
water. 
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Figure 2.6. Basolateral uptake of [3H]E1S (A, B) and [3H]fexofenadine (C) in Caco-2 cells. 
(A). Basolateral uptake of [3H]E1S in Caco-2 cells was determined over 3 minutes at the 
indicated concentrations. The solid, dashed and dotted lines represent the best fit to the 
[3H]E1S uptake data, the saturable and passive components of the uptake, respectively. (B). 
Basolateral uptake of [3H]E1S in Caco-2 cells was determined over 3 minutes in the absence 
(CTL) or presence of 500 µM unlabelled digoxin (DIG) or 500 µM fexofenadine (FEX). (C). 
Basolateral uptake of [3H]fexofenadine in Caco-2 cells was determined over 3 minutes in the 
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absence (CTL) or presence of 500 µM unlabelled digoxin (DIG), 500  µM  E1S (E1S) or 500 
µM fexofenadine (FEX). Data represent mean ± S.D. of a representative experiment in 
triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with control. 
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Figure 2.7. Immunostaining for MRP3 in Caco-2 cell monolayers. Indirect 
immunofluorescent staining was performed and viewed via confocal laser scanning 
microscopy. The X-Y image (center) is shown as projections through the whole plane of the 
cell monolayer viewed en face, and perpendicular X-Z (upper) and Y-Z (right) images are 
shown. 
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Figure 2.8. Accumulation (A) of fexofenadine in Caco-2 cells and its efflux (B, C) from the 
pre-loaded cells. Accumulation of fexofenadine from apical and basolateral sides of Caco-2 
monolayers was determined over 1 hour in the absence (CTL) or presence of 25 µM MK-
571, 1 µM GW918 or both. (B). Apical efflux clearances of fexofenadine from Caco-2 
monolayers was determined over 3 minutes after 1-hour preloading in the absence (CTL) or 
presence of 25 µM MK-571, 1 µM GW918 or both.  (C). Basolateral efflux clearances of 
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fexofenadine from Caco-2 monolayers was determined over 3 minutes after 1-hour 
preloading in the absence (CTL) or presence of 25 µM MK-571, 1 µM GW918 or both. Data 
represent mean ± S.D. of a representative experiment in triplicate. *** p < 0.001, ** p < 0.01 
and * p < 0.05 compared with control. 
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Figure 2.9. Absorptive and secretory transport of fexofenadine across Caco-2 cells. (A). 
Absorptive transport of fexofenadine across Caco-2 monolayers was determined in the 
absence (CTL) or presence of 25 µM MK-571, 1 µM GW918 or both. (B). Secretory 
transport of fexofenadine across Caco-2 monolayers was determined in the absence (CTL) or 
presence of 25 µM MK-571, 1 µM GW918 or both. Data represent mean ± S.D. of a 
representative experiment in triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared 
with control. 
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CHAPTER 3 
 
 
 
MRP4 MEDIATES BASOLATERAL EFFLUX OF ADEFOVIR FORMED IN 
CACO-2 CELLS FROM ITS PRODRUG - ADEFOVIR DIPIVOXIL 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics and is presented in the style of that journal.
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A. ABSTRACT. 
Adefovir dipivoxil, a diester prodrug of the antiviral drug adefovir, shows higher oral 
bioavailability than the active drug (32-45% compared to <12%). The prodrug is known to be 
metabolized completely into the active drug in the enterocytes. However, it is not known how 
the highly charged and hydrophilic active drug crosses the basolateral membrane in the 
intestine. The purpose of this study is to determine the role of specific basolateral 
transporter(s) in the egress of adefovir using Caco-2 cell monolayers as a model of intestinal 
epithelium. Results showed that multidrug resistance-associated protein 4 (MRP4), a known 
adefovir transporter, plays a role in its basolateral efflux when generated from adefovir 
dipivoxil in Caco-2 cells. Western blotting of Caco-2 cell lysates showed the presence of 
MRP4 protein in this cell line. Images of confocal microscopy showed that MRP4 is 
localized in the basolateral membrane of Caco-2 cells. This localization was further 
confirmed by Western blotting of the basolateral membrane fractions isolated by a novel 
method involving biotinylation of membrane proteins followed by affinity enrichment. 
MRP4-knockdown Caco-2 cells, constructed using a pRNATin-H1.2 siRNA expression 
vector, showed reduced MRP4 protein expression and 39% reduction in the availability of 
adefovir on the basolateral side when dosed with [3H]adefovir dipivoxil on the apical side. 
These results established that MRP4 plays a significant role in the egress of adefovir across 
the basolateral membrane of Caco-2 cells. A comparable reduction in the availability of 
adefovir on the basolateral side (48%) by the general MRP inhibitor indomethacin (30 µM) 
further established that among the MRP transporters, MRP4 plays a predominant role in the 
basolateral egress of adefovir in Caco-2 cells. The results highlight the importance of the 
basolateral MRP4 in oral absorption of adefovir dipivoxil, and suggest that the oral 
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bioavailability of adefovir can be significantly affected if an MRP4 inhibitor is co-
administered with the prodrug, adefovir dipivoxil. 
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B. INTRODUCTION. 
Acyclic nucleotide phosphonate adefovir is a reverse transcriptase inhibitor with the 
activities against a wide range of viruses such as retroviruses, immuno-deficiency virus type 1 
and 2 (HIV1 and HIV2), herpes viruses, and hepadnaviruses (De Clercq, 2003). However, 
the permeability of adefovir across biological membranes is very low due to the presence of 
highly negatively charged phosphonate group (successive pKa’s = 2.0 and 6.8), which results 
in low oral bioavailability of adefovir in humans (less than 12%) (Cundy et al., 1995). 
Therefore, esters of adefovir were synthesized in order to mask the negative charges and 
improve its membrane permeability. Adefovir dipivoxil is one of those prodrugs. 
Bioavailability of adefovir after oral administration of adefovir dipivoxil in humans is 
approximately 32-45% (Barditch-Crovo et al., 1997). The active phosphonate form of 
adefovir was the only component that was detected in plasma after oral administration of 
adefovir dipivoxil in humans (Noble and Goa, 1999), indicating that adefovir dipivoxil is 
converted to the active drug by presystemic metabolism. Further study showed that adefovir 
dipivoxil was not detected in the mesenteric vein in rat intestinal perfusion experiments 
(Annaert et al., 2000), which proved that adefovir dipivoxil is metabolized completely into its 
active phosphonate form in the intestine. The study using Caco-2 cell model confirmed this 
mechanism by showing that adefovir was the major component that was measured from the 
basolateral chamber when adefovir dipivoxil was dosed into the apical chamber of Caco-2 
monolayers (Annaert et al., 1997). Accordingly, intestinal absorptive transport of adefovir 
dipivoxil involves the diffusion of the prodrug across the apical membrane, followed by 
cellular metabolism into adefovir, and subsequent basolateral efflux of this active drug into 
the blood (Figure 3.6). It remains unclear as to how the highly charged and hydrophilic active 
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drug crosses the basolateral membrane of the enterocytes. A previous study showed that the 
basolateral efflux of adefovir in Caco-2 cells may involve a carrier-mediated transport 
process, and that the efflux was not mediated by P-gp (Annaert et al., 1998). Whether 
multidrug resistance-associated proteins (MRPs, ABCC subfamily) were involved in the 
intestinal basolateral efflux of adefovir was not known. 
MRP4, the fourth member of the ABCC family, was initially identified as a homolog 
of MRP1 (ABCC1) by screening databases of human sequence tags (Kool et al., 1997). 
MRP4 was the first MRP isoform identified that does not have a third (N-terminal) 
membrane spanning domain (Kool et al., 1997). The “short” members of this family, MRP4, 
MRP5, MRP8 and MRP9, are distinguished by their ability to transport cyclic nucleotides 
and nucleoside-based agents (Kruh et al., 2007). MRP4 is up-regulated in adefovir-resistant 
cells, which indicated that the enhanced efflux of adefovir by MRP4 leads to this resistance 
(Schuetz et al., 1999). The substrate specificity of MRP4 is particularly broad; it transports 
cAMP, cGMP, p-aminohippurate, urate, dehydroepiandrosterone sulfate, methotrexate, and 
estradiol-17β-D-glucuronide as well as adefovir (Schuetz et al., 1999; van Aubel et al., 2002; 
Zelcer et al., 2003; van Aubel et al., 2005). In human kidney, MRP4 is abundantly expressed 
(Hilgendorf et al., 2007) and localized in the apical membrane of the proximal tubules (van 
Aubel et al., 2002). Adefovir is actively secreted in the urine, and most of the administered 
dose is recovered in the urine as intact drug (Cundy, 1999). It has been established that the 
active renal secretion of adefovir involves uptake into tubular cells by the basolateral organic 
anion transporter 1 (OAT1, SLC22A6) (Cihlar et al., 1999), and the apical efflux into urine 
by MRP4 (Imaoka et al., 2007).  
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Recently, studies with Mrp4 knockout (Mrp4-/-) mice suggested that Mrp4 is 
expressed in mouse intestine (Belinsky et al., 2007). Mrp4-/- mice were significantly more 
sensitive to adefovir, as indicated by a clear separation of the dose-response curves for 
knockout and wild-type mice, and the intestine in the knockout mice suffered increased 
toxicity as compared to the wild-type mice (Belinsky et al., 2007). This result supported the 
notion that Mrp4 prevents the entry of adefovir into the enterocytes from the circulating 
blood in order to protect the enterocytes from the adefovir cytotoxicity; it further suggested 
that Mrp4 is present in the basolateral membrane of the enterocytes. Therefore, it is proposed 
that MRP4 may mediate the basolateral efflux of adefovir formed in the enterocytes during 
oral absorption of adefovir dipivoxil. In the present study, the expression and localization of 
MRP4 was investigated in Caco-2 cells and its possible role in the basolateral efflux of 
adefovir was examined during absorptive transport of adefovir dipivoxil in wild-type and 
MRP4-knockdown Caco-2 cells. 
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C. MATERIALS AND METHODS. 
Materials 
Caco-2 cells were obtained from the American Tissue Culture Collection (Manassas, 
VA). Eagle's minimum essential medium (EMEM) with Earle's salts and L-glutamate, 
nonessential amino acids (NEAA, 100x), N-hydroxyethylpiperazine-N'-2-ethanesulfonate 
(HEPES, 1M) and penicillin-streptomycin-amphotericin B solution (100x) were obtained 
from Gibco Laboratories (Grand Island, NY). Fetal bovine serum (FBS) and trypsin-EDTA 
solution (1x) were obtained from Sigma Chemical Co. (St. Louis, MO). Hank's balanced salt 
solution (HBSS) was obtained from Mediatech, Inc. (Herndon, VA). Geneticin was obtained 
from Invitrogen Co. (Carlsbad, CA). [3H]adefovir dipivoxil (11 Ci/mmol) was obtained from 
Moravek Biochemicals (Brea, CA). Other chemicals were purchased from Sigma (St. Louis, 
MO). 
Cell Culture 
Caco-2 cells were cultured in EMEM, supplemented with 10% FBS, 1% NEAA, 1% 
penicillin-streptomycin-amphotericin B solution at 37°C in a humidified atmosphere with 5% 
CO2. The cells were passaged every 4 days using trypsin-EDTA, and plated at densities of 
1:5 in 75 cm2 T-flasks. Caco-2 cells were seeded at a density of 60,000 cells/cm2 on 
TranswellTM filters. Medium was changed the day after seeding, and every other day 
thereafter. The cells were cultured for 21-25 days before use. Transepithelial electrical 
resistance (TEER) was measured to ensure cell monolayer integrity. Measurements were 
obtained using an EVOM Epithelial Tissue Voltammeter and an Endohm-12 electrode 
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(World Precision Instruments, Sarasota, FL). Cell monolayers with TEER values greater than 
300 Ω•cm2 were used in transport experiments. 
Immunoblot Analysis 
Caco-2 cells were lysed in a solution containing 1% SDS, 1 mM EDTA, and 
complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The protein 
concentration of the clear cell lysate was determined with the BCA protein assay reagent kit 
(Pierce, Rockford, IL) with bovine serum albumin as a standard. Ten or fifty µg of total 
protein per lane were resolved by electrophoresis on NuPAGE 4 to 12% Bis-Tris gel 
(Invitrogen, Carlsbad, CA) and were transferred onto polyvinylidene difluoride membranes 
(Invitrogen, Carlsbad, CA). The membrane was blocked and incubated with the M4I-10 
antibody (0.3 µg/ml) and then with an anti-rat IgG, horseradish peroxidase-linked antibody 
(Pierce, Rockford, IL). Signals were developed using the SuperSignal West Dura Extended 
Duration Substrate (Pierce, Rockford, IL). 
Immunofluorescent Staining 
Caco-2 cells were grown on 6.5-mm diameter TranswellTM inserts (Corning Inc., 
Lowell, MA) for the purpose of immunostaining. Inserts were washed three times in 
phosphate-buffered saline (PBS); similar washes were included between each of the 
following stages. Cells were fixed in 1% paraformaldehyde for 15 minutes and then 
permeabilized with 0.1% Triton X-100 for 10 minutes. Nonspecific binding sites were 
blocked by incubation for 30 minutes with 5% normal sheep serum. Inserts were incubated 
with primary antibody M4I-10 (Axxora, San Diego, CA) diluted to 5 µg/ml with PBS, for 60 
minutes. Primary antibody was detected by incubation with Alexa Flour 568 goat anti-rat 
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antibody for 60 minutes. Cell nuclei were stained with SYTO® 13 or DAPI (Invitrogen, 
Carlsbad, CA). Inserts were washed and mounted in Permount* Mounting Medium (Andwin 
Scientific, Addison, IL). Staining was viewed using a Zeiss LSM 510 laser scanning confocal 
microscope (Carl Zeiss Inc., Thornwood, NY). To obain X-Z image in immunostaining 
Caco-2 cells, inserts were frozen in Tissue-Tek Cryo-OCT Compound (Fisher Scientific, 
Pittsburgh, PA) and sectioned in longitudinal direction. 
Immunoblot Analysis of Apical and Basolateral Membrane Fractions of Caco-2 Cells 
Caco-2 cells were grown on six-well TranswellTM filters with the method described 
above. Biotinylation experiments were conducted 21 days post-seeding using the Cell 
Surface Protein Isolation Kit (Pierce, Rockford, IL) according to the manufacturer's protocol 
with modifications. After washing with ice-cold PBS, sulfo-N-hydroxysuccinimide-SS-biotin 
(1.5 mg/ml in PBS) was added to the apical chambers of three TranswellTM filters or the 
basolateral chambers of the other three TranswellTM filters and incubated for 30 minutes at 
4°C. Cells were washed three times with PBS, containing 100 mM glycine, and incubated for 
20 minutes at 4°C with the same buffer. Cells were washed with PBS, scraped into 1 ml of 
PBS, and pelleted by centrifugation at 800g for 2 minutes. The pellet was treated with 700 µl 
of lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100, 
pH 7.4, and protease inhibitors) for 1 h at 4°C with shaking. Cell lysates were spun at 
16,000g for 10 minutes and the supernatant was added to the column with NeutrAvidin™ 
Gel. The column was incubated for 60 minutes at room temperature with end-over-end 
mixing and then was washed with the washing buffer 4 times. The biotinylated proteins were 
released by incubation of the gel with 2 x Laemmli buffer for 30 minutes at room 
temperature. Samples of the biotinylated fractions (25 µl) were subjected to Western analysis 
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for detection of MRP4 with M4I-10 antibody (Axxora, San Diego, CA) after they were 
diluted to 0.3 µg/ml with PBS, and for detection of the basolateral protein Na+-K+ ATPase 
with the antibody (Abcam, Cambridge, MA) after dilution to 0.4 µg/ml. 
siRNA Knockdown Experiments 
An siRNA sequence was designed to silence the MRP4 gene expression based on a 
published report (Reid et al., 2003b). Chemically synthesized oligonucleotide encoding the 
siRNA sense strand, 5'-gatcccaatcctgcacatgcaccatcttgatatccggatggtgcatgtgcaggattttttttccaaa-
3', was annealed with the complementary DNA oligonucleotide, 5'-agcttttggaaaaaaaatcctgca-
catgcaccatccggatatcaagatggtgcatgtgcaggattgg-3'. The resulting double-stranded DNA was 
inserted into the BamH I and Hind III sites of the pRNATin-H1.2/Hygro vector (GenScript, 
Piscataway, NJ). Caco-2 cells at 60% confluence were transfected with the MRP4 siRNA 
plasmid, using the Nucleofector System (Amaxa, Gaithersburg, MD) according to the 
manufacturer's protocol specific to Caco-2 cells. Transfectants were selected with 0.2 mg/ml 
hygromycin B for 3 weeks and screened by Western blot for MRP4 expression. A clone with 
the lowest MRP4 expression was chosen as a stably transfected cell line for further functional 
study. 
Accumulation Study 
MRP4-knockdown and wild-type Caco-2 cells were seeded at 5 x 105 cells per well in 
six-well plates and grown for 48 hours. Cells were incubated with 10 µM [3H]adefovir 
dipivoxil in the absence or presence of 30 µM indomethacin for 2 hour. Then the dose 
solution was aspirated and cells were washed three times with 4ºC transport buffer. Cells 
were dissolved in 500 µl 0.1 N NaOH/0.1% SDS for 4 hours with shaking. Radioactivity was 
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determined by scintillation counting. Protein content was determined by the BCA protein 
assay (Pierce, Rockford, IL) with bovine serum albumin as a standard. 
Transport Studies 
Caco-2 cell monolayers were incubated for 30 minutes with transport buffer in the 
absence or presence of 30 µM indomethacin. Transport studies were initiated by replacing 
the donor chamber solution with 10 µM [3H]adefovir dipivoxil with or without 30 µM 
indomethacin. The receptor chamber was sampled at selected times and radioactivity was 
determined by scintillation counting. 
Data Analysis 
Data are expressed as mean ± SD from three measurements unless otherwise noted. 
Statistical significance was evaluated using t-test or ANOVA followed by Dunnet’s test for 
multiple comparisons. The data were analyzed with SigmaStat 2.0 (Systat Software, Inc., San 
Jose, CA). 
Basolateral availability (Fb) was defined as a new parameter to represent the 
availability of adefovir in the basolateral (receptor) compartment after dosing adefovir 
dipivoxil in the apical (donor) compartment, and was determined using Equation (1): 
o
b C
dt
dQ
F =      (1) 
where dQ/dt is determined from the amount of adefovir appearing in the basolateral 
compartment (Q) over time (t) during the experiment, and Co is the initial concentration of 
adefovir dipivoxil in the donor side. 
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D. RESULTS. 
Expression and Localization of MRP4 Protein in Caco-2 cells 
Western blot analysis was performed to measure the expression of MRP4 protein in 
Caco-2 cells. The M4I-10 antibody for human MRP4 labeled a protein in the lysates of Caco-
2 cells and MCF-7/ADR cells (positive control) with an apparent molecular weight around 
200 kDa (Figure 3.1). These results suggest that human MRP4 protein is expressed in Caco-
2. 
Laser scanning confocal images from immunostaining Caco-2 cells by MRP4 
antibody (X-Y sections) showed that the MRP4 stain was at the borders, surrounding nuclear 
staining, indicating the lateral localization (Figure 3.2). X-Z images of MRP4 staining 
showed distinct basal and lateral membrane localization and the stain was not co-localized 
with nuclear staining (Figure 3.2), supporting the basolateral localization of MRP4. 
As shown in Figure 3.3, immunoblot analysis of apical and basolateral membrane 
fractions of Caco-2 cells showed the separation of two membrane fractions. Western blotting 
with MRP4 and Na+-K+ ATPase antibodies showed that the same membrane fraction was 
enriched with MRP4 that was also enriched with Na+-K+ ATPase.  Since Na+-K+ ATPase is a 
basolateral membrane marker, it confirmed that MRP4 is mainly expressed in the basolateral 
membrane of Caco-2 cells. 
Construction of Caco-2 Cells that are Stably Expressing MRP4-specific siRNA  
Caco-2 cells were transfected with the MRP4 siRNA plasmid. After selection by 
hygromycin B, thirty-two clones were obtained and evaluated by Western blotting. As shown 
in Figure 3.4A, MRP4 expression in Caco-2 clones #5, 16 and 21 was suppressed compared 
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to the wild-type Caco-2 cells. The MRP4 function of those constructed cell lines was 
examined by measuring accumulation of [3H]adefovir dipivoxil with or without the MRP 
inhibitor indomethacin. Consistent with the reduced MRP4 expression, the ratios of the 
accumulation in the absence vs. presence of indomethacin decreased from 3.5 for wild-type 
Caco-2 cells to 1.4 for Clone #16 (Figure 3.4B). Cell Clone #16 showed the lowest MRP4 
protein expression and functional activity of MRP4, and was chosen to be used in the 
transport study. 
Transport of Adefovir Dipivoxil in MRP4-Knockdown and Wild-type Caco-2 Cells 
When absorptive transport of adefovir dipivoxil across Caco-2 cell monolayers was 
examined, only adefovir was detected in the basolateral compartment, indicating that (i) the 
dipivoxil prodrug was hydrolyzed completely in the cells and (ii) adefovir appeared in the 
basolateral compartment by egress across the basolateral membrane. Figure 3.5 depicts the 
basolateral availability (Fb) of adefovir in wild-type Caco-2 cells and those that are stably 
expressing MRP4-specific siRNA (Clone #16). The basolateral availability of adefovir was 
lower in the MRP4-knockdown Caco-2 cells than in the wild-type cells by 39%. For 
comparison, indomethacin (30 µM) treatment of the wild-type Caco-2 cells reduced the 
basolateral availability of adefovir by 48% with respect to that in the wild-type Caco-2 cells. 
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E. DISCUSSION. 
Our understanding about the role of transporters that either facilitate or attenuate 
intestinal absorption of drugs has grown rapidly over the past few years (Kunta and Sinko, 
2004; Thwaites and Anderson, 2007; Dobson and Kell, 2008).  However, most of the reports 
in this area have focused on the apical transporters involved in trafficking of compounds 
between intestinal lumen and the cellular compartment of enterocytes. Our understanding of 
the transport of hydrophilic and/or charged compounds are transported from the enterocytes 
into the mesenteric blood circulation is relatively poor. In a previous study (Chapter 2), it 
was discovered that MRP3 in the basolateral membrane of Caco-2 cells transports a 
zwitterionic drug, fexofenadine, out of the Caco-2 cell across the basolateral membrane. 
These results suggested that MRP3 likely plays a role in the intestinal transport of 
hydrophilic zwitterionic compounds that are able to enter the cells via one or more apical 
transporters. Another member of the ABCC family, MRP4, appears to be localized to the 
basolateral membrane of enterocytes as evident from the observations that (i) its mRNA was 
detected in human jejunum and Caco-2 cells (Hilgendorf et al., 2007), and the Mrp4 protein 
was detected in mouse intestine (Belinsky et al., 2007); (ii) intravenous dosing of adefovir 
caused increased toxicity to the intestine in the knockout mice as compared to the wild-type 
mice (Belinsky et al., 2007), suggesting that MRP4 may be functionally active in the 
basolateral membrane of the enterocytes to protect them from the cytotoxicity of adefovir in 
the blood circulation.   
In the present study, it was hypothesized that MRP4 plays an important role in the 
egress of anionic hydrophilic compounds like adefovir across the basolateral membrane of 
Caco-2 cells, used as a model for human intestinal epithelium. Immunostaining followed by 
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laser scanning confocal microscopy provided evidence that MRP4 is localized on the lateral 
and basal membranes of Caco-2 cells grown as monolayers. The localization of MRP4 was 
further investigated by isolation of apical and basolateral cell membrane and subjecting the 
membrane fractions to Western blot analysis. Isolation of the apical and the basolateral 
membranes was accomplished by a novel approach in which the surface proteins on each 
membrane were biotinylated in two separate experiments by reacting the cell monolayers 
with a biotin-linked electrophile on the apical or the basolateral side. Subsequent affinity 
enrichment allowed the isolation of apical and basolateral membrane fragments. Western blot 
analysis of the apical and basolateral membrane fractions revealed that the basolateral 
membrane was enriched in MRP4. Since Caco-2 cells are a good model for enterocytes in 
small intestine in terms of the qualitative transporter expression profile (Taipalensuu et al., 
2001; Hilgendorf et al., 2007), one can extrapolate these results to human intestinal 
epithelium and suggest that MRP4 protein is expressed in the basolateral membrane of the 
intestine. However, this needs to be confirmed considering at least one other study, which 
reported that Mrp4 was localized primarily to the basal cytoplasmic region, but not distinctly 
localized to the basolateral membrane of enterocytes in rats (Johnson et al., 2006). 
To determine the role played by MRP4 in the egress of hydrophilic anionic 
compound adefovir across the basolateral membrane of Caco-2 cells, the following 
experimental model was developed: [3H]adefovir dipivoxil, a prodrug of adefovir in which 
two phosphate anionic sites were masked by esterification, was placed in the apical 
compartment in a transport experiment; the basolateral compartment was sampled for 
[3H]adefovir as a function of time. It has been shown previously that adefovir dipivoxil can 
enter Caco-2 cells across the apical membrane, and is completely hydrolyzed in the cytosol 
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so that only adefovir is detected in the basolateral compartment (Annaert et al., 1997). The 
above experiment was performed in the wild-type Caco-2 cells and in MRP4-knockdown 
Caco-2 cells, which were created by stably expressing MRP4-specific siRNA (Figure 3.4).  
The fraction of the adefovir dipivoxil dose appearing on the basolateral side as adefovir was 
reduced by 39% when MRP4-knockdown Caco-2 cells were used instead of the wild-type 
Caco-2 cells. These results provided evidence that MRP4 plays an important role in the 
egress of adefovir formed in Caco-2 cells from adefovir dipivoxil. When wild-type Caco-2 
cells were treated with indomethacin, a general MRP inhibitor, the fraction of the adefovir 
dipivoxil dose appearing on the basolateral side as adefovir was reduced by 48%. Comparing 
these results with those obtained in the MRP4-knockdown cells, it can be concluded that 
MRP4 is the major player among ABCC subfamily in facilitating basolateral egress of 
adefovir in Caco-2 cells. 
Besides MRP4, other “short” members of the ABCC family, MRP5, MRP8 and 
MRP9, are also capable of transporting nucleoside based agents such as adefovir (Deeley et 
al., 2006; Kruh et al., 2007). Among these, MRP5 is minimally expressed in Caco-2 cells 
(Prime-Chapman et al., 2004). MRP8 is expressed in the apical membrane in polarized cells, 
whereas MRP9 shows basolateral localization (Kruh et al., 2007). The expression levels of 
MRP8 and MRP9 in the enterocytes or Caco-2 cells have not been determined. Therefore, 
their possible involvement in adefovir transport across the basolateral membrane of Caco-2 
cells is unknown. MRP8, if present in the apical membrane of the Caco-2 cells, could 
decrease adefovir egress across the basolateral membrane by pumping it across the apical 
membrane. Another apical transporter of adefovir is breast cancer resistance protein (BCRP, 
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ABCG2) (Takenaka et al., 2007), however, its role was not examined in this study due to its 
minimal expression level in Caco-2 cells (Taipalensuu et al., 2001; Hilgendorf et al., 2007). 
The physiological functions of MRPs in ABCC subfamily in the intestine have been 
unknown despite of their relatively high expression levels. Detoxifying the enterocytes by 
pumping out drugs and metabolites of the intestine was proposed (Kruh et al., 2007). 
However, definitive evidence is still missing. The present study suggests that the basolateral 
MRP4 may play an important role in the oral absorption of adefovir dipivoxil, an ester 
prodrug of the anionic drug adefovir, by mediating the egress of the anionic drug formed 
inside the enterocytes. The study thus provides a new insight about the role of MRPs in the 
intestinal absorption of hydrophilic anionic drugs. Design of ester prodrugs is a major 
strategy to improve the permeability of drugs that are higher charged and/or hydrophilic 
(Beaumont et al., 2003). However, due to the extensive presence of esterases in the 
enterocytes, many prodrugs are hydrolyzed in the intestine. The advantage of presystemic 
activation is that only the active drug enters systemic circulation, minimizing or eliminating 
the exposure of most organs and tissues to the prodrug or intermediate metabolites. 
Therefore, design of prodrugs for the drug, which can be transported by intestinal basolateral 
transporters, will yield not only good oral bioavailability but also minimal systemic exposure 
to additional chemical entities other than the active drug as depicted for adefovir and its 
dipivoxil prodrug (Figure 3.6). However, this study also shows that transporter-based drug-
drug interactions can occur during uptake into enterocytes but also during egress across the 
basolateral membrane.   
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Figure 3.1. Immunoblot analysis of MRP4 in Caco-2 cells. Caco-2 cells after 21-day culture 
on the transwell were lysed and total protein was subjected to Western blot analysis. The 
M4I-10 antibody (Axxora, San Diego, CA) was used to stain the membrane for detection of 
MRP4, and MCF-7/ADR cells were used as a positive control. 
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Figure 3.3. Immunoblot analysis of MRP4 in apical and basolateral membrane fractions of 
Caco-2 cells. Apical and basolateral membrane fractions of Caco-2 cells were isolated by 
biotinylation of plasma membrane proteins followed by affinity enrichment of the membrane 
fractions as described in Materials and Methods. Samples were analyzed by Western blot for 
MRP4 expression. Na+-K+ ATPase protein served as a basolateral marker. 
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Figure 3.4. Effects of siRNA on MRP4 expression and [3H]adefovir dipivoxil accumulation 
in Caco-2 cells. (A) The level of MRP4 protein in Caco-2 cells, stably transfected with 
MRP4-specific siRNA plasmid. The MRP4-specific siRNA plasmid was transfected into 
MRP4 
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Caco-2 cells using the Nucleofector System (Amaxa, Gaithersburg, MD) and transfectants 
were selected with 0.2 mg/ml hygromycin B for 3 weeks. Total proteins were analyzed by 
Western blot for MRP4 expression. GAPDH protein served as an internal control. (B) 
Accumulation of [3H]adefovir dipivoxil after treatment of wild-type Caco-2 cells and MRP4-
knockdown clones in the presence and absence of indomethacin (30 µM).  After culturing for 
4 days, the amount of [3H]adefovir dipivoxil (10 µM), with or without indomethacin in 
MRP4-knockdown clones of Caco-2 cells was examined. Data represent mean ± S.D. of a 
representative experiment in triplicate. 
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Figure 3.5. Basolateral availability of adefovir in wild-type or MRP4-knockdown Caco-2 
cells. Transport of 10 µM [3H]adefovir dipivoxil in the absence or presence of 30 µM 
indomethacin across MRP4 knockdown or wild-type Caco-2 cell monolayers were 
performed. Adefovir (radioactivity) was measured in the basolateral compartment. Data 
represent mean ± S.D. of a representative experiment in triplicate. *** p < 0.001, ** p < 0.01 
and * p < 0.05 compared with uptake in mock cells. 
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CHAPTER 4 
 
 
 
OCT1 MEDIATES BASOLATERAL EFFLUX OF FURAMIDINE FROM ITS 
DIAMIDOXIME PRODRUG 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics and is presented in the style of that journal. 
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A. ABSTRACT. 
Oral activity of antiparasitic aromatic diamidine drugs is poor due to low membrane 
permeability across intestinal epithelia. Prodrug strategies to mask positively charged 
amidine groups have been applied for improving their oral bioavailability. Diamidoxime 
prodrugs of diamidines have shown oral activity in rats, however, furamidine diamidoxime 
failed to show enhanced membrane permeability in Caco-2 and MDCKII cells, compared to 
furamidine itself. The goal of this study is to investigate whether human organic cation 
transporter 1 (hOCT1) in intestinal basolateral membrane enhances transcellular transport of 
furamidine diamidoxime by facilitating basolateral efflux of furamidine formed in 
enterocytes. Efflux of [14C]furamidine was inhibited by quinidine but trans-stimulated by 
TEA in CHO cells stably transfected with hOCT1. The results showed that OCT1 interacts 
with furamidine on the intracellular side and mediates efflux of this diamidine. Then, 
polarized expression of hOCT1 in Caco-2 cells and hOCT1 stably transfected MDCKII cells 
was examined by uptake of [14C]furamidine from apical and basolateral sides. The results 
showed that apical uptake of [14C]furamidine was 2.4-fold higher than basolateral uptake in 
Caco-2 cells, however, uptake was 2.0-fold higher from basolateral side compared to apical 
side in MDCKII-hOCT1 cells, indicating that hOCT1 is expressed in apical membrane of 
Caco-2 cells but mainly in basolateral membrane of MDCKII-hOCT1 cells. Finally, transport 
studies for furamidine diamidoxime in MDCKII-hOCT1 cells showed that prodrug was 
converted to furamidine in the cells and the rate of furamidine basolateral appearance was 
1.5-fold higher than that in mock cells and was trans-stimulated by TEA. These results 
indicated a possible role of OCT1 in the egress of cationic drugs in the intestine, although 
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this role is still questionable under physiological conditions since the electrical potential 
across the cell membrane does not favor efflux aided by the electrogenic transporter OCT1.
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B. INTRODUCTION. 
Pentamidine, an aromatic diamidine, has been used clinically since 1939 and 
continues to be an important agent to treat early-stage human African trypanosomiasis, 
Pneumocystis carinii pneumonia (PCP) in AIDS patients, and antimony-resistant 
leishmaniasis (Barrett et al., 2007). Furamidine is a diamidine analog of pentamidine in 
which the alkoxy chain linking the phenyl rings has been replaced with a furan ring (Figure 
4.1). Furamidine has shown excellent in vitro and in vivo activities in mouse and monkey 
models of early-stage African trypanosomiasis (Barrett et al., 2007). Clinical use of aromatic 
diamidines has been restricted by their poor oral activity. At physiologic pH, the two positive 
charges associated with the diamidine groups (successive pKa’s = 10.4 and 11.8) make 
furamidine highly hydrophilic (Saulter, 2005), which leads to poor oral absorption and 
consequently poor oral activity. Strategies for improving oral bioavailability for diamidine 
drugs have focused on masking these positive charges. For example, pafuramidine, the O-
methylamidoxime prodrug of furamidine, achieved over 100-fold higher permeability across 
Caco-2 monolayers compared to furamidine itself (Zhou et al., 2002a), and exhibits enhanced 
oral activity in animal models (Boykin et al., 1996) and humans (Yeates, 2003; Yeramian et 
al., 2005; Chen et al., 2007). 
Pafuramidine is efficiently converted to furamidine via stepwise O-demethylation and 
N-dehydroxylation of both O-methylamidoxime groups in tandem (Zhou et al., 2002b). 
Cytochrome P450 4F (CYP4F) enzymes are the major enzymes responsible for O-
demethylations (Wang et al., 2006) and N-dehydroxylation of amidoxime is mediated by 
cytochrome b5 and NADH cytochrome b5 reductase (Saulter et al., 2005). Multiple 
biotransformations may increase potential for interindividual variability due to drug-drug 
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interactions involving metabolic enzymes. CYP4F isoforms also metabolize a large number 
of endogenous substances and xenobiotics (Kalsotra and Strobel, 2006); therefore drug-drug 
and drug-food interactions involving these CYP enzymes may inhibit the conversion of the 
prodrug to active drug (Tirkkonen and Laine, 2004). Furamidine diamidoxime, formed by 
two O-demethylations of pafuramidine, is uncharged as both amidines are masked as 
amidoximes (Figure 4.1). Activation of furamidine diamidoxime to active furamidine only 
involves cytochrome b5 and NADH cytochrome b5 reductase (Figure 4.1) (Kurian et al., 
2004; Saulter et al., 2005). Therefore, furamidine diamidoxime may be a better prodrug 
candidate with good membrane permeability and lower potential for interindividual 
variability and drug-drug interaction compared to pafuramidine. Previous studies have shown 
that diamidoxime prodrugs of pentamidine and its analogs possess oral activity against 
Pneumocystis carinii in rats (Hall et al., 1998), although less active than pafuramidine. 
However, furamidine diamidoxime did not achieve higher transcellular permeability than 
furamidine itself in Caco-2 and MDCKII cell monolayers, although the loss of the dose in 
donor compartment was comparable to pafuramidine (Saulter, 2005). The possible 
explanation was that furamidine diamidoxime is metabolized into furamidine by reductases 
quickly, but highly charged furamidine cannot cross basolateral membrane to achieve good 
permeability. 
Recently, furamidine and pentamidine were proved to be substrates for human 
organic cation transporter 1 (hOCT1, SLC22A1) (Appendix), which is mainly expressed in 
the sinusoidal membrane of hepatocytes and mediates entry of organic cations into cells 
(Koepsell et al., 2007). hOCT1 interacts with many drugs, including the H2 antagonist 
ranitidine (Bourdet et al., 2005), the antidiabetic drug metformin (Wang et al., 2002), and the 
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anticancer drug oxaliplatin (Yokoo et al., 2007), and plays an important role in their 
disposition. OCT1 is also expressed in the basolateral membrane of intestine (Jonker et al., 
2001; Wang et al., 2002; Muller et al., 2005). Immunostaining of OCT1 in human small 
intestine showed basolateral localization (Muller et al., 2005). In Oct1-null mice, 
accumulation of TEA (Jonker et al., 2001) and metformin (Wang et al., 2002) was lower than 
wild type after intravenous administration, indicating that Oct1 is expressed in the basolateral 
membrane of mouse intestine and mediates basolateral uptake of cations into enterocytes. 
OCT1 is also capable of transporting cations such as TEA and MPP+ out of cells (Busch et 
al., 1996; Zhang et al., 1999). However, whether OCT1 plays a role in absorptive transport of 
cationic drugs has not been clear. Ranitidine, a hydrophilic cationic drug with good oral 
bioavailability, egresses across the basolateral membrane of Caco-2 cells via a non-saturable 
mechanism (Bourdet and Thakker, 2006). In contrast, metformin, a hydrophilic cationic drug 
with much higher pKa than ranitidine, does not cross the basolateral membrane readily after 
being transported into the Caco-2 cells via a cation-selective transporter in the apical 
membrane (Proctor et al., 2008). Immunostaining of hOCT1 showed that hOCT1 was 
localized in apical membrane of Caco-2 cells (Ng, 2003), whereas OCT1 is localized in 
basolateral membrane of the mouse and human intestinal epithelium (Jonker et al., 2001; 
Wang et al., 2002; Muller et al., 2005). Because of the disparity of localization of OCT1 in 
the intestine and in Caco-2 cells, it is conceivable that the poor membrane permeability of 
furamidine diamidoxime across Caco-2 cell monolayers may be due to the absence of OCT1 
mediated basolateral efflux in these cells. The results in this study demonstrate that hOCT1 
mediates efflux of furamidine, although at lower rate than the uptake process. Further, 
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expression of hOCT1 in the basolateral membrane of MDCKII can enhance the absorptive 
permeability of furamidine diamidoxime across the cell monolayers. 
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C. MATERIALS AND METHODS. 
Materials 
F-12 Nutrient Mixture, penicillin-streptomycin-amphotericin B solution (100x) and 
N-hydroxyethyl-piperazine-N'-2-ethanesulfonate (HEPES, 1M) were obtained from Gibco 
Laboratories (Grand Island, NY). Fetal bovine serum (FBS) and trypsin-EDTA solution (1x) 
were obtained from Sigma Chemical Co. (St. Louis, MO). Geneticin was obtained from 
Invitrogen Co. (Carlsbad, CA). Hank's balanced salt solution (HBSS) was obtained from 
Mediatech, Inc. (Herndon, VA). TEA chloride, MPP+ and quinidine were purchased from 
Sigma (St. Louis, MO). Furamidine dihydrochloride salt (purity > 98%) was synthesized by 
Medichem (Chicago, IL) using previously described methods (Das and Boykin, 1977). 
Furamidine diamidoxime (purity > 98%) was a gift from Dr. David W. Boykin (Georgia 
State University, Atlanta, GA). [3H]MPP+ (85 Ci/mmol) and [14C]TEA (55 mCi/mmol) were 
obtained from American Radiolabelled Chemicals (St. Louis, MO). [14C]furamidine (55.3 
mCi/mmol, purity 96%) was obtained from Huntingdon Life Sciences (Huntingdon, UK). 
Other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). Chinese 
Hamster Ovary (CHO) cells and Madin-Darby Canine Kidney II (MDCKII) cells were 
obtained from the American Tissue Culture Collection (Manassas, VA). hOCT1 cDNA in 
pcDNA3.1 vector was provided by Professor Hermann Koepsell (Julius-Maximilians-
University, Würzburg, Germany). 
Cell Culture and Transfection 
Construction of hOCT1 stably transfected CHO cells was described in Appendix. 
MDCKII cells were transfected with pcDNA3.1 empty vector or the vector containing the 
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full-length hOCT1 using the Nucleofector System (Amaxa, Gaithersburg, MD) according to 
the manufacturer's protocol specific for MDCKII cells. Transfectants were selected with 500 
µg/ml geneticin for 10 days. A clone with the highest [3H]MPP+ uptake activity was chosen 
to create a stably transfected cell line for further studies. The stably transfected MDCKII 
cells were cultured in DMEM with 10% FBS, 10% NEAA, 100 units/ml penicillin, 100 
µg/ml streptomycin and 0.25 µg/ml amphotericin B plus 0.5 mg/ml geneticin. The stably 
transfected CHO cells were cultured in F-12 Nutrient Mixture with 10% FBS, 100 unit/ml 
penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B plus 0.5 mg/ml geneticin. 
Caco-2 cells were cultured in EMEM, supplemented with 10% FBS, 1% NEAA, 100 
units/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B. Caco-2 cells 
were seeded at a density of 60,000 cells/cm2 on TranswellTM filters. Medium was changed 
the day after seeding, and every other day thereafter. The cells were cultured for 21-25 days 
before use. All cell lines were grown at 37°C in a humidified atmosphere with 5% CO2. 
Uptake Studies 
In general, uptake studies were carried out 5-7 days post-seeding. Cells were pre-
incubated for 30 minutes at 37ºC in transport buffer (HBSS with 25 mM D-glucose and 10 
mM HEPES pH 7.2). Experiments were initiated by replacement of the transport buffer with 
400 µl of radiolabelled dose solutions in transport buffer. Uptake was determined within the 
linear uptake region, after which the dose solution was aspirated and cells were washed three 
times with 4ºC transport buffer and lysed in 500 µl 0.1 N NaOH/0.1% SDS by shaking for 4 
hours. Radioactivity was determined by scintillation counting. Protein content was 
determined by the BCA protein assay (Pierce, Rockford, IL) with bovine serum albumin as a 
standard. 
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In trans-stimulation studies, each well of cells was preincubated with either 400 µl of 
transport buffer or 400 µl of transport buffer with 2 mM non-radiolabelled TEA, 200 µM 
quinidine or 100 µM furamidine at 37°C for 1 h. Cells were then rinsed twice with ice-cold 
transport buffer and once with 1 ml of the transport buffer before the uptake studies were 
performed as described above. 
Uptake studies were also conducted in Caco-2 cells and MDCKII-hOCT1 cells grown 
on Transwell™ filters, and 1 µM [14C]furamidine was added into the apical or basolateral 
chamber of monolayers and the uptake studies were performed as described above. 
Efflux Studies 
CHO-hOCT1 cells were incubated for 2 hours with 10 µM [14C]TEA or 
[14C]furamidine. After washing twice with ice-cold transport buffer and once with the 
transport buffer, efflux was determined within the linear efflux region in the absence or 
presence of 2 mM non-radiolabelled TEA and 200 µM quinidine. Then the dose solution was 
aspirated and cells were washed three times with 4ºC transport buffer and lysed in 500 µl 0.1 
N NaOH/0.1% SDS by shaking for 4 hours. Radioactivity of the effluxed and cellular 
samples was measured by scintillation counting. Protein content was determined by the BCA 
protein assay (Pierce, Rockford, IL) with bovine serum albumin as a standard. 
Transport Studies 
Caco-2 cell monolayers were incubated for 30 min with the transport buffer. 
Transport studies were initiated by replacing the donor chamber with 25 µM furamidine 
diamidoxime in the absence or presence of 2 mM TEA added only to the receiver chamber. 
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The receiver chamber was sampled at selected times and furamidine and furamidine 
diamidoxime were quantified by fluorescence HPLC. 
Analytical Methods 
Analytical methods for furamidine and its diamidoxime prodrug were employed as 
described previously (Zhou et al., 2002a) with modification. Samples were analyzed by 
reverse-phase HPLC with a photodiode array detector and a fluorescence detector (Hewlett 
Packard model 1100, Palo Alto, CA, USA). The column used was a 150 × 2.1 mm Zorbax 
Bonus-RP (5 µm particle size) column (Agilent Technologies, Wilmington, DE). UV 
detection with wavelength at 359 nm and fluorescence detection with excitation at 359 nm 
and emission at 461 nm were chosen for routine detection, without omitting any observable 
peaks. The solvent system consisted of solvent A (15 mM ammonium formate-30 mM formic 
acid in 100% HPLC-grade water) and solvent B with identical components in 4:1 
acetonitrile-HPLC-grade water. A gradient elution was used with a starting concentration of 
95% solvent A and 5% solvent B. This gradient increased linearly to 80% solvent B over 12 
min, followed by an 8-min reequilibration time to initial solvent conditions. The flow rate 
was 0.35 ml/min. Six-point standard curves of furamidine or furamidine diamidoxime were 
generated with concentration ranges covering the concentration in the samples. 
Data Analysis 
Data are expressed as mean ±SD from three measurements unless otherwise noted. 
Statistical significance was evaluated using T-test and ANOVA followed by Dunnett’s test 
for multiple comparisons. The data were analyzed with SigmaStat 2.0 (Systat Software, Inc., 
San Jose, CA). Uptake clearance (CLup) was determined using Equation. (1): 
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o
up C
dt
dX
CL =      (1) 
where dX/dt is the flux determined from the amount taken up (X) over time (t) during the 
experiment, and Co is the initial concentration in the donor side. 
Basolateral availability (Fb) was defined as a parameter to represent the availability of 
furamidine in the basolateral (receptor) compartment after dosing furamidine diamidoxime in 
the apical (donor) compartment, and was determined using Equation (2): 
o
b C
dt
dQ
F =      (2) 
where dQ/dt is determined from the amount of furamidine appearing in the basolateral 
compartment (Q) over time (t) during the experiment, and Co is the initial concentration of 
furamidine diamidoxime in the donor side. 
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D. RESULTS. 
trans-Stimulation of TEA Uptake Studies 
trans-Stimulation of [14C]TEA uptake studies was used to investigate whether 
furamidine interacts with hOCT1 on the intracellular side. As shown in Figure 4.2, after pre-
incubating CHO-hOCT1 cells with TEA (2 mM) for 1 h at 37°C, [14C]TEA uptake was 
enhanced by 2.8-fold (p < 0.01). Pre-incubating cells with 200 µM quinidine or 100 µM 
furamidine resulted in a significant decrease in [14C]TEA uptake (apparent trans-inhibition) 
to 16% (p < 0.01) and 13% (p < 0.01) of the control, respectively, indicating that furamidine 
binds to hOCT1 on the intracellular side, but its translocation rate is much slower than that of 
TEA. These trans-stimulation effects were not observed in mock cells. 
Efflux of Furamidine from CHO-hOCT1 Cells 
Efflux of [14C]TEA after preloading 10 µM [14C]TEA in CHO-hOCT1 cells for 1 
hour was linear up to 20 minutes (data not shown). As shown in Figure 4.3A, efflux of 
[14C]TEA from CHO-hOCT1 cells over 5 minutes was reduced by 74% (p < 0.01) by 200 
µM quinidine, but enhanced 1.8-fold (p < 0.01) by 2 mM TEA indicating that hOCT1 can 
mediate efflux of cations. Efflux of [14C]furamidine after preloading 10 µM [14C]furamidine 
in CHO-hOCT1 cells for 2 hour was linear up to 10 minutes (data not shown). As shown in 
Figure 4.3B, the efflux of [14C]furamidine over 5 minutes from CHO-hOCT1 cells was 
reduced by 21% (p < 0.05) by 200 µM quinidine, but enhanced 1.5-fold (p < 0.05) by 2 mM 
TEA, proving that hOCT1 also transports furamidine out of cells. 
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Cellular Localization of Functional hOCT1 in Caco-2 cells and MDCKII-hOCT1 Cells. 
Uptake of 1 µM [14C]furamidine from both sides of Caco-2 cell monolayers was 
linear up to 30 minutes (data not shown). Apical uptake of [14C]furamidine was 2.4-fold (p < 
0.01) higher than basolateral uptake in Caco-2 cells, and 1 mM ranitidine, an OCT1 
substrate/inhibitor (Bourdet et al., 2005), reduced it by 83% (p < 0.01); in contrast, the 
basolateral uptake was not reduced by ranitidine (Figure 4.4). These results provided 
evidence for expression of functional hOCT1 mainly in the apical membrane of Caco-2 cells, 
and supported the previous report (Ng, 2003) which provided immunohistochemical 
evidence for the presence of hOCT1 on the apical membrane of Caco-2 cells. Uptake of 1 
µM [14C]furamidine from both sides of MDCKII-hOCT1 cell monolayers was linear up to 30 
minutes (data not shown). In MDCKII-hOCT1 cells, the apical and basolateral uptake was 
1.5-fold (p < 0.05) and 2.6-fold (p < 0.01) higher, respectively, than that in mock cells 
(Figure 4.5), providing evidence for expression of functional hOCT1 mainly in the 
basolateral membrane of stably transfected MDCKII-hOCT1 cells.  
Transport of Furamidine Diamidoxime across MDCKII-hOCT1 Cells 
Based on the basolateral localization of hOCT1 in MDCKII-hOCT1 cells, this cell 
line was chosen for further transport study. The experiment involved placing 25 µM 
furamidine diamidoxime in the apical compartment, and measuring the concentration of 
furamidine appearing in the basolateral compartment as a function of time.  It was anticipated 
that the diamidoxime prodrug would be converted rapidly and quantitatively to furamidine in 
the MDCKII-hOCT1 cells, which would then appear in the basolateral compartment with the 
assistance of hOCT1 expressed in the basolateral membrane of MDCKII-hOCT1 cell 
monolayers.  As shown in Figure 4.6, the basolateral availability of furamidine in MDCKII-
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hOCT1 cell monolayers was 1.57-fold (p < 0.05) greater than that of mock cells. With 2 mM 
TEA in the receptor compartment (trans-stimulation), the basolateral availability of 
furamidine in MDCKII-hOCT1 cells was 2-fold (p < 0.01) greater than that across mock 
cells.   
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E. DISCUSSION. 
Investigation of transporters in the basolateral membrane of intestinal epithelium that 
may play a role in the oral absorption of hydrophilic drugs with net charge have revealed the 
presence of MRP transporters as well as OSTαβ, both of which can transport zwitterionic 
and/or anionic compounds. The present study was undertaken to determine if there are 
transporters in the basolateral membrane of intestinal epithelium that can facilitate egress of 
hydrophilic cations. Evidence exists for the presence of OCT1 in the basolateral membrane 
of human as well as mouse intestinal epithelium (Jonker et al., 2001; Wang et al., 2002; 
Muller et al., 2005). Furamidine was shown to be a substrate for OCT1 (Appendix); 
furthermore, the diamidoxime prodrug of furamidine is available in which the positive 
charges are masked and which is able to enter Caco-2 cell monolayers, used as a model for 
intestinal epithelium, across apical membrane via passive diffusion, and rapidly converted to 
furamidine via facile reductive metabolism mediated by cytochrome b5 and NADH 
cytochrome b5 reductase. Hence furamidine and its diamidoxime prodrug provided an 
excellent pair of compounds to determine if OCT1 can assist egress of hydrophilic cations 
across the basolateral membrane of enterocytes.   
Initial experiments with CHO-OCT1 cells could demonstrate that furamidine can 
egress out of cells via OCT1-mediated transport and that an organic cation outside the cell 
can accelerate this efflux (Figure 4.3). However, quinidine only decreased furamidine efflux 
by 21%, compared to 74% decrease for TEA efflux, indicating that hOCT1 mediated efflux 
of furamidine is not as efficient as that of TEA. Furthermore, activity of furamidine efflux by 
hOCT1 is lower than its uptake, which showed over 5-fold higher activity in CHO-hOCT1 
cells than mock cells (Appendix). Transport via OCTs is driven by membrane potential, and 
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the uptake of positively charged molecules is thermodynamically favorable while the efflux 
is unfavorable (Koepsell et al., 2007). With two positive charges in each molecule, aromatic 
diamidines have more energy to drive uptake but also have to overcome higher energy barrier 
in the efflux process. In addition, furamidine binds to DNA with high capacity (Lansiaux et 
al., 2002), which therefore decreases the free furamidine concentration inside the cells and 
reduces the driving force for cellular efflux. The divalent positive charge and high DNA 
binding of furamidine may result in its inefficient efflux by hOCT1. 
Functional studies further showed that OCT1 is expressed in the apical membrane of 
Caco-2 cells (Figure 4.4), which are routinely used as a model for intestinal epithelium. 
Hence Caco-2 cells were deemed inappropriate as a model for studies designed to assess the 
role of OCT1 in basolateral efflux of compounds. As a result, hOCT1 was stably expressed 
in MDCKII cells, and results in Figure 4.5 provided evidence that hOCT1 was localized in 
the basolateral membrane, thus making them a suitable cellular model. Results reported in 
Figure 4.6 showed that furamidine appeared in the basolateral compartment when 
diamidoxime prodrug of furamidine was placed in the apical compartment of MDCKII-
hOCT1 cell monolayers. Further, these results showed that the appearance of furamidine in 
the basolateral compartment is 1.6-fold faster in the MDCKII-hOCT1 cells compared to 
mock cells. The rate of furamidine appearance was significantly increased when an organic 
cation, TEA was placed in the basolateral compartment due to trans-stimulation.   
The overall permeability of furamidine diamidoxime cannot be calculated because the 
pure standard of the intermediate product, furamidine monoamidoxime, is not available. 
Based on the appearance of furamidine diamidoxime and furamidine in the donor 
compartment, the permeability of about 20 nm/sec is still much lower than that of 
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pafuramidine in MDCKII cells (355 nm/sec) (Saulter, 2005), though the increase of 
furamidine diamidoxime transport was shown in the presence of hOCT1 in the basolateral 
membrane of MDCKII cells. Furamidine diamidoxime is a neutral and lipophilic molecule 
with a ClogP of 3.1, which is close to that of pafuramidine (ClogP of 4.3) (Saulter, 2005). 
Thus, the transcellular permeability of furamidine diamidoxime is still lower than that 
expected based on its lipophilicity. Intestinal absorptive transport involves uptake across the 
apical membrane followed by cytosolic translocation and subsequent basolateral efflux into 
the blood. In the intestinal transport of furamidine diamidoxime, apical uptake of lipophilic 
prodrug is quick and not rate-limiting. After metabolism into furamidine by cellular 
reductases, the diamidine molecule binds to DNA extensively, leading to inefficient cytosolic 
translocation. Passive diffusion of the highly charged diamidine across the basolateral 
membrane is minimal and hOCT1 facilitates the efflux of furamidine, however, with lower 
efficiency compared to the uptake of furamidine by the same transporter. Therefore, cellular 
sequestration and basolateral efflux of furamidine are the rate limiting steps in transcellular 
transport of furamidine diamidoxime in the intestine. Binding of aromatic diamidines to 
DNA in kinetoplastid and mitochondrion of target trypanosomes has been considered as one 
of the main mechanisms for their antiparasitic action (Barrett et al., 2007). Therefore, it is not 
rational to design a diamidine compound without DNA binding in order to decrease the 
cellular sequestration. Design of diamidine prodrugs that are only metabolized by enzymes in 
the blood may be a better strategy to avoid the metabolism of prodrug followed by cellular 
sequestration in the intestine. 
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Figure 4.1. Metabolism of furamidine diamidoxime. The conversion of furamidine 
diamidoxime to furamidine monoamidoxime and the subsequent conversion to furamidine 
are both reductive N-dehydroxylation reactions. Such reactions have been shown to be 
catalyzed by the cytochrome b5/b5 reductase system . 
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Figure 4.2. trans-stimulation of [14C]TEA uptake in CHO-hOCT1 cells. CHO-hOCT1 (open 
bar) and mock cells (solid bar) were pre-incubated with either 0.4 ml of transport buffer 
(Control) or 0.4 ml of transport buffer with 2 mM non-radiolabelled TEA (TEA), 200 µM 
quinidine (Quinidine) or 100 µM furamidine (Furamidine) at 37°C for 1 h. Cells were then 
rinsed twice with ice-cold transport buffer and once with 1 ml of the buffer before [14C]TEA 
uptake was performed. Data represent mean ± S.D. of a representative experiment in 
triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with control. 
. 
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Figure 4.3. Efflux of [14C]TEA (A) and [14C]furamidine (B) from CHO-hOCT1 Cells. CHO-
hOCT1 cells were incubated for 2 hour with 10 µM [14C]TEA (A) or [14C]furamidine (B). 
After washing, efflux was determined within the linear efflux region within in the absence 
(Control) or presence of 2 mM non-radiolabelled TEA (TEA) and 200 µM quinidine 
(Quinidine). Data represent mean ± S.D. of a representative experiment in triplicate. *** p < 
0.001, ** p < 0.01 and * p < 0.05 compared with control. 
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Figure 4.4. Uptake of [14C]furamidine in Caco-2 Cells. After pre-incubation in transporter 
buffer for 30 minutes, 1 µM [14C]furamidine in the absence (solid bar) or presence of 1 mM 
ranitidine (open bar) was added into the apical or basolateral chamber of Caco-2 cell 
monolayers and uptake studies were performed. Data represent mean ± S.D. of a 
representative experiment in triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared 
with control. 
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Figure 4.5. Uptake of [14C]furamidine in MDCKII-hOCT1 Cells. MDCKII-hOCT1 (open 
bar) and mock cells (solid bar) were pre-incubated in transporter buffer for 30 minutes, 1 µM 
[14C]furamidine was added into the apical or basolateral chamber of the cell monolayers and 
uptake studies were performed. Data represent mean ± S.D. of a representative experiment in 
triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with uptake in mock cells. 
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Figure 4.6. Basolateral availability of furamidine across MDCKII-hOCT1 cell monolayers. 
MDCKII-hOCT1 (open bar) and mock cells (solid bar) were pre-incubated in transporter 
buffer for 30 minutes, 25 µM furamidine diamidoxime was added into the apical chamber of 
the cell monolayers and transport studies were performed in the absence (Control) or 
presence of 2 mM non-radiolabelled TEA (TEA(trans)) in the basolateral chamber. 
Appearance of furamidine in the basolateral chamber was measured to obtain the basolateral 
availability of furamidine. Data represent mean ± S.D. of a representative experiment in 
triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with uptake in mock cells. 
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CHAPTER 5 
 
 
 
CONCLUSIONS
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Roles of Basolateral Transporters in Intestinal Drug Absorption 
The studies undertaken for this dissertation project have broadly focused on 
elucidating the roles of the basolateral transporters in intestinal absorption of drugs and 
prodrugs. An understanding of the basolateral efflux mechanism in the intestine is of much 
interest because it is still a major missing link in transporter mediated drug absorption. In 
contrast, the presence of many transporters in the apical and basolateral membrane has been 
established in the liver and the kidney, and their roles in governing drug disposition in these 
organs have been elucidated. The importance of the basolateral transporters has been 
established for intestinal absorption of nutrients such as glucose and bile acids. Extrapolating 
from the known functions of basolateral transporters in the body, it was hypothesized that 
intestinal basolateral transporters may determine the transcellular transport of drugs when 
apical transporters mediate uptake efficiently, or prodrugs diffuse through the apical 
membrane efficiently and are metabolized into hydrophilic and/or charged drugs in the 
enterocytes. 
Fexofenadine, a zwitterionic anti-allergy medicine, represents a large class of drugs 
that contain both acidic and basic groups and possess molecular weight over 300. The 
charged nature of these compounds in the physiological pH makes it hard for them to 
permeate biological membranes. In addition, many of them are substrates for P-gp, which 
would make their intestinal absorption even less effective. However, these bulky zwitterionic 
drugs achieve greater bioavailability than that expected from their physicochemical 
properties and efflux by P-gp. Therefore, this work was undertaken to test the hypothesis that 
vectorial transport systems, including apical uptake and basolateral efflux transporters, play a 
pivotal role in the intestinal absorption of zwitterionic drugs such as fexofenadine. In Chapter 
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2 of this dissertation, the apical uptake transporter of fexofenadine was re-examined first. 
The results showed that OATP2B1, but not OCT3 or OCTN2, mediates transport of 
[3H]fexofenadine into transfected cells at pH 6.0. Apical uptake of fexofenadine decreased by 
half with an OATP inhibitor at pH 6.0, but not at pH 7.4. This result supported that 
OATP2B1 mediates apical uptake of fexofenadine into Caco-2 cells at acidic pH because 
OATP2B1 is the only OATP isoform showing pH dependent activity. OATP2B1-mediated 
uptake of fexofenadine may be the major mechanism in vivo because of the acidic 
microclimate in small intestine. The basolateral efflux of fexofenadine in Caco-2 cells was 
examined, and the studies focused on the facilitative transporter OSTαβ and the ABC 
transporter MRP3. These two transporters showed either protein localization (MRP3) or 
functional activity (OSTαβ) in the basolateral membrane of Caco-2 cells. However, studies 
showed that OSTαβ did not contribute to the basolateral transport of fexofenadine; this 
conclusion was based on the observations that its substrates/inhibitors did not interact with 
fexofenadine transport in the basolateral side of Caco-2 cells. MRP inhibitor reduced the 
basolateral efflux of cellular fexofenadine by 57%. This result indicated that basolateral 
efflux of fexofenadine is mediated by MRP but not by OSTαβ in Caco-2 cells.  Combining 
the findings from this work with the literature evidence showing that fexofenadine is a 
substrate for MRP3 but not for MRP4 (Matsushima et al., 2008a), it was concluded that 
MRP3 plays a role in the basolateral efflux of fexofenadine in Caco-2 cell monolayers. The 
MRP inhibitor MK-571 decreased the absorptive transport of fexofenadine moderately. 
However, MK571 decreased more dramatically when P-gp was also inhibited. The results 
showed apical entry dominated by P-gp mediated efflux is rate limiting in absorptive 
transport of fexofenadine in Caco-2 cells. However, basolateral efflux by MRP3 may control 
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the absorption rate of fexofenadine in human small intestine when P-gp’s influence in the 
intestinal absorption is diminished due to the inhibition by drugs and diets, and genetic 
variation of MDR1 gene.   
Another situation in which basolateral efflux transporters could be important is when 
lipophilic prodrugs diffuse through the apical membrane and are metabolized into the 
hydrophilic drugs in the enterocytes efficiently. Adefovir dipivoxil is known to be 
metabolized completely into adefovir in the enterocytes (Annaert et al., 1997; Annaert et al., 
2000). The studies in Chapter 3 examined whether MRP4, a known adefovir transporter 
(Schuetz et al., 1999), in Caco-2 cells plays a role in the basolateral efflux of adefovir 
generated from adefovir dipivoxil inside the cells. The presence of MRP4 protein in Caco-2 
cell was established by Western blotting and its basolateral localization was confirmed by 
immunofluorescence microscopy and Western blotting of membrane fractions isolated using 
a method involving biotinylation of surface membrane proteins followed by affinity 
enrichment. MRP4-knockdown Caco-2 cells were constructed in which the MRP4 protein 
level and activity were reduced; the availability of [3H]adefovir in the basolateral 
compartment after apical dosing the cell monolayers with [3H]adefovir dipivoxil was reduced 
by 39% in the MRP4-defficient Caco-2 cells. In a similar experiment, chemical inhibition of 
MRP4 in wild type cells reduced the availability of [3H]adefovir in the basolateral 
compartment by 48%. These results demonstrated that MRP4 in the basolateral membrane of 
Caco-2 cells contributes predominantly to the efflux of adefovir generated intracellularly 
from its prodrug, thus highlighting the importance of the basolateral MRP4 in oral absorption 
of adefovir dipivoxil. 
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The first two parts of this project focused on the roles of the ABC transporters, 
transporting anionic compounds, in the basolateral membrane of the intestine. Besides the 
ABC transporters, many SLC transporters are also expressed in the basolateral membrane of 
the intestine, including OCT1 that mainly transports cationic compounds (Muller et al., 2005; 
Koepsell et al., 2007). In the previous studies in the Thakker laboratory, it was found that this 
transporter is expressed in the apical membrane of Caco-2 cells (Ng, 2003). Further, evidence 
did not support an OCT1-mediated efflux of OCT1 substrates, ranitidine and metformin, 
across the basolateral membrane of Caco-2 cells; rather, both ranitidine and metformin 
appeared to be transported across the apical membrane via an OCT-like transporter (Bourdet 
and Thakker, 2006; Proctor et al., 2008a). In Chapter 4 of this dissertation project, hOCT1 
was expressed in the basolateral membrane of MDCKII cells. The possible efflux function of 
this transporter was examined using dicationic drugs pentamidine and furamidine. Both of 
these compounds were found to be substrates for hOCT1, which represents the first report 
showing that dicationic drugs are substrates for an OCT transporter.  It is conceivable that 
OCT1 may mediate hepatic elimination and toxicity of these aromatic diamidine drugs 
(Appendix). Whether hOCT1 in the intestinal basolateral membrane enhances the 
transcellular transport of the diamidoxime prodrug of furamidine, by facilitating basolateral 
efflux of furamidine formed in the enterocytes, was tested in Chapter 4. The results showed 
that efflux of [14C]furamidine from hOCT1 stably transfected CHO cells was inhibited by 
quinidine but trans-stimulated by TEA, indicating that hOCT1 can mediate efflux of this 
diamidine. Then, basolateral expression of hOCT1 in MDCKII-hOCT1 cells was confirmed 
by the result of 2.6-fold higher basolateral uptake of [14C]furamidine in the transfected cells 
compared to mock cells. Finally, transport of furamidine diamidoxime in MDCKII-hOCT1 
157 
cells showed that availability of furamidine on the basolateral side, after apical dosing of the 
diamidoxime prodrug, was 1.5-fold higher than that in mock cells and was trans-stimulated 
by TEA in the basolateral compartment. This study showed that hOCT1 facilitates the 
basolateral efflux of furamidine after metabolism from its diamidoxime prodrug in the cells. 
However, the efflux of furamidine by OCT1 is not as efficient as the uptake process, because 
OCT1-mediated transport is driven by the outside-positive membrane potential, which resists 
thermodynamically the efflux process of positively charged molecules (Koepsell et al., 2007). 
In addition, intracellular metabolism and consequently cellular sequestration may play an 
important role in limiting the transport of furamidine diamidoxime across the intestinal 
epithelium. 
In conclusion, intestinal basolateral transporters may determine the transcellular 
transport rate when apical transporters mediate uptake efficiently; or prodrugs diffuse 
through the apical membrane efficiently and are metabolized into hydrophilic drugs in the 
enterocytes. Although not tested in this dissertation project, intestinal basolateral transporters 
in ABC superfamily may also protect the enterocytes preventing entry of drugs or their 
metabolites from blood; for example, Mrp4 prevented the entry and toxicity of adefovir into 
the enterocytes from the blood circulation (Belinsky et al., 2007). In addition, the basolateral 
transporters in the SLC family may play a role in intestinal secretion of xenobiotics via 
uptake of substrates from blood circulation into the enterocytes (Arimori and Nakano, 1998), 
for example, the basolateral Oct1 facilitates the secretion of its substrates from the circulating 
blood into the intestinal lumen by mediating the basolateral uptake process (Jonker et al., 
2001; Wang et al., 2002). 
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Factors Influencing the Importance of Intestinal Basolateral Transporters 
Being a drug substrate for an intestinal basolateral transporter does not necessarily 
mean that this transporter must play an important role in intestinal absorption of the drug. In 
addition to the substrate activity of the drug toward the basolateral transporter, the 
importance of this transporter in overall absorptive transport is also influenced by other 
factors, including the paralleled mechanisms in the basolateral efflux step and the other steps 
in the transcellular transport process. 
The transport across the basolateral membrane is a combination of carrier-mediated 
transport and passive diffusion as described in Equation 1. If the clearance for passive 
diffusion Kd >> Jmax/Km (intrinsic clearance of the transporter), modulation of the basolateral 
transporter activity, which is represented as Jmax*C/(Km+C), will not affect the overall 
transport rate J dramatically. 
                                              CK
CK
CJJ d
m
**max ++=     (1) 
The basolateral transporter activity is represented as Jmax*C/(Km+C). The membrane 
expression level of the transporter determines Jmax. The basolateral transporter only functions 
when the substrate does not saturate it (when C << Km), so the activity is also related to the 
intracellular concentration of the compound, which is controlled by multiple factors 
including apical entry, cellular binding and basolateral efflux. The basolateral transporters 
have typical high Km values to ensure not being saturated. In vitro measurement of the Km 
value of a specific substrate for a specific transporter is still important to assess whether this 
transporter is functional in the basolateral egress of the test compound in vivo. 
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Barrier epithelia are known to have more permeable basolateral membranes compared 
to apical membranes (Zeidel, 1996), due to higher fluidity of the exofacial leaflet of the 
basolateral membranes (Negrete et al., 1996). The higher membrane permeability of digoxin 
across the basolateral membrane has been reported in the transcellular transport across 
MDCKII cells (Ito et al., 1999). Therefore, changes in basolateral transporter activity will not 
affect the transport rate across of the basolateral membrane if a drug is reasonably lipophilic. 
In addition, if a drug crosses apical membrane by passive diffusion efficiently, then it 
transports through the basolateral membrane will be even faster via the same mechanism. 
Therefore, if an apical uptake transporter is not involved in intestinal transport of a lipophilic 
drug, then the possibility is even lower that a carrier-mediated process is important in the 
basolateral egress, unless the lipophilic drug is metabolized into hydrophilic metabolites in 
the enterocytes. 
Another factor that affects passive permeability is the ionization of the compounds. In 
small intestine, intestinal lumen has acidic microclimate with pH of 6.0-6.5 (Daniel et al., 
1985), and intracellular cytosol of villus tips and circulating blood are at neutral pH (around 
7.4) (Hayashi and Suzuki, 1998) (Figure 5.1). The different pH values across the intestinal 
epithelium can lead to differential ionization of a drug in these three compartments (apical, 
intracellular, and basolateral) and therefore influence the permeability of acidic and basic 
compounds differently across the apical and basolateral membranes of the enterocytes. For 
an acidic compound, the passive permeability across the apical membrane is likely to be 
greater than that across the basolateral membrane because the acidic compound is less 
ionized in intestinal lumen than intracellular cytosol. However, similar pH values between 
the cytosolic compartment and the blood make the permeability across the basolateral 
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membrane lower than that across the apical membrane. In contrast, the differential pH values 
lead to higher permeability across the basolateral membrane than the apical one for basic 
drugs. Because of the lower passive diffusion across the basolateral membrane, acidic 
compounds may have greater component of carrier-mediated transport compared to basic 
compounds. In addition, small cationic (basic) compounds tend to transport across the 
intestinal epithelium in paracellular pathway due to the favorable interaction with negative 
charges in the paracellular space including tight junctions (Lee and Thakker, 1999; 
Anderson, 2001; Bourdet and Thakker, 2006; Proctor et al., 2008a), thus carrier-mediated 
basolateral egress would be less important for small cationic drugs. The pH gradient across 
the intestinal epithelium and its influence on the differential permeability of acidic and basic 
drugs across the apical and basolateral membranes may explain why only anion-specific 
MRPs, and none of the cation-specific ABC transporters, are present on the basolateral 
membrane of intestinal epithelium  
The importance of basolateral transporters in absorptive transport of a compound is 
also influenced by other steps in the transcellular transport process. Intestinal drug absorption 
involves at least three steps: the apical entry, cytosolic translocation and basolateral egress. 
According to Equation 2, 
                                              
PbPcPaPt
1111 ++=                  (2) 
(where Pt, Pa, Pc and Pb represent the permeability of a compound across the 
intestinal epithelium, apical membrane, cytosol and basolateral membrane, respectively), the 
overall transcellular transport is limited by the slowest step, so called the rate-limiting step. 
Accordingly, if the basolateral transport is not rate limiting, the overall rate will not be 
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sensitive to the modulation of the basolateral transporter, even if a carrier-mediated transport 
mechanism contributes to the basolateral egress of a compound. For example, inhibition of 
MRPs in Caco-2 cells only decreased the absorptive transport of fexofenadine moderately, 
but when P-gp was inhibited, inhibition of MRPs decreased the absorptive transport more 
dramatically. The results indicate that apical entry, dominated by P-gp mediated efflux, is 
rate limiting in the absorptive transport of fexofenadine in Caco-2 cells. When the rate 
limiting step is shifted by inhibition of P-gp, the overall transport is more sensitive to the 
modulation of the basolateral MRP3.   
Predicting the Importance of Intestinal Basolateral Transporters 
It is difficult to predict the importance of intestinal basolateral transporters in drug 
absorption because many factors may influence in vivo functions of these transporters besides 
their activity for transporting drugs. Biopharmaceutics Classification System (BCS) has been 
applied to categorize drugs into four classes according to their solubility and permeability in 
order to predict in vivo pharmacokinetics of drug products, mainly oral bioavailability, from 
in vitro measurements of permeability and solubility (Figure 5.2) (Amidon et al., 1995). 
Recently, BCS was applied to predict drug disposition in vivo, including effects of efflux and 
absorptive transporters on drug absorption (Wu and Benet, 2005). This system is used here as 
a guideline to predict the importance of intestinal basolateral transporters in drug absorption. 
Effects of intestinal basolateral transporter will be important for a few Class 1 
compounds. The high permeability and solubility of the class 1 compounds leads to high 
concentrations in the intestinal lumen that saturate any transporter. Therefore, Class 1 
compounds may be substrates for transporters using in vitro cellular systems, but transporter 
effects may not be important clinically. Furthermore, most of class 1 compounds are 
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lipophilic and able to cross both membranes by passive diffusion. However, some class 1 
compounds achieve higher permeability because they act as substrates for absorptive 
transporters; for example, L-dopa is classified into Class 1  (Wu and Benet, 2005) because it 
is absorbed via high capacity amino acid transport systems in the intestine (Lennernas et al., 
1993). In this case, the intestinal basolateral transporters such as TAT1 (Ramadan et al., 
2006) and LAT2 (Soares-da-Silva et al., 2004) are as important as the apical transporters in 
intestinal absorption of L-dopa. Therefore, effects of intestinal basolateral transporter will be 
important for the class 1 compounds that achieve higher permeability by absorptive 
transporters, including L-dopa and valacyclovir. 
Effects of intestinal basolateral transporter will be minimal for Class 2 compounds, 
but may be important for disposition of their metabolites. 
The class 2 compounds are typically bulky and lipophilic and are able to cross both 
membranes by passive diffusion. The low solubility leads to low concentrations in intestinal 
lumen. Many of the class 2 compounds are substrates for apical efflux transporters such as P-
gp, and the rate-limiting step of intestinal transport is the apical entry controlled by the efflux 
by P-gp. Therefore, the effects of the basolateral transporters will be minimal because of the 
high passive permeability and efflux by apical transporters. However, some of class 2 
compounds are prodrugs that are metabolized in the intestinal epithelium, for example, 
adefovir dipivoxil; or they are the active drugs but are metabolized to active metabolites in 
the enterocytes, for example, terfenadine is metabolized to fexofenadine, which possesses 
even higher antihistamine activity, in the intestine (Grant et al., 1999). For these class 2 
compounds that are prodrugs or generate active metabolites in the enterocytes, the intestinal 
basolateral transporters may be important for their oral activity.  
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Intestinal basolateral transporter effects will predominate for Class 3 and 4 
compounds, and are more important for anionic compounds. For the Class 3 and 4 
compounds, absorptive transport systems, including apical uptake and basolateral efflux 
transporters, will be necessary to overcome the poor passive permeability characteristics of 
these compounds. Many class 3 and 4 compounds are ionizable, and are either positively or 
negatively charged at physiological pH in the intestine. For the hydrophilic anionic drugs 
such as pravastatin and methotrexate, the passive permeability across apical membrane is 
higher than that across the basolateral membrane; therefore, the basolateral transporters may 
have a more significant influence on their oral absorption. On the contrary, for the 
hydrophilic cationic drugs such as ranitidine, a basolateral transporter may have less 
influence on oral absorption because of their likely relatively high permeability across the 
basolateral membrane. In addition, the preferred paracellular transport of hydrophilic cationic 
drugs also decreases the importance of the basolateral transporters. The basolateral 
transporter effects in BCS were summarized in Figure 5.2. 
Future Direction 
The obstacles to understanding the role of the basolateral transporters in intestinal 
drug absorption are the small number of these transporters identified in the intestine and 
somewhat unclear in vivo functions of the known basolateral transporters. A combination of 
mechanistic studies with in vitro systems and functional research in animals and humans is 
needed to overcome these obstacles, which is the future direction in this field. 
Molecular cloning of novel transporters is needed for identification of the key 
basolateral transporters in the intestine; for example, the peptide basolateral transporter, 
which is expressed in the basolateral membrane of Caco-2 cells (Terada and Inui, 2004), has 
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not yet been identified in the intestine. Localization of “orphan” transporters, for example, 
MRP5, MRP8 and MRP9, in the enterocytes and characterization of their functional activity 
may be an important near-term objective. In addition, for the known basolateral transporters 
such as MRP3 and OSTαβ, their substrate specificity should be explored by measuring 
substrate activity in the transporter transfected models because few drugs have proven to be 
substrates for these transporters.  
In vivo functional characterization of intestinal basolateral transporters in drug 
absorption is more demanding compared to the in vitro studies. Pharmacokinetic studies in 
transporter knockout mice have been a successfully used method in exploring the roles of 
transporters in hepatic and renal disposition of drugs and their metabolites. Recently, 
transport of bile acids using everted gut sac and absorption of bile acids were studied in 
Ostα-/- and Ostα-/-Mrp3-/- mice (Rao et al., 2008).  This is the first study to investigate the in 
vivo function of intestinal basolateral transporters, and represents a significant breakthrough 
in this area. This kind of studies in transporter knockout animals will be applied to study 
other intestinal basolateral transporters in the near future. 
The most convincing evidence of transporter effects is from clinical studies. Co-
administration of a test drug as a transporter substrate with a transporter inhibitor is a typical 
design in these clinical studies. However, limited by the availability of an appropriate 
substrate and/or an inhibitor that is suitable for human use and the broad distribution of 
transporters, these studies have generated ambiguous results. Understanding of the impact of 
genetic variations of drug transporters on drug disposition continues to emerge. Knowing the 
effects of mutations on transporter activity using in vitro systems along with pharmacokinetic 
analysis of clinical data tend to generate more meaningful conclusions on transporter effects. 
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Clearly, the loss or reduction of transporter activities in the basolateral membrane due to 
genetic variation in these transporters could potentially limit intestinal absorption of their 
substrates. Therefore, clinical studies on the effect of genetic variation in these transporters 
on drug absorption will be an important area of future research. To avoid being confused by 
the effects of liver transporters, a human in vivo jejunal perfusion technique, which enables 
direct determination of the effective jejunal permeability of drugs (Tannergren et al., 2003b), 
may help understand mechanisms about intestinal transporters from clinical data. 
Research on intestinal basolateral transporters will lead to more complete 
understanding of carrier-mediated intestinal drug absorption, for example, the failure of 
modulation of fexofenadine permeability by P-gp inhibitor verapamil may be partly 
explained by the reduction of MRP3 mediated basolateral efflux by this inhibitor 
simultaneously (Zeng et al., 2001; Tannergren et al., 2003b). Current research has focused on 
the drug-diet interaction mediated by intestinal apical transporters; however, plant phenols in 
vegetables, fruits and many food sources inhibit activity of multiple MRP transporters in 
intestinal basolateral membrane (Wu et al., 2005), which may lead to alterations to drug 
absorption mediated by these transporters. Although modulation of intestinal basolateral 
transporters does not always change pharmacokinetics of drugs dramatically, their effects 
definitely increase the inter-individual variability of drugs due to drug-drug interactions and 
genetic variations of the basolateral transporters. On the other hand, if a drug is a substrate 
for intestinal basolateral transporters, but not for the apical transporters, then design of their 
prodrugs, which are labile to intestinal enzymes, can also lead to great oral availability. In 
conclusion, knowledge generated from the research on intestinal basolateral transporters will 
provide the theoretical foundation in understanding drug-drug and food-drug interactions, 
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predicting individual variability in drug absorption, designing and developing drugs that will 
be effective when administered orally.  
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Figure 5.1. pH dependent passive diffusion of acidic or basic compounds across apical and 
basolateral membranes of the enterocytes. Based on the pH partition theory, acidic 
compounds cross apical membrane with higher permeability than that of basolateral 
membrane, whereas basic compounds cross basolateral membrane with higher permeability. 
 
GI Tract 
pH 6.0-6.5 
 
 
Cytosol 
pH 7.4 
 
Blood 
pH 7.4 
 
GI Tract 
pH 6.0-6.5 
 
Cytosol 
pH 7.4 
 
Blood 
pH 7.4 
168 
 
 
Figure 5.2. Intestinal basolateral transporter effects on drug absorption by BCS class. 
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APPENDIX 
 
 
 
TRANSPORT OF DICATIONIC DRUGS PENTAMIDINE AND FURAMIDINE 
BY HUMAN ORGANIC CATION TRANSPORTERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
This appendix was submitted to the Journal of Pharmacology and Experimental 
Therapeutics and was presented in the style of that journal. 
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A. ABSTRACT. 
Transport by membrane transporters in pathogenic protozoa is critical for the 
antiparasitic activity of aromatic diamidine drugs, pentamidine and furamidine. However, no 
such diamidine transporter has been identified in mammalian cells. Aromatic diamidines are 
primarily eliminated in the bile, but cause toxicity in both liver and kidney, suggesting a role 
of transporters in trafficking these molecules in both elimination organs. The goal of this 
study is to investigate whether human organic cation transporters (hOCTs, SLC22A1-3) 
mediate the elimination and cytotoxicity of aromatic diamidines in humans. Inhibitory and 
substrate activities of pentamidine and furamidine were studied in stably transfected Chinese 
Hamster Ovary (CHO) cells. The results of [3H]1-methyl-4-phenylpyridinium (MPP+) uptake 
inhibition study showed that pentamidine is a potent inhibitor for all three OCT isoforms 
(IC50 < 20 µM), whereas furamidine is a potent inhibitor for hOCT1 and hOCT3 (IC50 ≤ 20 
µM), but less potent inhibitor for hOCT2 (IC50 = 189.2 µM). Both diamidines are good 
substrates for hOCT1 (Km = 36.4 and 6.1 µM, respectively), and weak substrates for hOCT2, 
but neither is a substrate for hOCT3. hOCT1 enhanced the cytotoxicity of pentamidine and 
furamidine by 4.4-fold and 9.3-fold, respectively, in CHO-hOCT1 cells compared to mock 
cells. Ranitidine, an OCT1 inhibitor, reversed the OCT1-mediated potentiation of toxicity. 
This is the first finding that aromatic diamidines are substrates for mammalian transporters. 
These transporters may play important roles in the disposition of aromatic diamidines in 
humans, and resultant drug-drug interactions as well as toxicity involving diamidine drugs. 
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B. INTRODUCTION. 
Pentamidine, an aromatic diamidine, has been used in the clinic for over 60 years 
against early-stage human African trypanosomiasis, to treat Pneumocystis carinii pneumonia 
(PCP) in AIDS patients, and to treat antimony-resistant leishmaniasis (Barrett et al., 2007). 
Furamidine is a diamidine analog of pentamidine in which the alkoxy chain linking the 
phenyl rings has been replaced with a furan ring (Figure A.1). Furamidine has shown 
excellent in vitro and in vivo activity in mouse and monkey models of early-stage African 
trypanosomiasis (Barrett et al., 2007). The O-methyl amidoxime prodrug of furamidine, 
pafuramidine, is in phase III clinical trials to orally treat human African trypanosomiasis 
(Barrett et al., 2007). 
Pentamidine is eliminated slowly in humans with a plasma half-life of over four days 
after intravenous administration (Vohringer and Arasteh, 1993). Hepatic metabolism and 
excretion is the major elimination pathway for pentamidine, and renal excretion only 
accounts for a small fraction (<10%) of the administered dose in humans (Conte, 1991; 
Bronner et al., 1995). Furamidine is metabolically stable, and hepatic excretion is the major 
elimination pathway in rats (unpublished data). The elimination pathway of the diamidines is 
unusual because renal excretion is preferred over hepatic elimination for small cationic 
molecules (Meijer et al., 1999), partly due to the presence of multiple cation transport 
systems in kidney. Adverse drug reaction is the primary limitation for parenteral pentamidine 
therapy; nephrotoxicity, hepatotoxicity, gastrointestinal discomfort and pancreatitis 
accounted for the majority of toxicity in humans (Balslev and Nielsen, 1992; O'Brien et al., 
1997). Furamidine was also associated with severe nephrotoxicity and hepatotoxicity in mice 
(Werbovetz, 2006). 
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Carrier mediated uptake and accumulation in target parasites is crucial for the toxicity 
of aromatic diamidines to parasites (de Koning et al., 2005; Barrett et al., 2007). The 
intracellular concentration of pentamidine achieved was over 1 mM in trypanosomes when 
exposed to 1 µM of the drug (Carter et al., 1995). This process is mediated by multiple 
transport systems, including the P2 transporter, the high-affinity pentamidine transporter 1, 
and the low-affinity pentamidine transporter 1 (Barrett et al., 2007). Mutations of these 
transporters in target parasites cause resistance of the target parasites to pentamidine and 
other aromatic diamidines (Barrett et al., 2007). However, no such diamidine transporter has 
been identified in mammalian cells, although carrier mediated transport in mammalian cells 
has been speculated because furamidine was  rapidly taken up by B16 melanoma cells 
(Lansiaux et al., 2002). Renal clearance of pentamidine showed saturation at high doses, 
indicating possible involvement of an active secretion mechanism in kidney (Lidman et al., 
1994). Poola et al. (2003) studied the renal excretion of pentamidine in the isolated perfused 
rat kidney and showed that tetraethylammonium (TEA), a protypical substrate for organic 
cation transporters (OCTs), reduced renal excretion of pentamidine, indicating the possible 
role of OCTs in its renal excretion. However, the definite role of OCTs in pharmacokinetics 
and toxicity of pentamidine in humans has not been established. 
In this study, aromatic diamidines, pentamidine and furamidine, were first tested as 
substrates and inhibitors for OCTs in the SLC22A family, which are mainly expressed in the 
major elimination organs, kidney (the basolateral membrane of tubular cells) and liver (the 
sinusoidal membrane of hepatocytes) (Koepsell et al., 2007). There are three distinct OCT 
transporters, namely OCT1, OCT2, and OCT3, which mediate the entry of organic cations 
into cells (Koepsell et al., 2007). In humans, hOCT1 is the predominant OCT transporter 
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expressed in the liver while hOCT2 is expressed predominantly in the kidney (Koepsell et al., 
2007). The majority of OCT substrates are monovalent, and comparatively small, cations, the 
so called type I organic cations (Meijer et al., 1999; Wright, 2005) as exemplified by the 
protypical substrates TEA and the neurotoxin, MPP+ (Koepsell et al., 2007). In addition, 
OCTs interact with many drugs, including the H2 antagonist ranitidine (Bourdet et al., 2005), 
the antidiabetic drug metformin (Wang et al., 2002) and the anticancer drug oxaliplatin 
(Yokoo et al., 2007). The results in this study clearly demonstrate that the aromatic 
diamidines, pentamidine and furamidine, are potent inhibitors for hOCT1, hOCT2, and 
hOCT3, and are substrates for hOCT1, and to a lesser extent for hOCT2. The results further 
demonstrate the ability of hOCT1 to potentiate the cellular toxicity of the diamidines. 
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C. MATERIALS AND METHODS. 
Materials 
F-12 Nutrient Mixture, penicillin-streptomycin-amphotericin B solution (100x) and 
N-hydroxyethyl-piperazine-N'-2-ethanesulfonate (HEPES, 1M) were obtained from Gibco 
Laboratories (Grand Island, NY). Fetal bovine serum (FBS) and trypsin-EDTA solution (1x) 
were obtained from Sigma Chemical Co. (St. Louis, MO). Geneticin was obtained from 
Invitrogen Co. (Carlsbad, CA). Hank's balanced salt solution (HBSS) was obtained from 
Mediatech, Inc. (Herndon, VA). Pentamidine isethionate salt (purity > 98%), TEA chloride, 
MPP+ and quinidine were purchased from Sigma (St. Louis, MO). Furamidine 
dihydrochloride salt (purity > 98%) was synthesized by Medichem (Chicago, IL) using 
previously described methods (Das and Boykin, 1977). [3H]MPP+ (85 Ci/mmol) was 
obtained from American Radiolabelled Chemicals (St. Louis, MO). [3H]pentamidine (4.6 
Ci/mmol, purity 97.4%) was obtained from Moravek Biochemicals (Brea, CA). 
[14C]furamidine (55.3 mCi/mmol, purity 96%) was obtained from Huntingdon Life Sciences 
(Huntingdon, UK). Chinese hamster ovary (CHO) cells were obtained from the American 
Tissue Culture Collection (Manassas, VA). 
cDNA 
hOCT1 cDNA in pcDNA3.1 vector and hOCT2 cDNA in pCMV vector were 
provided by Professor Hermann Koepsell (Julius-Maximilians-University, Würzburg, 
Germany). hOCT3 cDNA in pSPORT1 vector was provided by Dr. Vadivel Ganapathy 
(Medical College of Georgia, Augusta, GA, USA) and was subcloned into pcDNA3.1 vector 
(Invitrogen, Carlsbad, CA). 
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Cell Culture and Transfection 
CHO cells were transfected with pcDNA3.1 empty vector or the vectors containing 
the full-length hOCT1, hOCT2 and hOCT3 using the Nucleofector System (Amaxa, 
Gaithersburg, MD) according to the manufacturer's protocol specific for CHO cells. 
Transfectants were selected with 500 µg/ml geneticin for 10 days. A clone with the highest 
[3H]MPP+ uptake activity was chosen as a stably transfected cell line for further studies. The 
stably transfected CHO cells were cultured in F-12 Nutrient Mixture with 10% FBS, 100 
unit/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B plus 500 µg/ml 
geneticin. All cell lines were grown at 37°C in a humidified atmosphere with 5% CO2. 
Cellular Transport 
Stably transfected CHO cells were grown as monolayers in 24-well plates. Medium 
was changed every other day. The cells were used 5-7 days post-seeding. Cells were pre-
incubated for 30 minutes at 37ºC in transport buffer (HBSS with 25 mM D-glucose and 10 
mM HEPES pH 7.2). Experiments were initiated by replacement of the transport buffer with 
0.4 ml of radiolabelled dose solutions in transport buffer. Uptake was determined within the 
linear uptake region after which the dose solution was aspirated and cells were washed three 
times with 4ºC transport buffer and dissolved in 500 µl 0.1 N NaOH/0.1% SDS for 4 hours 
with shaking. Radioactivity was determined by scintillation counting. Protein content was 
determined by the BCA protein assay (Pierce, Rockford, IL) with bovine serum albumin as a 
standard. 
For kinetic studies, varying amounts of unlabeled diamidines were added to the 
uptake solutions to give increasing total (radiolabeled plus unlabeled) substrate 
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concentrations. Nonspecific cell-associated radioactivity was determined by measuring 
substrate uptake in mock cells at each substrate concentration, and these values were then 
subtracted from the results in transfected cells to obtain uptake values and the final kinetic 
data. The Km and Vmax values were obtained by fitting the Michaelis-Menten equation V = 
Vmax x [S]/(Km + [S]) to the data using WinNonlin (Pharsight, Mountain View, CA), where V 
refers to the rate of substrate transport, Vmax refers to the maximum rate of substrate transport, 
[S] refers to the concentration of substrate, and Km is defined as the concentration of substrate 
at the half-maximal transport rate. 
For inhibition studies, different concentrations of unlabeled inhibitors were added to 
uptake solution containing 1 µM [3H]MPP+. Nonspecific cell-associated radioactivity was 
determined by measuring [3H]MPP+ uptake in mock cells at each inhibitor concentration, and 
these values were then subtracted from the values in hOCT1-transfected cells to give 
corrected data that were used for generation of the inhibition curves. The IC50 value was 
estimated by fitting the data to the equation V = Vo/[1 + (I/IC50)n] using WinNonlin 
(Pharsight, Mountain View, CA), where V is the uptake rate of [3H]MPP+ in the presence of 
inhibitor, Vo is the uptake rate of [3H]MPP+ in the absence of inhibitor, I is the concentration 
of inhibitor, and n is the Hill coefficient. 
Cytotoxicity Assay 
The cytotoxicity of diamidines was measured by the Alamar Blue assay (Schoonen et 
al., 2005). In brief, cells were seeded in 96-well plates at 3000 cells/well. After 24 hours, 
cells were exposed to different concentrations of diamidines in the presence or absence of 1 
mM ranitidine, an OCT1 inhibitor (Bourdet et al., 2005), for 24 hours. Drug-containing 
medium was replaced with fresh medium, and cells were incubated for another 24 hours. 
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Alamar Blue reagent was added and incubated for 4 hour. The samples were read in a 
microplate reader set at 544 nm excitation wave length and 584 nm emission wave length. 
The IC50 values were obtained by fitting F, the percentage of the maximal cell growth at 
different drug concentrations, to the equation F = 100/[1 + (C/IC50)n] using WinNonlin 
(Pharsight, Mountain View, CA); the maximal cell growth was the cell growth in the medium 
without diamidine; C is the concentration of diamidine, and n is the slope factor. 
Statistical Analysis 
Data are expressed as mean ± SD from three measurements unless otherwise noted. 
Statistical significance was evaluated using ANOVA followed by Dunnet’s test for multiple 
comparisons. The data were analyzed with SigmaStat 2.0 (Systat Software, Inc., San Jose, 
CA). 
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D. RESULTS. 
Expression of Functional hOCT1, hOCT2, and hOCT3 in Stably Transfected CHO 
Cells. 
Uptake of 1 µM [3H]MPP+, a model substrate for OCTs, as a function of time was 
determined in CHO cells transfected with hOCT1 (CHO-hOCT1), hOCT2 (CHO-hOCT2), 
and hOCT3 (CHO-hOCT3), and compared with its uptake in mock cells.  Uptake of 
[3H]MPP+ in each transfected cell line was linear up to 5 minutes, and was several-fold 
greater than in the mock cells (Figure A.2), providing evidence for expression of functional 
hOCT transporters in stably transfected CHO cells.   
Inhibition of hOCT1, hOCT2, and hOCT3 by Aromatic Diamidines in CHO Cells 
As expected, uptake of [3H]MPP+ into CHO-hOCT1, CHO-hOCT2, and CHO-
hOCT3 cells was inhibited in a concentration-dependent manner by TEA and quinidine 
(Figure A.3), with quinidine showing over an order of magnitude greater potency than TEA 
(Table A.1).  The two aromatic diamidine compounds tested, pentamidine and furamidine 
(Figure A.1), proved to be potent inhibitors of all three hOCTs. The IC50 values in Table A.1 
show that pentamidine inhibits all three hOCTs with similar potency; it inhibits hOCT1 and 
hOCT2 with a potency (IC50 of 16.4 ± 1.7  and 10.6 ± 2.4 µM, respectively) similar to that of 
quinidine and is a more potent hOCT3 inhibitor than quinidine (IC50 of 14.8 ± 3.4 µM). 
Furamidine, a structural analog of pentamidine, also is a potent inhibitor of hOCT1 and 
hOCT3 (IC50 of 7.4 ± 0.9 and 20.4 ± 2.8 µM, respectively), but a weak inhibitor of hOCT2 
with the IC50 value of 182.0 ± 30.3 µM, which is close to that of TEA (189.2 ± 11.2 µM). 
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Uptake of Pentamidine and Furamidine into hOCT1-, hOCT2-, and hOCT3-expressing 
CHO Cells 
As shown in Figure A.4A, the uptake of 0.1 µM [3H]pentamidine into CHO-hOCT1 
cells was 5.1-fold (p < 0.001), greater than that into mock cells. The [3H]pentamidine uptake 
into CHO-hOCT2 and CHO-hOCT3 cells was only marginally greater (1.2-fold, p < 0.05) 
than the control and equivalent to the control, respectively. The uptake of 1 µM 
[14C]furamidine was 4.6-fold (p < 0.001) and 1.6-fold (p < 0.01) greater into CHO-hOCT1 
and CHO-hOCT2 cells, respectively, compared with mock cells, whereas the uptake into 
CHO-OCT3 cells was not above the control value (Figure A.5A). These data suggest that 
pentamidine and furamidine are good substrates of hOCT1 and weak substrates of hOCT2, 
but neither of them is a substrate of hOCT3. In CHO-hOCT1 cells, accumulation of 
pentamidine (Figure A.4B) and furamidine (Figure A.5B) was linear over 10 minutes. The 
uptake, measured as a function of concentration, was saturable (Figures A.4C and A.5C) with 
Km values of 36.4 ± 8.3 µM and 6.1 ± 1.1 µM, respectively, and Vmax values of 156.0 ± 3.7 
pmol/mg/min and 27.2 ± 1.3 pmol/mg/min, respectively. The uptake of two diamidine drugs 
in mock cells also showed concentration-dependent mechanism (data not shown), indicating 
endogenous transporters in CHO cells may transport aromatic diamidines. 
Cytotoxicity of Diamidines in CHO-hOCT1 Cells 
The question that was addressed next was whether the hOCT1-mediated cellular 
uptake of the diamidines could increase their cytotoxicity.  The toxicity of pentamidine 
toward CHO-hOCT1 cells was  4.4-fold greater than toward mock cells (IC50 of 46.2 ± 5.3 
µM and 202 ± 16.4 µM, respectively), indicating that hOCT1 enhances pentamidine-induced 
cytotoxicity (Figure A.6A, Table A.2). The IC50 values of furamidine in CHO-hOCT1 cells 
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and mock cells were 1.1 ± 0.05 and 10.2 ± 0.7 µM, respectively, indicating that expression of 
hOCT1 greatly enhances furamidine-induced cytotoxicity (Figure A.6B, Table A.2). The 
cytotoxicity of pentamidine and furamidine was also determined in the presence or absence 
of 1 mM ranitidine, an OCT1 substrate and inhibitor (Bourdet et al., 2005). At this 
concentration, ranitidine itself showed no cytotoxicity toward CHO or CHO-hOCT1 cells. 
Ranitidine treatment almost completely eliminated the hOCT1-mediated enhancement of the 
diamidine cytotoxicity (Figures A.6A and A.6B). The IC50 values of pentamidine and 
furamidine in CHO-hOCT2 and CHO-hOCT3 cells were not significantly different than 
those in CHO-Mock cells (data not shown), consistent with the results reported here that the 
diamidines are not good substrates of hOCT2 or hOCT3. 
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E. DISCUSSION. 
Pentamidine, an aromatic diamidine, has been used to treat protozoal infections 
(Barrett et al., 2007).  Both pentamidine (Conte, 1991; Bronner et al., 1995) and furamidine 
(unpublished data) are mainly eliminated in the liver in contrast to small cationic molecules, 
such as metformin (Pentikainen et al., 1979) and cimetidine (Weiner and Roth, 1981), which 
are mainly excreted via the kidney. Renal cation transport systems appear to contribute to the 
preferred renal elimination of these compounds since both metformin (Kimura et al., 2005) 
and cimetidine (Tahara et al., 2005) are superior substrates for hOCT2, predominantly 
expressed in the kidney, rather than hOCT1 that is predominantly expressed in the liver  
(Koepsell et al., 2007). In the present study, we examined the substrate activity of 
pentamidine and furamidine towards hOCTs in order to determine the molecular mechanisms 
responsible for disposition of aromatic diamidines in the liver and the kidney, the major 
elimination organs. The results showed that pentamidine and furamidine are indeed good 
substrates for hOCT1; in contrast, these diamidines are poor substrates for hOCT2, and do 
not exhibit any substrate activity toward hOCT3. These results are consistent with previous 
reports that pentamidine (Conte, 1991; Bronner et al., 1995) and furamidine (unpublished 
data) are eliminated predominantly via hepatic clearance mechanisms. These results also 
provide the first evidence that aromatic diamidines are substrates for mammalian transporters. 
OCTs had previously been found to interact mainly with monovalent organic cations 
(Type I cations) (Wright, 2005; Koepsell et al., 2007). Recently, one divalent organic cation, 
paraquat, has been identified to be substrate for OCT2 (Chen et al., 2007). Our finding of 
aromatic diamidines, divalent organic cations, as substrates of hOCT1 suggests that this 
transporter, like hOCT2, also can transport dications. This is the first report in which a drug 
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with divalent cation functionality is shown to be an OCT substrate. The three OCT isoforms 
seem to have differential inhibition profiles and substrate activities for dicationic compounds. 
As shown in the present study, aromatic diamidines are better substrates for hOCT1 
compared to hOCT2. In contrast,  paraquat has been reported as a better substrate for hOCT2 
(Chen et al., 2007). Although aromatic diamidines are potent inhibitors of hOCT3, the 
aromatic diamidines are not transported by it. Irrespective of the mechanism, the data suggest 
that hOCT1 contributes to and may be the predominant mechanism for the uptake of aromatic 
diamidines by the hepatocytes.  
Parenteral pentamidine therapy caused adverse drug reactions including 
nephrotoxicity, hepatotoxicity, gastrointestinal discomfort and pancreatitis (Balslev and 
Nielsen, 1992; O'Brien et al., 1997).  Pentamidine and furamidine are DNA minor groove 
binders (Barrett et al., 2007) and furamidine selectively accumulates in nuclei of tumor cells 
(Lansiaux et al., 2002). The rapid entry of these charged compounds into cells could not be 
accounted for by a simple diffusion process (Lansiaux et al., 2002).  Specific transporters, 
analogous to those for the entry of aromatic diamidines into parasites (Barrett et al., 2007), 
were speculated to promote intracellular accumulation. In this study, we observed that 
overexpression of hOCT1 not only increased the uptake of pentamidine and furamidine, but 
also enhanced the cytotoxicity of these agents. OCT-mediated transport has been reported to 
enhance the cytotoxicity of cisplatin (Ciarimboli et al., 2005), oxaliplatin (Zhang et al., 2006) 
and paraquat (Chen et al., 2007). Transport via OCTs is driven by membrane potential, and 
uptake of positively charged molecules is thermodynamically favorable, which can produce 
over 10-fold higher intracellular concentrations compared with the dose concentration 
(Koepsell et al., 2007). With two positive charges in each molecule, aromatic diamidines can 
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achieve even higher intracellular concentrations, driven by membrane potential. The results 
in this study suggest that hOCT1 promotes the accumulation of aromatic diamidines in 
mammalian cells, and may play an important role in diamidine-induced cytotoxicity in the 
organs expressing hOCT1, such as liver.  
In human kidney, hOCT2 is highly expressed, but not hOCT1 (Koepsell et al., 2007). 
Aromatic diamidines are poor substrates for hOCT2; therefore, transport by renal OCTs may 
not account for the severe toxicity of pentamidine in human kidney (Balslev and Nielsen, 
1992; O'Brien et al., 1997). In a recent study, the expression of hOCT1 mRNA was shown to 
be only a few-fold lower than that of hOCT2 in the kidney (Hilgendorf et al., 2007), 
indicating that hOCT1 may also contribute to basolateral uptake of cations, including 
diamidines, in the kidney. Therefore, whether OCTs modulate nephrotoxicity of diamidines 
needs further investigation. In rats, the highest Oct1 expression was observed in the kidney 
(Grundemann et al., 1994), which may explain why TEA reduced the renal excretion of 
pentamidine in this species (Poola et al., 2003). These results highlight the possibility that 
differential expression of transporters across different species may contribute to different 
profile of organ toxicities for molecules like diamidines whose toxicity appears to be 
dependent on OCT1-dependent cellular uptake.   
Drug-drug interaction via OCTs has been well documented (Ho and Kim, 2005; Li et 
al., 2006). For example, cimetidine is a potent hOCT2 inhibitor and coadministration with 
cimetidine reduced renal clearance of other cationic drugs (Ayrton and Morgan, 2001). 
Pentamidine is a potent inhibitor of hOCT2 with an IC50 value below that of quinidine and is 
one the most potent hOCT2 inhibitors among the marketed drugs. Therefore, pentamidine 
may affect the renal clearance of other cations by inhibiting hOCT2.  Further, pentamidine 
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and furamidine are potent inhibitors to hOCT1 and may be able to reduce the hepatic uptake 
of other hOCT1 substrates, such as metformin, and thus change their pharmacokinetics and 
pharmacodynamics (Shu et al., 2007; Shu et al., 2008). 
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Table A.1. 
Inhibition of hOCT1-, hOCT2-, or hOCT3-mediated [3H]MPP+ Uptake by Pentamidine and 
Furamidine in CHO Cells.  
Inhibitor hOCT1 IC50 (µM) hOCT2  IC50 (µM) hOCT3  IC50 (µM) 
Quinidine 5.7 ± 0.9 13.3 ± 0.7 22.7 ± 1.9 
Pentamidine 16.4 ± 1.7 10.6 ± 2.4 14.8 ± 3.4 
Furamidine 7.4 ± 0.9 182.0 ± 30.3 20.4 ± 2.8 
TEA 469.7 ± 12.7 189.2 ± 11.2 1476.6 ± 160.1 
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Table A.2. 
Cytotoxicity of Pentamidine and Furamidine in hOCT1 Transfected and Mock CHO Cells.  
Drug hOCT1 IC50 (µM) Mock IC50 (µM) Fold change a 
Pentamidine 46.2 ± 5.3 202.2 ± 16.4 4.4 
+ ranitidine 109.9 ± 12.4 170.2 ± 25.6 1.5 
Furamidine 1.1 ± 0.05 10.2 ± 0.7 9.3 
+ ranitidine 7.3 ± 0.4 10.3 ± 1.3 1.4 
 
a Fold increase in the sensitivity of CHO-hOCT1 cells to pentamidine and furamidine 
compared with mock cells incubated under identical conditions. 
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Figure A.1. Chemical structures of pentamidine and furamidine. 
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Figure A.2. Functional expression of hOCT1, hOCT2, and hOCT3 in stably transfected CHO 
cells. CHO cells, stably transfected with hOCT1, hOCT2, hOCT3 cDNA (●) or empty vector 
(Mock, ○), were incubated with [3H]MPP+ (1 µM) at 37ºC for the indicated time. Data 
represent mean ± S.D. from a representative experiment. 
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Figure A.3. Concentration-dependent inhibition hOCT1, hOCT2, and hOCT3 in CHO cells 
by organic cations. Uptake of [3H]MPP+ in CHO-hOCT1, CHO-hOCT2, CHO-hOCT3 and 
mock cells was determined in the absence or presence of increasing concentrations of 
pentamidine (●), furamidine (▼), quinidine (○) and TEA (□) for 4 minutes. Nonspecific cell-
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associated radioactivity was determined by measuring substrate uptake in mock cells at each 
inhibitor concentration, and these values were then subtracted from the values in hOCT1-
transfected cells to give corrected data that were used for generation of the inhibition curves. 
Thus, the data represent inhibition of the transporter-mediated portion of [3H]MPP+ uptake. 
Data are expressed as mean ± S.D. of experiments in triplicate. 
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Figure A.4. Uptake of [3H]pentamidine by CHO-hOCT1, CHO-hOCT2, and CHO-hOCT3 
cells. A, uptake of [3H]pentamidine (0.1 µM) was determined in CHO-hOCT1, CHO-
hOCT2, and CHO-hOCT3 and mock cells over 10 minutes. B, uptake of [3H]pentamidine 
(0.1 µM) was determined in mock or CHO-hOCT1 cells for the indicated time periods. C, 
uptake of [3H]pentamidine (indicated concentration) was determined in mock or CHO-
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hOCT1 cells for 10 minutes. Nonspecific cell-associated radioactivity was determined by 
measuring the compound uptake in mock cells at each substrate concentration, and these 
values were then subtracted from the values in hOCT1-transfected cells to obtain the data 
used to generate final kinetic curves. Data represent mean ± S.D. of a representative 
experiment in triplicate. *** p < 0.001, ** p < 0.01 and * p < 0.05 compared with uptake in 
mock cells. 
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Figure A.5. Uptake of [14C]furamidine by CHO-hOCT1, CHO-hOCT2, and CHO-hOCT3 
cells. A, uptake of [14C]furamidine (1 µM) was determined in CHO-hOCT1, CHO-hOCT2, 
and CHO-hOCT3 and mock cells over 10 minutes. B, uptake of [14C]furamidine (1 µM)  was 
determined in mock or CHO-hOCT1 cells for the indicated time periods. C, uptake of 
[14C]furamidine (indicated concentration) was determined in mock or CHO-hOCT1 cells for 
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10 minutes. Nonspecific cell-associated radioactivity was determined by measuring the 
compound uptake in mock cells at each substrate concentration, and these values were then 
subtracted from the values in hOCT1-transfected cells to obtain the final kinetic curves. Data 
represent mean ± S.D. of a representative experiment in triplicate. *** p < 0.001, ** p < 0.01 
and * p < 0.05 compared with uptake in mock cells. 
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Figure A.6. Effect of hOCT1 on pentamidine and furamidine cytotoxicity. After 1-day 
culture in 96-well plates, CHO-hOCT1 (circle) or mock cells (square) were incubated with 
different concentrations of pentamidine (A) or furamidine (B) in the presence (solid) or 
absence (empty) of 1 mM ranitidine, an OCT1 inhibitor, for 24 hours followed by another 
24-hour culture in fresh media. Alamar blue assays were performed afterwards and the IC50 
values of cell growth inhition were calculated. Studies were performed in triplicate in each 
individual experiment. 
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